

Db 1 KADRPSTYTYVEEPDSAGHSSGGPVSAGVTKALQSDVNAFGMLMEGLKQPNLHNCVNIIV 60

```

QY 370 LADHGMDDQTYCNKWEYMTDFFPRINFFYMYEGPAPRAHNPDPFFSNSEIIVRNLS 429
Db 61 LADHGMDDQTYCNKWEYMTDFFPKIN-FYMYQGFAPRIRTNIPQDFFSNSEIIVRNLS 119
QY 430 RKPDDHFKPYLTPDLKRLHYAKNVRIDKHVLFVQOQWLAVRSKNTNCGGNHYNNEF 489
Db 120 RKPDDHFKPYLTPDLKRLHYAKNVRIDKAHLMDVDRQWLAFRSKGSSNCGGTHGYNNEF 179
QY 490 RSMELFLAHGSPFKEKTEVEPENIEVNLMDLLRIOPAEVNGTHGSLAHLKAVPE 549
Db 180 KSMELFLAHGSPFKEKTEVEPENIEVNLMDLLRIOPAEVNGTHGSLAHLKAVPE 239
QY 550 PSMAEVSKFSGVFANPLTESLDCFCPLHQLNQL-EQVQMLNLTQEEITATVKNL 608
Db 240 PSMAEVSKFSGVFANPLTESLDCFCPLHQLNQL-EQVQMLNLTQEEITATVKNL 299
QY 609 PGRPRVLONVDHCLLYHREYVSGFKAMRPMSSYTVFOLGDTSLPPTVPDCLRAD 668
Db 300 PGRPRVLONVDHCLLYHREYVSGFKAMRPMSSYTVFOLGDTSLPPTVPDCLRAD 359
QY 669 VRPPSESQKSFYLADKNIITHGFLYPPASNETSDQDALITSNLVPMYEFKQWDF 728
Db 360 VRPPSESQKSFYLADKNIITHGFLY-PAIKGTNESRYDALITSNLVPMYEFKQWDF 418
QY 729 HSVLLIKHATERNGVNVSGPIFDVNYDGHFADPDEITKHLANTDVPPTHYFVLTSC 788
Db 419 HEVLLIKHATERNGVNVSGPIFDVNYDGHFADPDEITKHLANTDVPPTHYFVLTSC 478
QY 789 NKSHTPENCGLDVLPTIIPRPTNVESCPBGKPEALWVERFTAHARVDRDVELLTL 848
Db 479 DQTHPDSGGLDVLPTIIPRPTNVESCPBGKPEALWVERFTAHARVDRDVELLTL 538
QY 849 DFYQKQVPSVILQKTYLPTFTT 875
Db 539 DFYQKQVPSVILQKTYLPTFTT 565

RESULT 2
Q924C4 PRELIMINARY; PRT; 906 AA.
AC Q924C4;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Ectonucleotide pyrophosphatase/phosphodiesterase 1 allotype b
DE (EC 3.1.4.1).
GN ENPPI.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxId=10090;
RN [1]
SEQUENCE FROM N.A.
RA Banakh I., Sai A., Dubljevic V., Grobten B., Slegers H., Goding J.W.;
RT "structural basis of allotypes of ecto-nucleotide
RT pyrophosphatase/phosphodiesterase (plasma cell membrane glycoprotein
RT PC-1) in the mouse and rat";
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF339910; AAK84174.1; -.
DR MGI; MGI:97370; Enppi.
DR GO; GO:0001501; P:skeletal development; IMP.
DR InterPro; IPR001604; Endonuclease.
DR InterPro; IPR002591; Phosphodiesterase.
DR InterPro; IPR001212; Somatomedin_B.
DR Pfam; PF01223; Endonuclease; 1.
DR Pfam; PF01663; Phosphodiesterase; 1.
DR PRINTS; PR00033; Somatomedin_B; 2.
DR PRINTS; PR00022; SOMATOMEDINB.
DR SMART; SM00477; NUC; 1.
DR SMART; SM00201; SO; 2.
DR PROSITE; PS00524; SOMATOMEDIN_B; 2.
KW Hydrolase.

```

```

SQ SEQUENCE 906 AA; 103125 MW; 1FA071071E4B9C50 CRC64;
Query Match 50.78; Score 2435; DB 11; Length 906;
Best Local Similarity 51.04; Pred. No. 5.8e-198;
Matches 447; Conservative 152; Mismatches 250; Indels 28; Gaps 9;
QY 10 EQPVKK-----NTLKKYKIACIVLIALVIMSLGLGLGLGRKLEKQGSCKKCF 59
Db 39 EEPLEKAEARPAKDPNT---YKVLVLVSVCLTILGICIFGLKPKSCAKVKSKGRCF 95
QY 60 DASPRGLENCRDVACHDRGDCWDPEDTCTVETRIWCMKPRCGETRIEASLCSSDDC 119
Db 96 ERTF---SNCRDAACVSLGNCCLDFQETCTVETRIWCMKPRCGEKRLSRFVCSADDC 152
QY 120 LQKDCADYKSCVCOGETSWELENCDTAQOSQCEGFDLPVILFMDGDFRAEYLTWDT 179
Db 153 KTHNDCCINYSVQCQDKKSWETCSIDTPECPAEFESPTLLFLDGFRAEYLTWGG 212
QY 180 LMPNINKLTCGTHSKYMRAMYPTKTFPNHYTIVTGLYPESHGIIIDNNYDVNLKNFSL 239
Db 213 LLPVISKLNCGTYTKMRPMYPTKTFPNHYTIVTGLYPESHGIIIDNNYDVNLKNFSL 272
QY 240 SSKEONNPAMHOGPWLTAQYGLKAATYFVSGVAINGSPSTYMPYNGSVPEERI 299
Db 273 KSKEFNPLWYKQPIWVTANHOEVKSGTYFPGSDVEIDGILPDIYKYNVSGVPEERI 332
QY 300 STLLKMLDLKPAERPRFYTMYPEPSSGHAGPVSARVICALQVVDHAFGLMEGLKOR 359
Db 333 LAVLEWLQPLSHRPHFYTLYLEPSSGHSHGSPVSSEVIKALQKVDRLVGLMDGLKOL 392
QY 360 NLHNCVNIILLADHGMDDQTYCNKWEYMTDFFPRINFFYMYEGPAPRAHNPDPFFSN 419
Db 393 GLDKCNLNLISDHGMEQGSCKKYVYLNKYLGVNWNKVYVGYGAARLRTDVPETYSN 452
QY 420 SEBIVRNLSCKRQDQHFKPYLTPDLKRLHYAKNVRIDKHVLFVQOQWLAVRSKNTWC 478
Db 453 YEALAKNLSCEPNQHFRLYKPLKRLHFAKSDRIEPLTFYLDPOWQALNPSEKVC 512
QY 479 GGNHGVNNEFRSMEAI FLAHGSPFKEKTEVEPENIEVNLMDLLRIOPAEVNGTHGS 538
Db 513 GSGFHGSDNLFNMQALFYGPAFKHGAEDVSFENIEVNLMDLLRIOPAEVNGTHGS 572
QY 539 LNHLKVPFVPSHAEVSKFSGVFANPLTESLDCFCPLHQLNQL-EQVQMLNLTQES 598
Db 573 LNHLKVPFVPSHAEVSKFSGVFANPLTESLDCFCPLHQLNQL-EQVQMLNLTQES 628
QY 599 EITATVKNALPGRPRVLONVDHCLLYHREYVSGFKAMRPMSSYTVFOLGDTSLP 658
Db 629 DVDDIYHMTVPYGRPRILLKQHRVCLLQOQQLTGYSLDMLPLWASYTF--LSNDQFSR 686
QY 659 PTVPDCLRADVRPPSESQKSFYLADKNIITHGFLYPPASNETSDQDALITSNLVPM 717
Db 687 DPFNSCLYQDLRIPLSPFVHKSKSYKSNGLSYGFTLTPPLNRVSNHIVSEALLTNIVPM 746
QY 718 YSEFRKMWYFFHSVLLIKHATERNGVNVSGPIFDVNYDGHFADPDEITKH---LANIDV 774
Db 747 YQSFQVIMHVLHDTLLQRYAHERNGINNVSGVDFDYDGYDYSLEILKQNSRVSQEI 806
QY 775 PIPTHYFVLTSCNKSHTPENCPOWLVDLPPIIHRPTNVESCPBGKPEALWVERFTA 834
Db 807 LIPTHFVILTCKQLSETPLECSA-LESSAVILPHRPDNEBSCTHGKRESSWVEELLTL 865
QY 835 HIARVDRVELLTGLDFYQKQVPSVILQKTYLPTFT 871
Db 866 HRAVTDVELITGLSFYQDRQSVSEVSELLKTLHPIF 902

RESULT 3
Q7ZXN7 PRELIMINARY; PRT; 874 AA.
AC Q7ZXN7;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
KW

```

```
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Embryo;
RA Klein S., Strausberg R.;
RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC044675.1;
DR GO; GO:0004519; F:endonuclease activity; IEA.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0003676; F:nucleic acid binding; IEA.
DR GO; GO:0003117; F:nucleotide metabolism; IEA.
DR InterPro; IPR001604; Endonuclease.
DR InterPro; IPR002591; Phosphodiesterase.
DR InterPro; IPR001212; Somatomedin_B.
DR Pfam; PF01223; Endonuclease; 1.
DR Pfam; PF01663; Phosphodiester; 1.
DR Pfam; PF01033; Somatomedin_B; 2.
DR PRINTS; PR00022; SOMATOMEDINB.
DR SMART; SM00477; NUC; 1.
DR SMART; SM00201; SO; 2.
DR PROSITE; PS00524; SOMATOMEDIN_B; 2.
KW Hypothetical protein.
SQ SEQUENCE 874 AA; 99650 MW; 7EA5B4EC1D9FCE46 CRC64;

Query Match 45.6%; Score 2191; DB 13; Length 874;
Best Local Similarity 45.1%; Pred. No. 3.2e-177;
Matches 409; Conservative 161; Mismatches 255; Indels 82; Gaps 14;

QY 15 KNTLKKYKTAIVLALLVIMSLGSLGLGLGRK-----LEKQSCRRKC 58
DB 4 KNGFSFHKVISLVTAIGINVCGLGTANRFRKSEWDEGVASVLSDSPIWSSGSKERC 63
QY 59 FDSAPRGLNCRCDVACDRGCCDFEDTCVSTRIMWKNFRCGEITRLASLSCSDD 118
DB 64 FELIEAEPACRCDNLCKSYNSCCDFDEHCLKTGRGECTKDRGETRNEENACHCED 123
QY 119 CLKQKCCADYKSVCGQTSWLENCDTAQOQCCEGPDLPVILFSDMGFRAEVLTYWD 178
DB 124 CLAKGDCCTNYQWCKGTHWADDDCEEMKHCEPAGFVRPLLIIFSDVGRASYMKXGH 183
QY 179 TLMENINKLCTGHSKYNRMVPTKTPNHYTIVTGLYPESHGIIIDNNVDVNLKNFS 238
DB 184 KYNPNIDKRSCTGTHSPYWRPVYPTKTPNLYTLAGLYPESHGIVGSMVDPVEDANFS 243
QY 239 LSSKEQNPANWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSFSPSYMYNGSVPFBER 298
DB 244 LRSREKFNHRWGGQPIWITASKQGLKAATFPWP---VAISQ-----ERR 285
QY 299 ISTLLKWLDPKAEPRFTYMYFEPSDSSGHAGGVSARVKAQOVVDHAFQWMEGLKQ 358
DB 286 IFTVLQWLHPNERPPYVVALYSEQDQAGHKYQFPQPELAQLKNDKIVQQLMDGLKQ 345
QY 359 RNLHNCVNIILLADHMDQTCNCKEYMTDYPFRINFFYMWEGPAPIRAHN--IPHDFF 416
DB 346 MXLHRCVNVIFVGDHGWBEATCETEFNLNSYLSNVDDFALLPGSIGRMSRPANKHD-- 403
QY 417 SPNSEIIVNLSCRKPDQHFKPYLTPDLKRLHYAKNVRIDKVHLFVQOQWLAVRS---- 472
DB 404 ---PKAVANLTKCKPDQHFKPYLKOHLKRLHYAFNRRIEDIHLLVDRKWHVAKPMVD 460
QY 473 -KSNTWCG- GNGHYNNEFRSMEAFIPLAHGPFKEKTEVEPFENIEVNLCDLLRIOPA 530
DB 461 YKQKCAQCGDHGVNKNITSQCTVFLGHGPFKFKYKTPPENIELYNVACDVGLKPA 520
QY 531 PNNGTHGSLNHLKVPFYPSPSHAEVSKFVCGFANPLP-----TESLDCFCFHLQNS 582
DB 521 SNNGTHGSLNHLRVASYPKPAIDEVSK-----PLPIVTSPTWNEELGSC---DD 569

583 STOLEQVQNML-----NLTOBEITATVK-----VNLPGRPVRLQKNDVHCLLYHR 628
570 KNKAEELNRELKYLKGTDDVAVEELSNEIKELTSRNTDKNLLYGRPAVLK-TKYSVLHHS 628
629 EYVSGFGKAMRPMWSSYTPQLGDTSPLPPTVPDCLRADRVRPVPSSESQKCSFYLDKNI 688
629 DFESGFSESLMPLWTSYTIISKQADVSGIPEHLSNCRVLDPRISPGNSQSCSAYKADQM 688
689 THGLYPPASNRSTDSQYDALITSNLPVMEYEPKQWDYFHSVLLIKHATERGNVVS 748
689 SYGFLPFPQLSSADSADKYAFITNVIPIYPAFKKIWNYPQRLVYKRFATERGNV 748
749 PIPDYNVDGHFADPDEITKHLANTDPIPHYFVWLTSCKNKSHTPENCFGWLDVLPFII 808
749 PIFDYDYGVDYDWDKI-KMFVDGSPVPHYHYIITSQWDFNQAVNDCDGLSVSVFI 807
809 PHEPTNVESCEPGKPEALWVEERFTHAHARVDRVELLTGLDFYQDKVQPVSEILQKTYL 868
808 PHRPDNDESCNSEESKWEVDLLKXHTTRIDIELLTGLDFYKTRNSYTEILSLKTYL 867
869 PTFETTI 875
868 HTVESEI 874

RESULT 4
Q9NQW9 PRELIMINARY; PRT; 251 AA.
AC Q9NQW9
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE D1100SH11.3 (Phosphodiesterase 1/nucleotide pyrophosphatase 3)
DE (Fragment).
GN PNP3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Lovell J.;
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
RL EMBL; ALI35904; CAB99214.1; -.
DR GO; GO:0004519; F:endonuclease activity; IEA.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0003676; F:nucleic acid binding; IEA.
DR GO; GO:0009117; P:nucleotide metabolism; IEA.
DR InterPro; IPR001604; Endonuclease.
DR InterPro; IPR002591; Phosphodiester.
DR Pfam; PF01663; Phosphodiester; 1.
DR SMART; SM00477; NUC; 1.
FT NON TER 1
FT NON TER 251
SQ SEQUENCE 251 AA; 28265 MW; C726FD4719D4880C CRC64;

Query Match 28.3%; Score 1360; DB 4; Length 251;
Best Local Similarity 100.0%; Pred. No. 2.7e-107;
Matches 251; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

472 SKSNTNCGNGHYNNEFRSMEAFIPLAHGPFKEKTEVEPFENIEVNLCDLLRIOPAP 531
DB 1 SKSNTNCGNGHYNNEFRSMEAFIPLAHGPFKEKTEVEPFENIEVNLCDLLRIOPAP 60
532 NNGTHGSLNHLKVPFYPSPSHAEVSKFVCGFANPLPTESLDCFCFHLQNSQLEQVQ 591
DB 61 NNGTHGSLNHLKVPFYPSPSHAEVSKFVCGFANPLPTESLDCFCFHLQNSQLEQVQ 120
592 MLNLTQBEITATVKVNIIPGRPRVRLQKNDVHCLLYHREYVSGFGKAMRPMWSSYTPQL 651
DB 121 MLNLTQBEITATVKVNIIPGRPRVRLQKNDVHCLLYHREYVSGFGKAMRPMWSSYTPQL 180
```



```

Query Match      15.5%; Score 746; DB 4; Length 274;
Best Local Similarity 54.5%; Pred. No. 5.3e-55;
Matches 140; Conservative 37; Mismatches 78; Indels 2; Gaps 2;

QY 322 EEPDSSGAGGVPARVIALQVDPHAFGMLMEGLKQRLNHCNVNIIILLADHGMDDQTCYN 381
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 3 EEPDSSGSHGVPSEVIKALQVDMVGMMLDGLKELNLRCLNLIILSDHGMEOGSGCK 62
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 382 KNEYMTDYPFRINFFYMEGAPAPRIRAHNI PHDFSFNSSEIIVRNLSCKRQDQHKPKYLT 441
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 63 KYIYNKYLGVDKNTIKVIYGPAPRIRAHNI PHDFSFNSSEIIVRNLSCKRQDQHKPKYLT 441
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 442 PDLKELHAKNVRIDKVLHFDVQQW-LAVRSKSNNTCGGNGHGNNEFRSMEAI FLAAG 500
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 123 HFLPKLHFAKSDRIEPLTFYLDPOWQLALNPSERKCYGSGFGHSDNVFNSMQALFVGYG 182
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 501 PSFKKTEVEPENIEVYNLMCDLLRIQAPNNGTHGSLNHLKVPFFPEPSHAEVSKFS 560
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 183 PGFKHGEADTTEVIEVYNLMCDLLNLTAPNNGTHGSLNHLKVPFFPEPSHAEVSKFS 560
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 561 VCGFANPLTESLDCFC 577
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 243 QCFFTRN-PRDNLGSC 258
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 12
Q9SU83 PRELIMINARY; PRT; 496 AA.
AC Q9SU83;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Nucleotide pyrophosphatase-like protein (EC 3.6.1.9).
GN T16L4.190 OR A74G29680.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosid II; Brassicales; Brassicaceae; Arabidopsi.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Bevan M., Rose M., Hempel S., Entian K.-D., Bancroft I., Mewes H.W.,
RA Mayer K.F.X., Lemcke K., Schueller C.;
RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA EU Arabidopsis sequencing project;
RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RA Rose M., Hempel S., Entian K.-D., Mewes H.W., Lemcke K., Mayer K.F.X.;
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RA EU Arabidopsis sequencing project;
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL079344; CAB45328.1; -.
DR EMBL; AL161575; CAB79726.1; -.
DR F1R; T09931; T09931.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0004551; F:nucleotide diphosphatase activity; IEA.
DR GO; GO:0009117; P:nucleotide metabolism; IEA.
DR InterPro; IPR002591; Phosphodiester.
DR Pfam; PF01663; Phosphodiester; 1.
KW Hydrolase.
SQ SEQUENCE 496 AA; 54678 MW; 8DC2B4346121D732 CRC64;

Query Match      15.5%; Score 743.5; DB 10; Length 496;
Best Local Similarity 41.0%; Pred. No. 2e-54;
Matches 159; Conservative 71; Mismatches 141; Indels 17; Gaps 9;

QY 157 DLPVILFNDGGRASYLYTWDTLMPNINKLTCGHSKY-WFAMYPTKTFNHYTIVTG 215
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

Db 105 DKPWLLISSDGRF--FGYQFKTLPISIRHLIANGTEAGTGLIPFPTLTLPNHYSIVTG 162
QY 216 LYPESHGIIDNNYDYNLNKNFSLSKQONNPWWHQPMLTAMYGGLKAATYFWPGSE 275
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 163 LYFAYHGIINHHFVDBETGNVFTMASHE---PEWILGEPLWETVWNGGLKAATYFWPGSE 219
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 276 VAINGSF--PSIYMPYNGSVPEERISTLLKWLDPKAEPRFRFTYMYPEEPDSSGHAGG 332
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 220 VH-KGSWNCQGLQCNVNGSVDPDDRVDITLSYFDLPSEIIPSEMTLYPEDPDHGHQVHG 278
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 333 PVSAVVKALQVVDHAFGMLMEGLKQRLNHCNVNIIILLADHGMDDQTCYNKMEYMTDYFPR 392
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 279 PDPQITEAVYNTDRILGLDLEKRGIFEDVTIMVGDHGMVGTCDKCLVVLDDLPW 338
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 393 INF---PYMYEGAPAPRIRAHNI PHDFSFNSSEIIVRNLSCKRKP--QHKFPYLTPLPKR 447
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 339 IKPSSNVQYITPLLAIQPPS-GHDAADIVA-KINELSSGKVENGYKLVKYLKEDLPKR 396
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 448 LHYAKNVRIDKVLHFDVQQW-LAVRSKSNNTCGGNGHGNNEFRSMEAI FLAAGPSFKKTK 507
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 397 LHYVDSDRIPPIIICLVDEGFKEVKSKAKCEGGAHGYDNAFTSMRTIFIGHGFMFSKGR 456
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 508 EVEPFENIEVYNLMCDLLRIQAPNNGT 535
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 457 KVPSEFNVQIYNNVISSILGKAAAPNNGS 484
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 13
Q42974 PRELIMINARY; PRT; 479 AA.
AC Q42974;
DT 01-NOV-1996 (Tremblrel. 01, Created)
DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Nucleotide pyrophosphatase precursor (EC 3.6.1.9) (OSE4) (Nucleotide
DE pyrophosphatase homolog).
GN OSE4 OR B0419B01.2;
OS Oryza sativa (Rice).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzaceae; Oryza.
OX NCBI_TaxID=4530;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=TAIUNG 67;
RA Hsing Y.C., Tsao C.V., Chow T., Hsieh J., Chen Z.;
RL Submitted (APR-1995) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. IR64;
RA Hsing Y.-I.C., Hsu T.-F., Chen Z.-Y., Chung M.-C., Tsou C.-H.,
RA Hsieh J.-S.;
RT "Characterization of a rice early embryogenesis specific gene OSE4.";
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Nipponbare;
RA Sasaki T., Matsumoto T., Yamamoto K.;
RT "Oryza sativa nipponbare (GA3) genomic DNA, chromosome 1, PAC
clone: P0419B01.";
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
CC -!- CATALYTIC ACTIVITY: A DINUCLEOTIDE + H(2)O = 2 MONONUCLEOTIDE.
DR EMBL; U25430; AAA67067.1; -.
DR EMBL; AF245483; AA65458.1; -.
DR EMBL; AF003244; BAB56086.1; -.
DR F1R; T03293; T03293.
DR Gramene; Q42974; -.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0004551; F:nucleotide diphosphatase activity; IEA.
DR GO; GO:0009117; P:nucleotide metabolism; IEA.
DR InterPro; IPR002591; Phosphodiester.
DR Pfam; PF01663; Phosphodiester; 1.
KW Hydrolase; Signal.

```

FT SIGNAL 1 19 POTENTIAL.
 FT CHAIN 20 479 NUCLEOTIDE PYROPHOSPHATASE.
 SQ SEQUENCE 479 AA; 52198 MW; 8E209C3DA1B7920 CRC64;

Query Match 15.4%; Score 737.5; DB 10; Length 479;
 Best Local Similarity 42.0%; Pred. No. 6.3e-54;
 Matches 163; Conservative 64; Mismatches 140; Indels 21; Gaps 10;

QY 159 PPVILFSMDGFAEYLTYTWTLPNKLKTCGIHSKY-MRMYPTKTFPHNYTIVTGLY 217
 DB 90 PVVILISSDGFPGVQHKAAAT--PHIRLIGNGTSAATGLVIFPILTFPHNYSTATGLY 147
 QY 218 PSHGIIDNNMDVNLKNFSLSSKEQNNPANHQPWMLTAMYOGKLAATYFPGSEVA 277
 DB 148 PSHGIINNYFPDPISGDYFTSSHE--PKWMLGEPLWVTAADQGIQAATYFPGSEVK 204
 QY 278 INGSF--PSIY-MPYNGSVPPFERISTLLKWLDPKAEPRFVTVYVEPDSSGHAGGPV 334
 DB 205 -KGSWDCPKYCRHYNGSVPPFERVDAIIGYFDLSDENMPQFLTLYFSDPDHQHGVGD 263
 QY 335 SARVICALQVDFHAFGLMEGLKQRLNHCNVNIIILLADHGMDQTCNVQVYMTDYFPRIN 394
 DB 264 DPAITEAVVRIDEMIGRLIAGLEERGVRPVDNVVLGDMVGTCDKLVFLDELAPWK 323
 QY 395 F---FMYEGPAPRIAHNIPHDFFSFS--BEIVRNLSCKPD--QHFKPYLPDLPKR 447
 DB 324 LEEDWVLSMTPLAIR-----PPDDSLPDVVAKMEGLSGKVENGEYLRMYLKEDLFSR 379
 QY 448 LHYAKNVRIDKVLHFDVQOQLAVRSKNTNCGGNHGYNNERSMEALFLAHGSPFKEKT 507
 DB 380 LHYADSYRIPPIIGLPEEGYKVMKSKDNKCGGAGHYDNAFFSNRTIFIAHGPFEGGR 439
 QY 508 EYEPENIEVYNMCDLLRIQAPNNGT 535
 DB 440 VVPSFENVEIYNVIASILNLEPAPNGS 467

RESULT 14
 Q84WJ3
 ID Q84WJ3 PRELIMINARY; PRT; 457 AA.
 AC Q84WJ3;
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE At4g29690.
 OS Arabidopsis thaliana (Mouse-ear cress).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
 OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
 OX NCBI_TaxID=3702;
 RN [1] SEQUENCE FROM N.A.
 RP Shinn P., Chen H.A., Cheuk R., Kim C.J., Bowser L., Carninci P.,
 RA Chan M.M., Chang C.H., Dale J.M., Hayashizaki Y., Hsuan V.W.,
 RA Ishida J., Jones T., Kaniya A., Karlin-Neumann G., Kawai J., Lam B.,
 RA Lee J.M., Lin J., Miranda M., Narusaka M., Nguyen M., Oncidera C.S.,
 RA Palm C.C., Quach H.L., Sakurai T., Satou M., Seki M., Southwick A.,
 RA Tang C.C., Toriumi M., Wong C., Wu H.C., Yamada K., Yu G., Yuan S.,
 RA Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
 RT "Arabidopsis ORF clones";
 RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BT003154; AAO24586.1;
 DR GO; GO:0016787; F:hydrolase activity; IEA.
 DR GO; GO:0009117; P:nucleotide metabolism; IEA.
 DR InterPro; IPR002591; Phosphodiester.
 DR Pfam; PF01663; Phosphodiester, 1.
 SQ SEQUENCE 457 AA; 51233 MW; 3F85F9D8A9131D0D CRC64;

Query Match 14.9%; Score 713.5; DB 10; Length 457;
 Best Local Similarity 38.5%; Pred. No. 6.4e-52;
 Matches 166; Conservative 76; Mismatches 149; Indels 41; Gaps 12;

QY 148 QSQCPGEGFDLPVILFSDMGDFRABLYLTWDTLMPNKLKTCGIHSKY-MRMYPTKTF 206

Db 44 RRQPPKLANPVLVLLISCDGFRFGYQFKTET--PNIDLLISRGTEAKTGLIPVFTMTF 101
 QY 207 PNHYTIVTGLYPESHGIIIDNNMDVNLKNFSLSSKEQNNPANHQPWMLTAMYOGKLA 266
 Db 102 PNHYSTATGYPASHGIIIMNKFTDPVSGELFN----RNLPKRWLGEPLWVTAVNOGLMA 157
 QY 267 ATYFWPQSEVAINGSF--PSIY--MPYNGSVPPFERISTLLKWLDPKAEPRFVTVYMEF 322
 Db 158 ATYFWPQADVH-KGSWNCCKGFCCKAPYNSVPLEERVDILNLYFDLPEREIPDFMALYFD 216
 QY 323 EPDSSGHAGGPVARSVICALQVDFHAFGLMEGLKQRLNHCNVNIIILLADHGMDQTCNVK 382
 Db 217 EPDIQHEYGPDPRVTEAVSKVDKMGRIIMGLKRVKFSVDVHVLGDMGDMATNCDKK 276
 QY 383 MEYMTDYFPRINFFYMEGAPAPRIAHNIPHDFFSFSN-----SEIVRN--- 426
 Db 277 VIIDDLADWIKI-----PADWIQDYS---PVLAMPKGDVKVPGQKNALVRQKME 327
 QY 427 -LSCK--PDQHPKPYLPDLPKRLHYAKNVRIDKVLHFDVQOQLAVRSKNTNCGGNH 483
 Db 328 ALSSGKVGANGFEFLQVYLKENLPORLHYSDDSRIPPIIGWVGEGLMVKQNRVYVQECGTH 387
 QY 484 GYNNERSMEALFLAHGSPFKEKTEVEPEPTEVYNMCDLLRIQAPNNGTHGSLNHL 543
 Db 388 GYDNMFSSMRISFVGYGPRFRGIRKVPSENVQVYNAVAIILGLRPAPNNGSLFTRSL 447
 QY 544 KVPFEPESHAE 554
 Db 448 -LPGETSQVE 457

RESULT 15
 Q8SU82
 ID Q8SU82 PRELIMINARY; PRT; 457 AA.
 AC Q8SU82;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Nucleotide pyrophosphatase-like protein (EC 3.6.1.9).
 GN T16L4.200 OR At4G29690.
 OS Arabidopsis thaliana (Mouse-ear cress).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
 OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
 OX NCBI_TaxID=3702;
 RN [1] SEQUENCE FROM N.A.
 RP Bevan M., Rose M., Hempel S., Entian K.-D., Bancroft I., Mewes H.W.,
 RA Mayer K.F.X., Lemcke K., Schueller C.;
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
 RN [2] SEQUENCE FROM N.A.
 RP EU Arabidopsis sequencing project;
 RA Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
 RN [3] SEQUENCE FROM N.A.
 RP Rose M., Hempel S., Entian K.-D., Mewes H.W., Lemcke K., Mayer K.F.X.;
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 RN [4] SEQUENCE FROM N.A.
 RP EU Arabidopsis sequencing project;
 RA Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AL079344; CAB45329.1;
 DR EMBL; AL161575; CAB79727.1;
 DR PIR; T09332; T09932.
 DR GO; GO:0016787; F:hydrolase activity; IEA.
 DR GO; GO:0004551; F:nucleotide diphosphatase activity; IEA.
 DR GO; GO:0009117; P:nucleotide metabolism; IEA.
 DR InterPro; IPR002591; Phosphodiester.
 DR Pfam; PF01663; Phosphodiester, 1.
 DR Hydrolase.
 KW Hydrolase.
 SQ SEQUENCE 457 AA; 51261 MW; 3B95E6C0AE1B1215 CRC64;

Query Match		14.8%;	Score 712.5;	DB 10;	Length 457;
Best Local Similarity		38.5%;	Pred. No. 7.8e-52;		
Matches 166;		Conservative 76;	Mismatches 148;	Indels 41;	Gaps 12;
QY	148	QSQCPGEGDLPVILFSDGPRABYLYTWTLMNINKLKTGCIHSKY-NRAMYPTKTP	206		
Db	44	RRQPQPKLNKEVLLISCDGFRFGYQFKTET--FNIDLLISRGTEAKTGLIPVPTMTF	101		
QY	207	PNHYTIVTGLYPESHGIIDNNYDYNLKNFSLSSKEQNPAWHGQPMWLTAMYQGLKA	266		
Db	102	PNHYSIATGLYPASGIIIMNKTDPVSGELFN-----RNINFKWLGEPFWTAVNQGLMA	157		
QY	267	ATYFWPGSEVAINGSF--PSIY--MPYNGSVPFEEIRSTLLKWLDPKAERPRFVTMYFE	322		
Db	158	ATYFWPGADVH-KGSWNCCKGCKAPXNVSVPLEERVDTILNYFDLPEREIPDFMAYFD	216		
QY	323	EPDSSGHAGGPVSARVICALQVVDHAFQMLMEGLKQRLNHCNVIILLADHGMQOTYCNK	382		
Db	217	EPDIQGHYGPDDPRVTEBAVSKVDKMGRIIMGLEKRVFSDVHVILGDHGMVTCNCK	276		
QY	383	MEYMTDYFPRINFFYMYGPAPRIRAHNIPHDFFSFN-----SEEIVRN---	426		
Db	277	VIIYIDDADWIKI-----PADWIODYS---PVLAMNPRWGKDVKNPGQKNAELVRKWE	327		
QY	427	LSCRK--PDQHKPYLTPDLPKRLHYAKNVRIDKHLFVDOQWLAVRSKNTNCGGNH	483		
Db	328	ALSSGKVANGEFLQVLYLKENLPQRLHYSDSSRIPIIGMWGEGLMVKQRTYVQECSTH	387		
QY	484	GYNNEFRSMEATFLAHGSPFKEKTEVEPENIEVYNLACDLLRIOPAPNNGTHGSLNHL	543		
Db	388	GYDNMFFSNRSIFVGYGFRFRGCIKVPSEFENVQVINAENAILGLRPAPNNGSSLFTRSLL	447		
QY	544	KVPFVEPSSHAE	554		
Db	448	LPFGETSQVE	457		

Search completed: July 6, 2004, 13:19:49
Job time : 52 secs

This Page Blank (uspto)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 6, 2004, 12:47:02 ; Search time 18 Seconds
(without alignments)
2531.188 Million cell updates/sec

Title: US-10-005-480A-743

Perfect score: 4804

Sequence: 1 MESTLTLATEQPVKNTLKK.....QPVSEILQKLYLPTFFETI 875

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	4804	100.0	875	1 NPP3_HUMAN	O14638 h ectonucle
2	3982	82.9	875	1 NPP3_RAT	P97675 r ectonucle
3	2498.5	52.0	925	1 NPP1_HUMAN	P22413 h ectonucle
4	2434	50.7	906	1 NPP1_MOUSE	P06802 m ectonucle
5	2405	50.1	906	1 NPP1_RAT	Q924c3 r ectonucle
6	2111	43.9	862	1 NPP2_MOUSE	Q9186 m ectonucle
7	2091.5	43.5	863	1 NPP2_HUMAN	Q13822 h ectonucle
8	2043.5	42.5	885	1 NPP2_RAT	Q64610 r ectonucle
9	434.5	9.0	742	1 YCR6_YEAST	P25353 saccharomyc
10	412.5	8.6	493	1 YEB6_YEAST	P39997 saccharomyc
11	301	6.3	61	1 PP1_BOVIN	P15396 bos taurus
12	130	2.7	476	1 TNAG_HUMAN	Q91jw2 homo sapien
13	129	2.7	369	1 PP11_HUMAN	P21128 homo sapien
14	126	2.6	2004	1 YP73_YERPE	Q8zdj2 versinia pe
15	121	2.5	4543	1 LRPI_CHICK	P98157 gallus gall
16	119	2.5	1378	1 WR32_ARATH	Q9fh83 arabidopsis
17	116.5	2.4	758	1 YAP3_SCHPO	Q09782 schizosach
18	115.5	2.4	704	1 SSP2_BOMMO	P20613 bombyx mori
19	114	2.4	1106	1 STC_DROME	P40798 drosophila
20	114	2.4	4544	1 LRPI_HUMAN	Q07954 homo sapien
21	113.5	2.4	368	1 NUGL_HUMAN	Q9y2c4 homo sapien
22	113.5	2.4	1808	1 TENA_CHICK	P10039 gallus gall
23	113	2.4	474	1 KLF4_MOUSE	Q60793 mus musculu
24	112.5	2.3	322	1 PNUI_SCHPO	Q10480 schizosach
25	112.5	2.3	854	1 LDLR_CFRIG	P35950 cricetus
26	112.5	2.3	2352	1 MOKC_SCHPO	Q9uul4 schizosach
27	112	2.3	879	1 LDLR_RAT	P35952 rattus norv
28	111	2.3	329	1 NUCI_YEAST	P08466 saccharomyc
29	111	2.3	662	1 FAS1_SCHAM	P10675 schistocer
30	111	2.3	1442	1 DP03_UREPA	Q9pqb4 ureaplasma
31	110	2.3	1700	1 BAR3_CHITE	Q03376 chironomus
32	110	2.3	1926	1 LPH_RABIT	P09849 cryptotagus
33	109.5	2.3	871	1 SUI1_HUMAN	Q81w6 homo sapien

RESULT 1

NPP3_HUMAN

ID NPP3_HUMAN STANDARD; PRT; 875 AA.

AC O14638;

DT 28-FEB-2003 (Rel. 41, Last Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 28-FEB-2003 (Rel. 41, Last annotation update)

DE Ectonucleotide pyrophosphatase/phosphodiesterase 3 (E-NPP 3)

DE (Phosphodiesterase I/nucleotide pyrophosphatase 3) (Phosphodiesterase

I beta) (PD-beta) (CD203c antigen) [includes: Alkaline

DE phosphodiesterase I (EC 3.1.4.1); Nucleotide pyrophosphatase

DE (EC 3.6.1.9) (NPPase)].

GN ENPP3 OR PDNP3.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Prostate;

RX MEDLINE=98008933; PubMed=9344668;

RA Piao J.-H., Goding J.W., Nakamura H., Sano K.;

RT "Molecular cloning and chromosomal localization of PD-beta (PDNP3), a

new member of the human phosphodiesterase I genes.";

[2]

RP SEQUENCE OF 189-875 FROM N.A.

RA Hou S., Wohldmann P., Le T.;

RL Submitted (SEP-1998) to the EMBL/GenBank/DBJ databases.

CC -!- FUNCTION: Cleaves a variety of phosphodiester and phosphosulfate

bonds including deoxynucleotides, nucleotide sugars, and NAD (By

similarity).

CC -!- CATALYTIC ACTIVITY: Hydrolytically removes 5'-nucleotides

successively from the 3'-hydroxy termini of 3'-hydroxy-terminated

oligo-nucleotides.

CC -!- CATALYTIC ACTIVITY: A dinucleotide + H(2)O = 2 mononucleotide.

CC -!- SUBCELLULAR LOCATION: Type II membrane protein.

CC -!- SIMILARITY: Contains 2 somatomedin-B type domains.

CC -!- DATABASE: NAME=PROW; NOTE=PROW 1:47-49(2000);

WWW=http://www.ncbi.nlm.nih.gov/prow/guide/575821061.g.htm".

CC

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL outstation -

the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way

modified and this statement is not removed. Usage by and for commercial

entities requires a license agreement (see http://www.isb-sib.ch/announce/

or send an email to license@isb-sib.ch).

CC

CC EMBL; AF005632; AAC51813.1; -;

CC EMBL; AC005587; AAD05192.1; -;

CC Genew; HGNC:3358; ENPP3.

CC MIM; 602182; -;

CC GO; GO:0005897; C:integral to plasma membrane; TAS.

CC GO; GO:0004551; F:nucleotide diphosphatase activity; TAS.

CC GO; GO:0004528; F:phosphodiesterase I activity; TAS.

CC

DR MIM; 602475; -- C: integral to membrane; TAS.
 DR GO; GO:0016021; F: nucleotide diphosphate activity; TAS.
 DR GO; GO:0004551; F: energy pathways; TAS.
 DR GO; GO:0006091; P: phosphate metabolism; TAS.
 DR GO; GO:0006796; P: response to nutrients; TAS.
 DR GO; GO:0007584; P: response to nutrients; TAS.
 DR InterPro; IPR001604; Endonuclease.
 DR InterPro; IPR002591; Phosphodiesterase.
 DR InterPro; IPR001212; Somatomedin_B.
 DR Pfam; PF01223; Endonuclease; 1.
 DR Pfam; PF01663; Phosphodiesterase; 1.
 DR Pfam; PF01033; Somatomedin_B; 2.
 DR PRINTS; PR00022; SOMATOMEDINB.
 DR SMART; SM00477; NUC; 1.
 DR SMART; SM00201; SO; 2.
 DR PROSITE; PS00524; SOMATOMEDIN_B; 2.
 KW Glycoprotein; Transmembrane; Repeat; signal-anchor; Hydrolase;
 KW Multifunctional enzyme; Polymorphism; Disease mutation;
 KW Phosphorylation.
 FT DOMAIN 1 76 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 77 97 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN) (POTENTIAL).
 FT 98 925 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 104 144 SOMATOMEDIN-B LIKE 1.
 FT DOMAIN 145 188 SOMATOMEDIN-B LIKE 2.
 FT DOMAIN 191 591 PHOSPHODIESTERASE.
 FT DOMAIN 654 925 NUCLEASE.
 FT ACT_SITE 256 256 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 179 179 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 285 285 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 341 341 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 477 477 N-LINKED (GLCNAC. .) (POTENTIAL).
 Query Match 52.0%; Score 2498.5; DB 1; Length 925;
 Best Local Similarity 53.1%; Pred. No. 4e-171;
 Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;
 QY 10 EQPVKK---NTLK---KYKACIVLLALLVIMSLGLGLGLRLKLEKQGRCKKCPDAS 62
 DB 57 EEPLEKAARARTAKDNTYKVLVLVSVCLVTLGICFGLKPKSCAKVCKSGRCFERT 116
 QY 63 FRLGNCRDVAKRGDCDWPEDTCVESTIWNCKNRCGETLEASLSCSDCLQK 122
 DB 117 F---GNCRCDAAVCLGNCLDYQETCIEPHIWTNCKNRCGETLEASLSCSDCLQK 173
 QY 123 KDCADYKVCQGETSWLENCDDTAQSCQCPGFLPPVILFSLMDGFAEYLYTWDTLMP 182
 DB 174 GDCCLNYSVCQGEKSWVEEPCEINPCQAGFPTPTLLSLDGFRAEYLYTWGLLP 233
 QY 183 NINKLCTGHSKYMPEYTKTFPNHYITVTLGIPESHGIIIDNNYVNLKNFSLSK 242
 DB 234 VISLKKCGTYTKMPEVYTKTFPNHYISIVTLGIPESHGIIIDNNYVNLKNFSLSK 293
 QY 243 EQNPFAWHGQPMWLTAMYGKLAATYFWPGSEVAINGFPISLYMPYNGSVFEEIRISL 302
 DB 294 EKNPFWYGEPIWVTAKYQGLKSGTFWPGSDVEINGFPDIYKMYNGSVFEEIRILAV 353
 QY 303 LKWLDPKAEPRFYTYFEEDSSGHAGPSARVVKALQVVDHAFGLMGLKORNLH 362
 DB 354 LQWLQPKQERPHFYTYLEEDPSGSHSYGPSSEVIKALQVVDHAFGLMGLKORNLH 413
 QY 363 NCNVIILLADHGMQDYCKNMEYTDYFPRNFYVGEPAEIRAHNIPHPDPSFNSSE 422
 DB 414 RCLNLIISDHGMEQSCCKYIYLNKYLGDVKNKVIYGAARLRSDDPKYFNYBG 473
 QY 423 IVNLSCKRQDQHPKPYLTLDPLKRLHYAKNVRIDKVLHFDQW--LAVRSKNTNCGGG 481
 DB 474 IARNSCRENQHPKPYLHFLPKRLHFAKSDRIEPLTFYLDPQWLALNPSEKCYCGSG 533
 QY 482 NHGVNNEFRSMEAFIAGHSFKEKTEVEPFENIEVNLMDLLRLOPAPNNGTHGSLNH 541
 DB 534 FHGSDNVFSNNQALFVYGFGPKHGIEADTFENIEVNLMDLLNLTAPNNGTHGSLNH 593

QY 542 LLKVPFEPFHAEBVSKFVCGFANPLPTESLDQFC--PHLQNSTQLEQVNMNLTOEEI 600
 DB 594 LLKNFYVTKPKHEVHPLVQCFTTN--PRDNLGCSNPSI---LPEDFQTFNLTVAE 649
 QY 601 TATVKVNLFPGRPRVLQKVDHCLLYHREYVSGFKAMPMWSSYTVPOLGCTSPLPPT 660
 DB 650 KLIKHTETLYGRPRVLQKENTICLLSQHQFMGSGQDILMPLMTSYVDR--NDSFSTED 707
 QY 661 VPDCLRADVRVPSESQKCSFYLADKNITHGLYPASNRTSDSQY--DALITSNLVPME 719
 DB 708 FSNCLYQDFRPLSPVHKCSFYKNNTKVSYGFLSPQLNKNSSGIYSEALLTINIVPMYQ 767
 QY 720 EFRKMDYFHSVLLIKHATERNGVNVVSGPIFDYNDYGHFDAPDEITKH---LANTDVI 776
 DB 768 SFQVWXYFHTLLRKYAERNGVNVVSGPVEDFDYDGRCDLSENLQRKRRVIRNOEILI 827
 QY 777 PTHFYVLTSCNKSHTPENCPLDVLFPILPHRTNVSCPEGKPEALWVEERTTAHI 836
 DB 828 PTHFFIVLTSCKDTSTPLHCEN--LDTLAFILPHRTDNSESCVGHKXDSWVEELMLHR 886
 QY 837 ARVRDVELLTGLDFYQDKVPVSEILQLKTYLPTF 871
 DB 887 ARITDVEHITGLSFYQQRKEFVSDILKTLHPTF 921
 RESULT 4
 ID NP1 MOUSE STANDARD; PRT; 906 AA.
 AC P06802;
 DT 01-JAN-1988 (Rel. 06, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Ectonucleotide pyrophosphatase/phosphodiesterase 1 (E-NPP 1)
 DE (Phosphodiesterase I/nucleotide pyrophosphatase 1) (Plasma-cell
 DE membrane glycoprotein PC-1) (IY-41) [includes: Alkaline
 DE phosphodiesterase I (EC 3.1.4.1); Nucleotide pyrophosphatase
 DE (EC 3.6.1.9) (NPPase)].
 GN ENP1 OR PDNP1 OR PC1 OR NPPS.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BALEB/C;
 RX MEDLINE=87165906; PubMed=3104326;
 RA van Driel I.R., Goding J.W.;
 RT "Plasma cell membrane glycoprotein PC-1. Primary structure deduced
 RT from cDNA clones.";
 RL J. Biol. Chem. 262:4882-4887(1987).
 RP [2]
 REVISIONS TO 24; 46-47; 640-641 AND 692, VARIANTS ARG-651 AND SER-680,
 RP AND ALTERNATIVE SPLICING.
 RX MEDLINE=22117315; PubMed=12121276;
 RA Banah I., Sali A., Dubljevic V., Grobhen B., Slegers H., Goding J.W.;
 RT "Structural basis of allozymes of ecto-nucleotide
 RT pyrophosphatase/phosphodiesterase (plasma cell membrane glycoprotein
 RT PC-1) in the mouse and rat, and analysis of allele-specific
 RT xenogeneic antibodies.";
 RL Eur. J. Immunogenet. 29:307-313(2002).
 RN [3]
 RP FUNCTION, AND SEQUENCE FROM N.A.
 RX MEDLINE=91271356; PubMed=1647027;
 RA Rebbe N.F., Tong B.D., Finley E.M., Hickman S.;
 RT "Identification of nucleotide pyrophosphatase/alkaline
 RT phosphodiesterase I activity associated with the mouse plasma cell
 RT differentiation antigen PC-1.";
 RL Proc. Natl. Acad. Sci. U.S.A. 88:5192-5196(1991).
 RN [4]
 RP SEQUENCE OF 203-219 FROM N.A.
 RX MEDLINE=86094275; PubMed=3001713;
 RA van Driel I.R., Wilks A.F., Pietersz G.A., Goding J.W.;
 RT "Murine plasma cell membrane antigen PC-1: molecular cloning of cDNA

and analysis of expression.";
 [5]
 RL Proc. Natl. Acad. Sci. U.S.A. 82:8619-8623(1985).
 RN
 RP PARTIAL SEQUENCE.
 RX MEDLINE=85056299; PubMed=3917281;
 RA Stearne P.A., van Driel I.R., Grego B., Simpson R.J., Goding J.W.;
 RT "The murine plasma cell antigen PC-1: purification and partial amino
 RT acid sequence.";
 RL J. Immunol. 134:443-448(1985).
 RN [6]
 RP DISEASE.
 RX MEDLINE=98324779; PubMed=9662402;
 RA Okawa A., Nakamura I., Goto S., Moriya H., Nakamura Y., Ikegawa S.;
 RT "Mutation in Nps in a mouse model of ossification of the posterior
 RT longitudinal ligament of the spine.";
 RL Nat. Genet. 19:271-273(1998).
 RN
 CC -1- FUNCTION: Has a broad specificity and cleaves a variety of
 CC substrates, including phosphodiester bonds of nucleotides and
 CC nucleotide sugars and pyrophosphate bonds of nucleotides and
 CC as ATP, GTP, CTP, TTP and UTP to their corresponding
 CC monophosphates with release of pyrophosphate. Can hydrolyze
 CC diadenosine polyphosphates and 3',5'-cAMP to AMP. It may play a
 CC role in the regulation of pyrophosphate production, the regulation
 CC of the availability of nucleotide sugars in the endoplasmic
 CC reticulum and Golgi, and the regulation of purinergic signaling
 CC (By similarity).
 CC
 CC -1- CATALYTIC ACTIVITY: Hydrolytically removes 5'-nucleotides
 CC successively from the 3'-hydroxy termini of 3'-hydroxy-terminated
 CC oligo-nucleotides.
 CC
 CC -1- CATALYTIC ACTIVITY: A dinucleotide + H(2)O = 2 mononucleotide.
 CC
 CC -1- SUBUNIT: Homodimer; disulfide-linked.
 CC
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=2;
 CC IsoId=P06802-1; Sequence=Displayed;
 CC Name=1;
 CC IsoId=P06802-2; Sequence=VSP_006748;
 CC
 CC -1- TISSUE SPECIFICITY: SELECTIVELY EXPRESSED ON THE SURFACE OF
 CC ANTI-BODY-SECRETING CELLS.
 CC
 CC -1- PTM: Autophosphorylated as part of the catalytic cycle of
 CC phosphodiesterase/pyrophosphatase activity (By similarity).
 CC
 CC -1- PTM: The N-terminus is blocked.
 CC
 CC -1- DISEASE: Defects in ENPP1 are the cause of the tiree walking
 CC (ttw) phenotype. Ttw mice exhibit ossification of the spinal
 CC ligaments.
 CC
 CC -1- SIMILARITY: Contains 2 somatomedin-B type domains.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; J02700; AAA39893.2; -;
 CC EMBL; M12552; AAA39892.1; -;
 CC PIR; A27410; A27410.
 CC MGD; MGI:97370; Enppi.
 CC GO; GO:0001501; P:skeletal development; IMP.
 CC InterPro; IPR001604; Endonuclease.
 CC InterPro; IPR002591; Phosphodiesterase.
 CC InterPro; IPR001212; Somatomedin_B.
 CC Pfam; PF01223; Endonuclease; 1.
 CC Pfam; PF01663; Phosphodiesterase; 1.
 CC Pfam; PF01033; Somatomedin_B; 2.
 CC PRINTS; PR00022; Somatomedin_B.
 CC SMART; SM00477; NUC; 1.
 CC SMART; SM00201; SO; 2.
 CC PROSITE; PS00524; SOMATOMEDIN_B; 2.
 CC Glycoprotein; Transmembrane; Repeat; Signal-anchor; Hydrolase;

Multifunctional enzyme; Polymorphism; Phosphorylation;
 KW Alternative splicing. CYTOPLASMIC (POTENTIAL).
 KW DOMAIN 1 58 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT TRANSMEM 59 79 (POTENTIAL).
 FT EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 80 906 SOMATOMEDIN-B LIKE 1.
 FT DOMAIN 86 126 SOMATOMEDIN-B LIKE 2.
 FT DOMAIN 127 170 PHOSPHODIESTERASE.
 FT DOMAIN 173 573 NUCLEASE.
 FT DOMAIN 535 906 BY SIMILARITY.
 FT ACT_SITE 238 238 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 161 161 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 267 267 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 323 323 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 459 459 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 567 567 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 624 624 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 630 630 Missing (in isoform 1).
 FT VARIANT 651 651 H -> R (IN ENPP1-B).
 FT VARIANT 680 680 R -> S (IN ENPP1-B).
 SQ SEQUENCE 906 AA; 103175 MW; 068045B0ED0F224D CRC64;
 Query Match 50.7%; Score 2434; DB 1; Length 906;
 Best Local Similarity 51.0%; Pred. No. 1.6e-166;
 Matches 447; Conservative 152; Mismatches 250; Indels 28; Gaps 9;
 QY 10 EQPVKK-----NTLKVKYACIVLALLVMSLGLGLGLKLEKQSGRKKCF 59
 DB 39 EELEKAEARPAKDNVT---YKLSLVLSVCLTILGICIFGLPSCAKVSKNGRCF 95
 QY 60 DASFRGLENCRDVACKRGDCWDFEDTCESTRIMCMKFCRGTREASLCSCSDDC 119
 DB 96 ERTF---SNCRDAAACVSLGNCCLDFQETCEVPTHTWTCNKFRCGEKLSRFVCSADDC 152
 QY 120 LOKKCCADYKSVCOGETSWLENCDTAQOQSCPGFDLPVILFSMDGFRAYLYTWD 179
 DB 153 KTHNCCINYSVCQDKSWVEETCESIDTPCPAEFSPPTLLFSLDGFRAEYLHTWGG 212
 QY 180 LMPNINKLTCGIHSKYMEAMPTKTFPNHYITVITGLYPESHGIIDNNYDYNLNKNSL 239
 DB 213 LLPVISKLKNGTYTKNMEPTKTFPNHYITVITGLYPESHGIIDNNYDYNLNKNSL 272
 QY 240 SKEQNNPAWHGQPMWLTAMTQGLKAATYFPGSEVAINGSPDIYMPYNGSVFPERI 299
 DB 273 KSEKEFNPLWYQPIWTWTANQEVKSGTYFPGSDVEIDGILPDIYKYNGSVFPERI 332
 QY 300 STILLKWLDPKAEPRFYTMFEEDPSGHAGGVSARVIALQVVDVHAFGLMGLKQR 359
 DB 333 LAVLEWLQPSHERPHFTLYLEEDPSGHSHGVSSEVIALQVVDVHAFGLMGLKQR 392
 QY 360 NLHNCVNIILLADHMDQTYCNWMEYMTDYPFRINFFYMGEPAPRIAHNIPHDFFSN 419
 DB 393 GLDKCLNLILLSDHMEQSGCKYVYLNKYLGDVNNVKNVYVYVYVYVYVYVYVYV 452
 QY 420 SEIIVENISCRPDQHPKPYLTPDLPKELHYAKNVRIDKVLFDVDOQ--LAVRKSNINC 478
 DB 453 YEALAKNISCREPNQHFPRYLPKPLKLFHAKSDRIEPLTFYDQQLALNPSERYK 512
 QY 479 GGNHGYNNFRSMEAI FLAHGPSFKTEVEPPEFENIEVYLMCDLLRIQAPNNGTHGS 538
 DB 513 GSGPHGSDNLFNNMQALFYGPAFKHGAEDVSFENIEVYLMCDLLGLIPAPNNGSHGS 572
 QY 539 LNHLLKVPYBPSHAEVSKSVCFANPLPTESIDCFPHLQNSLQLEQVQNLNLQEQ 598
 DB 573 LNHLLKVIYNSHPKESGFLSQ-----PIKTSNDLGCCTCDPMIVIPKDFEKLNLITE 628
 QY 599 EITATVKVNLFPGRPVRLQKNVDHCLLYHREYVSGFGKAMEMPMWSSYTVFQLGTSPLP 658
 DB 629 DVDDIYHMTVPYGRPIILKQHHVCLLQKQQQCLFGTGLSLLMPLWASYTF--LRNDQFSR 686
 QY 659 FTVPCLEADVRVPPSESKCSFYIADKNVTHFLYPPASNRTSDSQY-DALITSNLVPM 717

Db 697 DDFNSCLYQDLRIPLSPVHKCSYKSKSLSYGFLTPPLNRVSNHXYSEALLTGNVPM 746
 QY 718 YEEPRKMDYFHSVLKIKHATERNGVNVSGPIFDYNDYDGHDADEITKH---LANTDV 774
 Db 747 YQSFQVILWYHLDLTLQRYAHERNGINVSGPVDFDYGYSLSLEILKQNSVRVRSQEI 806
 QY 775 PIPHYFVILTSCKNSKHPENCGMLDVLPIIHRPNTWNSCEGKPEALWVERPTA 834
 Db 807 LIPHFVILTSCKNSKHPENCGMLDVLPIIHRPNTWNSCEGKPEALWVERPTA 834
 QY 835 HIARVRDVELLGLTDFYQKQVQVSVBILOKLYLPTF 871
 Db 866 HRAVRTDVELLGLTDFYQKQVQVSVBILOKLYLPTF 902

RESULT 5

NPPI RAT STANDARD; PRT; 906 AA.
 ID Q924C3; Q920C8;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Ectonucleotide pyrophosphatase/phosphodiesterase 1 (E-NPP 1)
 DE (Phosphodiesterase I/nucleotide pyrophosphatase 1) (Plasma-cell
 DE membrane glycoprotein PC-1) [includes: Alkaline phosphodiesterase I
 DE (EC 3.1.4.1); Nucleotide pyrophosphatase (EC 3.6.1.9) (NPPase)].
 GN ENPP1 OR PDNP1 OR PC1 OR NPPs.
 OS Rattus norvegicus [Rat].
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus;
 OC NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND VARIANTS.
 RC STRAIN=Lewis, Louvain, and Wistar;
 RX MEDLINE=22117315; PubMed=12121276;
 RA Banath I., Sali A., Dubljevic V., Grobden B., Slegers H., Goding J.W.;
 RT "Structural basis of allotypes of ecto-nucleotide
 RT pyrophosphatase/phosphodiesterase (plasma cell membrane glycoprotein
 RT PC-1) in the mouse and rat, and analysis of allele-specific
 RT xenogeneic antibodies.";
 RL Eur. J. Immunogenet. 29:307-313(2002).
 CC -!- FUNCTION: Has a broad specificity and cleaves a variety of
 CC substrates, including phosphodiester bonds of nucleotides and
 CC nucleotide sugars and pyrophosphate bonds of nucleotides and
 CC nucleotide sugars. Can hydrolyze nucleoside 5' triphosphates such
 CC as ATP, GTP, CTP, TTP and UTP to their corresponding
 CC monophosphates with release of pyrophosphate. Can hydrolyze
 CC diadenosine polyphosphates and 3',5'-cAMP to AMP. It may play a
 CC role in the regulation of pyrophosphate production, the regulation
 CC of the availability of nucleotide sugars in the endoplasmic
 CC reticulum and Golgi, and the regulation of purinergic signaling
 CC (By similarity).
 CC -!- CATALYTIC ACTIVITY: Hydrolytically removes 5'-nucleotides
 CC successively from the 3'-hydroxy termini of 3'-hydroxy-terminated
 CC oligo-nucleotides.
 CC -!- CATALYTIC ACTIVITY: A dinucleotide + H(2)O = 2 mononucleotide.
 CC -!- SUBUNIT: Homodimer; disulfide-linked (By similarity).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=2;
 CC IsoId=Q924C3-1; Sequence=Displayed;
 CC Name=1;
 CC IsoId=Q924C3-2; Sequence=VSP_006749;
 CC -!- PTM: Autophosphorylated as part of the catalytic cycle of
 CC phosphodiesterase/pyrophosphatase activity (By similarity).
 CC -!- SIMILARITY: Contains 2 somatomedin-B type domains.

 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC -----

CC EMBL; AF340185; AK69653.1; --
 CC EMBL; AF340186; AK69654.1; --
 CC EMBL; AF320054; AL26912.1; --
 CC InterPro; IPR001604; Endonuclease.
 CC InterPro; IPR002591; Phosphodiesterase.
 CC InterPro; IPR001212; Somatomedin_B.
 CC Pfam; PF01223; Endonuclease; 1.
 CC Pfam; PF01663; Phosphodiesterase; 1.
 CC Pfam; PF01033; Somatomedin_B; 2.
 CC PRINTS; PR00022; SOMATOMEDINB.
 CC SMART; SMO0477; NUC; 1.
 CC SMART; SMO0201; SO; 2.
 CC PROSITE; PS00524; SOMATOMEDIN_B; 2.
 CC Glycoprotein; Transmembrane; Repeat; Signal-anchor; Hydrolase;
 CC Multifunctional enzyme; Polymorphism; Phosphorylation;
 CC Alternative splicing.
 CC DOMAIN 1 58 CYTOPLASMIC (POTENTIAL).
 CC TRANSMEM 59 79 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 CC (POTENTIAL).
 CC FT EXTRACELLULAR (POTENTIAL).
 CC FT SOMATOMEDIN-B LIKE 1.
 CC FT SOMATOMEDIN-B LIKE 2.
 CC FT PHOSPHODIESTERASE.
 CC FT NUCLEASE.
 CC FT BY SIMILARITY.
 CC FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT CARBOHYD 161 161 N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT CARBOHYD 267 267 N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT CARBOHYD 323 323 N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT CARBOHYD 459 459 N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT CARBOHYD 567 567 N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT CARBOHYD 624 624 N-LINKED (GLCNAC. . .) (POTENTIAL).
 CC FT VARSPLIC 630 630 Missing (in isoform 1).
 CC FT /FTID=VSP_006749.
 CC FT VARIANT 440 442 RPT -> NPF (IN STRAIN WISTAR).
 CC FT VARIANT 457 457 A -> T (IN STRAIN LEW).
 CC FT VARIANT 555 555 M -> I (IN STRAIN LEW).
 CC FT VARIANT 568 568 E -> G (IN STRAIN WISTAR).
 CC FT VARIANT 583 583 T -> V (IN STRAIN LEW).
 CC FT VARIANT 592 592 F -> V (IN STRAIN LEW).
 CC FT VARIANT 624 624 N -> K (IN STRAIN LEW).
 CC FT VARIANT 640 640 N -> H (IN STRAIN LEW).
 CC FT VARIANT 774 774 V -> I (IN STRAIN LEW).
 CC FT VARIANT 806 806 N -> I (IN STRAIN LEW).
 CC FT VARIANT 850 850 T -> I (IN STRAIN LEW).
 CC FT VARIANT 898 898 H -> Q (IN STRAIN LEW).
 CC SQ SEQUENCE 906 AA; 102942 MW; 71F56780B279A919 CRC64;

Query Match 50.1%; Score 2405; DB 1; Length 906;

Best Local Similarity 50.9%; Fred. No. 1.9e-164;

Matches 445; Conservative 146; Mismatches 261; Indels 22; Gaps 9;

Qy 10 EQPVKK---NTLK---KYKIACIVLLALLVIMSLGLGLKLEKQSGCRKKCFDAS 62
 Db 39 EEPLAEKARAKTADNTYKVLVSVLVCVLTILGCI FGLKPSCAKEVKSGKRCFERT 98
 Qy 63 FRGLNCRCDVAKDGDCCDWPDETCVETPIWMKFRGCTEFLASLCSDDCLQK 122
 Db 99 F---SNCRDAAACVSLGNCCLDFOETCTVEPTHTWCNKRFCGRKLSRFVSCADDDCAH 155
 Qy 123 KDCADYKVCQGETSWLENCETDAQQCQCPGDFLPPVILFSDMDGPPRAEVLTYWDTLMP 182
 Db 156 NDCCIYSSVCQEKSKSWEACETTDAPCPAEFFSPPTLLFLSDGPPRAEVLTYWDTLMP 215
 Qy 183 NINKLTCGHSKYRAMPYPTTTPNHYTIVTGLYPESHGIDNNMYDNLNKNFSLSK 242
 Db 216 VTSKLNCCYTKNMRPVPTKTFPNHYSIVTGLYPESHGIDNNMYDNLNKNFSLSK 275
 Qy 243 EQNNPAWHGQPMWLTAMYGKLAATYFWPGSEVAINGSFPSIYMPYNGSVPFPERISTL 302
 Db 276 EKENPLWYKQPIWVTANHQEVRSYGTYPWPGSDVEIDGLPDIYKYNVSVPFPERILAV 335

QY 303 LKWLDFKABRPFRYTYMFEEDSSGHAGPVSARVIALQVVDHAFGLMGLKQRLNH 362
D 336 LEWLQLPYSRPHFYTLYLEEDSSGHSGPVSSEVIALQVVDHAFGLMGLKQRLNH 395
QY 363 NCYNIILLADHGMQDYCNKQEMTYDFFRNFYFEGAPRIRAHNIPHPDFFSBNSE 422
D 396 KCLNLILISDHGMEQSCSKYVYLNKYLGDVNNKVVYVGPFAARLPTEVPYVFNSEA 455
QY 423 IVNLSCKPQDHFKEVLPDLPKRLHYAKNVIDKHVLFVDOOW-LAVRSKNTNCGGG 481
D 456 LAKNLSRETNQHFYLYLXFLPKRLHFAKNDRIEPLTFYLPQWOLANPSERKYCGSG 515
QY 482 NHGYNNEFRSMEALFIAHGPSFKETVEFFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
D 516 FHGSDNLFNMQLFTCYGPAFKGAEDVSFENIEVYNLMCDLLGLIPAPNNEHSGSLNH 575
QY 542 LLKVPFVPEASHAEVSKFVCGFANPLPTESLDCRPHLQNSTQLEQVNMNLTOBEIT 601
D 576 LLKXPIYTESHPKESFLSQ-----PIKSVSDLGCTCDPSIVPIMDFEKFQNLTTDAVE 631
QY 602 ATKVNLPRPRVRLQXNDHCLLYHREYVSGFKAMRPMWSSYTVPLQGLTSLPLPTV 661
D 632 DVYSMTVPNGRPRNLQKHQVCLLHQOQPLTGYSLDLMLPLWTSYTF--LSNDQFSTDDF 689
QY 662 PCLRADVRVPSQSKCSFYLDKXNTHGFLYPPASVRTSDSQY-DALITSNLVPMYEE 720
D 690 SNCLQDRLIPUSPMHKCSYKSTSLGYGLTPPRLNRVSRQIYSEALLTSNIVPMYQS 749
QY 721 FRKMDYHSHVLLIKHATERNVNVVSGPIPDYNDGHDFDAPD---ETTKHLANTDVP 777
D 750 FQVINYQLDHTVLRVYAQERNVNVVSGPVDYDGRYDSSEILKQNRVIRSQENLIP 809
QY 778 THYFVILSKNKSHTPCNGWLVDLPFIHPRTNVESCEPKALWYEEFTAHIA 837
D 810 THFFVILTSCKLSPLKCTA-LESSAFLLPHRPDNIESTHKGQESAWVEELALHRA 868
QY 838 RYVDVELLTGLDFYDQKQVSEILQKTYLPTF 871
D 869 KYTDVELITGLSFYQDRQESVSELLRLKTHLP 902

RESULT 6

ID NPP2 MOUSE STANDARD; PRT; 862 AA.
AC Q9RLI6; Q9RLG9;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 42, Last sequence update)
DE Ectonucleotide pyrophosphatase/phosphodiesterase 2 (E-NPP 2)
DE (Phosphodiesterase I/nucleotide pyrophosphatase 2) (Phosphodiesterase
DE I alpha) (pD-Ialpha) [includes: Alkaline phosphodiesterase I
DE (EC 3.1.4.1): Nucleotide pyrophosphatase (EC 3.6.1.9) (NPPase)].
GN ENP2 OR NPP2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
RN STRAIN=C57BL/6;
RC MEDLINE=20169177; PubMed=10702660;
RX Pao J.-H., Matsuda Y., Nakamura H., Sano K.;
RA "Assignment of pDnp2, the gene encoding phosphodiesterase I/nucleotide
RT pyrophosphatase 2, to mouse Chromosome 1502.";
RL Cytogenet. Cell Genet. 87:172-174(1999).
[2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield J.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RA "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- CATALYTIC ACTIVITY: Hydrolytically removes 5'-nucleotides
successively from the 3'-hydroxy termini of 3'-hydroxy-terminated
oligo-nucleotides.
CC -!- CATALYTIC ACTIVITY: A dinucleotide + H(2)O = 2 mononucleotide.
CC -!- SUBCELLULAR LOCATION: Type II membrane protein.
CC -!- SIMILARITY: Contains 2 somatomedin-B type domains.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@sib-sib.ch).
CC EMBL; AF123542; AAD46480.1; -;
CC ENBL; BC003264; AAO03264.1; -;
CC MGD; MG1:1321390; Enpp2.
CC InterPro; IPR001604; Endonuclease.
CC InterPro; IPR002591; Phosphodiesterase.
CC InterPro; IPR001212; Somatomedin-B.
CC Pfam; PF01223; Endonuclease; 1.
CC Pfam; PF01653; Phosphodiesterase; 1.
CC Pfam; PF01033; Somatomedin-B; 2.
CC PRINTS; PR00022; SOMATOMEDINB.
CC SMART; SM00477; NUC; 1.
CC SMART; SM00201; SO; 2.
CC PROSITE; PS00524; SOMATOMEDIN_B; 2.
KW Glycoprotein; Transmembrane; Repeat; Signal-anchor; Hydrolase;
KW Multifunctional enzyme.
FT DOMAIN 1 11
FT TRANSMEM 12 30
FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
FT CYTOPLASMIC (POTENTIAL)
FT (POTENTIAL).
FT EXTRACELLULAR (POTENTIAL).
FT SOMATOMEDIN-B LIKE 1.
FT SOMATOMEDIN-B LIKE 2.
FT PHOSPHODIESTERASE.
FT NUCLEASE.
FT BY SIMILARITY.
FT CELL ATTACHMENT SITE (POTENTIAL).
FT N-LINKED (GLCNAC. . .) (POTENTIAL).
FT N-LINKED (GLCNAC. . .) (POTENTIAL).
FT N-LINKED (GLCNAC. . .) (POTENTIAL).
FT N-LINKED (GLCNAC. . .) (POTENTIAL).
FT G -> S (IN REF. 1).
FT G -> T (IN REF. 1).
FT E -> K (IN REF. 1).
FT D -> N (IN REF. 1).
FT SEQUENCE 862 AA; 98886 MW; C43744DEAA85A355 CRC64;
Query Match 43.9%; Score 2111; DB 1; Length 862;
Best Local Similarity 44.1%; Pred. No. 2,1e-143;
Matches 385; Conservative 171; Mismatches 263; Indels 54; Gaps 10;
QY 32 LVMSLGLGLGLG-----LRKLE-----KQSGCRKCKFDASFRGLNCR 70
D 15 LFTFAIGNLCLGFTASRIKRAEDGEPPTVLSDSPWNTSGSKGRCFELVEGPPDCR 74

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC EMBL; L35594; AAA64785.1; --
 CC EMBL; L46720; AAB00855.1; --
 DR EMBL; D45421; BAA08260.1; --
 DR EMBL; BC034961; AAH34961.1; --
 DR EMBL; HGNC:3357; ENPP2.
 DR MIM; 601060; --
 DR GO; GO:0005857; C: integral to plasma membrane; TAS.
 DR GO; GO:004551; F: nucleotide diphosphatase activity; TAS.
 DR GO; GO:0004528; F: phosphodiesterase I activity; TAS.
 DR GO; GO:0008134; F: transcription factor binding; TAS.
 DR GO; GO:0006928; P: cell motility; TAS.
 DR GO; GO:0007186; P: G-protein coupled receptor protein signalin. . .; TAS.
 DR GO; GO:0006796; P: phosphate metabolism; TAS.
 DR InterPro; IPR001604; Endonuclease.
 DR InterPro; IPR002591; Phosphodiesterase.
 DR InterPro; IPR001212; Somatomedin B.
 DR Pfam; PF01223; Endonuclease; 1.
 DR Pfam; PF01663; Phosphodiesterase; 1.
 DR Pfam; PF01033; Somatomedin B; 2.
 DR PRINTS; PR00022; SOMATOMEDINB.
 DR SMART; SM00477; NUC; 1.
 DR SMART; SM00201; SO; 2.
 DR PROSITE; PS00524; SOMATOMEDIN B; 2.
 KW Glycoprotein; Transmembrane; Repeat; Signal-anchor; Hydrolase;
 KW Multifunctional enzyme; Alternative splicing.
 FT DOMAIN 1 11 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 12 30 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN) (POTENTIAL).
 FT DOMAIN 31 863 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 55 98 SOMATOMEDIN-B LIKE 1.
 FT DOMAIN 99 143 SOMATOMEDIN-B LIKE 2.
 FT DOMAIN 145 502 PHOSPHODIESTERASE.
 FT DOMAIN 598 863 NUCLEASE.
 FT ACT SITE 210 210 BY SIMILARITY.
 FT SITE 127 129 CELL ATTACHMENT SITE (POTENTIAL).
 FT CARBOHYD 54 54 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 411 411 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 525 525 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 807 807 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT VARSPLIC 324 324 E -> EESSYGGSPFTPAKPKPKVAPKRRQRRPAPPKRR
 FT RTHRMVHAAETRODK (in isoform 2).
 FT FTID-VSP 006750.
 FT N -> S (IN REF. 1).
 FT D -> H (IN REF. 3).
 FT G -> A (IN REF. 2).
 FT Q -> R (IN REF. 1).
 FT H -> R (IN REF. 1).
 FT P -> L (IN REF. 1).
 FT S -> R (IN REF. 3).
 FT V -> A (IN REF. 3).
 FT Y -> H (IN REF. 3).
 FT Y 769 769
 SQ SEQUENCE 863 AA; 05B8A2E55C464BC CRC64;
 Query Match 43.5%; Score 2091.5; DB 1; Length 863;
 Best Local Similarity 43.1%; Pred. No. 5.3e-142;
 Matches 381; Conservative 176; Mismatches 267; Indels 59; Gaps 10;
 QY 24 ACTVALLVIMSLGLGLGLKLEK-----QSCCKKCFDASF 63
 DB 9 SCQLISLFTAVGUNCLEAFTAHRIKAEWGEGPTVLSDSPWNISGCKRCFLEQ 68
 QY 64 RGLNCRCDVACRQDCCWDPEDTCVETRWCMKPRCGTRLEASLCSCSDCLQK 123
 DB 69 AGPPDCRCDNLKSYSCCHDFDELCLKTARGWECTKRCGEVRNEENACHCEDCLARG 128
 QY 124 DCADYKSCQGTSLWLENCDFQAQSCQCGFDLPVILFMSDMCGFRAEYLTYWDTLMPN 183
 DB 129 DCTNTQVUCKGSHWDDCEIEKAACPAAGFAPPLIIFSVSDGFRAKYKSKWKNPN 188
 QY 184 INKLKTCGIHSKYRMAMYPTKTPFNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSLSSKE 243

DB 189 IEXLRSCGTHSPYMPVPTKTFPNLYTLATGLYPESHGIVGNSMYDFVDFDATHLRGRE 248
 QY 244 QNNPAWHGQPMWLITAMYQCLKAATYFWPGSEVAINGSPFPIYMPYNGSVFEEERISTLL 303
 DB 249 KFNHRWGGQPLWITATKGVKAGTFFW-----SVVIPH-----ERRILITIL 290
 QY 304 KMLDLPKAPRPFYTYPEEPDSSGHAGPGVAVIKALQVVDHAFGLMGLKQRLNHN 363
 DB 291 QMLTLPDHERPSVYAFYSEQDFSGHKYGPFGPEMTNPLREIDKIVQGLMDGLKQLKLR 350
 QY 364 CVNIILLADHGMDQVYCNKMEYMTDYFRINPFYVMEGPAPRIR---AHNIPHPDFPSFNS 420
 DB 351 CVNVIFVGDHGMEDVTCDETEFLSNLTVDDITLVPCTGLIRSKFSNNAKYD-----P 405
 QY 421 EELVRNLSCKDDQHFKPYLTDPDLPRLHYAKNVRIDKHLFVDOQW-----LAVRSKS 474
 DB 406 KAIIANLTCKXPQDFKPYLQKHLKRLFYANNRIEDIHLLVRRMHWAKPLDVYKPK 465
 QY 475 NTNC-GGGNHGYNNEFRSMEALFLAHGSPFKKTEVEPFENIEVNLNMLCDLRIQAPANN 533
 DB 466 SGKCFQGDHGFNDKVNQVTVFVCGYGTFKYTKVPPFENIELYNMCDLGLKAPANN 525
 QY 534 GTHGSLNHLKVPFVEPDSHAEVSKFSVCGFANPLPTESLDCFC-PHLQNSTQLEQVNM 592
 DB 526 GTHGSLNHLRTNTPRTMPEEVRNYPGIMYLSQDFDLGCTCDDKVEPKNKLDELNKR 585
 QY 593 LNLQTEBITATVKVNLPGFRPRVLOKNDHCLLYHREYVSGFGKAMPMPSSYTVPOLG 652
 DB 586 LHTK-----GSTERHLLYGRPAVLYR-TEYDILYHTDFESGYSEIFLPLMTSYTVSKQA 640
 QY 653 DTSPDPPTVDDCLRADRVPPSSQKSFYLDKXNTHGFLYPPASRTSOSQDALITS 712
 DB 641 EVSSVPDLHTSCVRPDRVSPFSQNCIAYKXDKQMSYGLFPFPLSSPEAKYDAELVT 700
 QY 713 NLVPMVEEPRKMDYFVHSLIKHATERNVNVSGPIFDYNDYDGLDHDTEKIKQYVEGS 772
 DB 701 NVPMYPAKRVNYPQVRLVKYASERNVNVISGLPIFDYDGLDHDTEKIKQYVEGS 760
 QY 773 DVPIPTHYVLTSCNKSHTPENCQWLDVLPFIIPHRPTNVESCEGKPEALWBERF 832
 DB 761 SPIPVTHYIITSCLDTQPADKCDGSLVSSFILPHRPDNEESSCSSEDESKWVEELM 820
 QY 833 TAHIAVRVDELLTGLDFYQDKQVQVSEILOLKYLPFTFTTI 875
 DB 821 KKHARVRDIEHLTSLDFFRKTSRYPPELLTKYLYHTESEI 863
 RESULT 8
 NPP2_RAT
 ID_NPP2_RAT STANDARD; PRT; 885 AA.
 AC Q646I0;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Ectonucleotide pyrophosphatase/phosphodiesterase 2 (E-NPP 2)
 DE (Phosphodiesterase I/nucleotide pyrophosphatase 2) (Phosphodiesterase I alpha) (PD-Ialpa) [Includes: Alkaline phosphodiesterase I (EC 3.1.4.1); Nucleotide pyrophosphatase (EC 3.6.1.9) (NPPase)].
 GN ENPP2 OR NPP52.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OC NCBI_TaxID=10116;
 RN [1]
 RN SEQUENCE FROM N.A.
 RC STRAIN=Sprague-Dawley; TISSUE=Brain;
 RX MEDLINE=95050605; PubMed=7961762;
 RA Narita M., Goto J., Nakamura H., Sano K.;
 RT "Molecular cloning, expression, and localization of a brain-specific
 RT phosphodiesterase I/nucleotide pyrophosphatase (pd-Ialpa) from rat
 RT brain.";
 RL J. Biol. Chem. 269:28235-28242 (1994).

[illegible]

QY	233	LNKNFSSLSKEQNPAWHGQPMWLTAMVYGLKAATYFWPGSEVAINGSPFSIINPINGS	299
Dd	235	FDASFHLGRGEKFNHRWGQPLWTATKQGVRACTFFW-----SVS	276
QY	293	VPPERISTLLKWLDLPKAEPRFYTWYEEDSDSHAGGPVSARVIKALQVDHAPGML	352
Dd	277	IPHERRIITLQLMSLPDNERPSVAFYSEQDFSGHKYGPPGPEWTHLEIDTKVTQGL	336
QY	353	MEGLKORNLHCNVNIILLADHGMDQYCNCKMYMTDYDFRINFYYMGEPAPIRAHNIP	412
Dd	337	MDGLKQLRLHRCNNVIFVGDHGMEDVTCDRTEFLSNLTNVDDITLVPTGLGRAKSIN	396
QY	413	HDFSFSNEEIVRNLSCRKDDQHFKYLPTDIDLPKRLHYAKNRVIDKVHLFVDOOM----	467
Dd	397	NS--KYDPKTIIANLTCKPDQHFKPDKQHLFPKLHYANNRRIEDIHLVDRRHVARVARK	454
QY	468	LAVRSKSNTNC-GGGNHGYNNSFRSWEAIFAHGSPSFKEKTEVPFFENIEVYNLMCDLL	525
Dd	455	PLDVYTKFGSKCFTQGDRGFNDKVNSTQTVFVGCGPTFKYRTKVPFFENIELYNMCDLL	514
QY	526	RTPAPNNGTHGS LNHLLKVPFYPEGHABEVSKFCGFANPLPTESLDCFC-PHLQNST	584
Dd	515	GLKPAPNNGTHGS LNHLIRTNTTRPTMDDEVSRPNYPGIMYLQSEFDLGCTCCDKVEPKN	574
QY	585	GLEQVNMNLN-----TQEETATVKV----NALPFGRPRVLQKNVDHC	623
Dd	575	KLEEELNKSLHTKGSTEATGKFRGSKHENKKUNGSVEPRKHLLYGRPAVLVR-TSYD	633
QY	624	LYIHREYVSGFKAMRPMMSSYTPVLGDTSPLPTVPDCLRADRVVRPPSSQCSFYL	683
Dd	634	LIYHTDPSGYSEIFLMPLWTSYITSQAQESSIPEHLINCVRPDRVSPGFSQNCLAYK	693
QY	684	ADKNITHGLFYPPASNTSSQDALITSNLVMYEEFRKMWDYFHSVLLIKHATERNGV	743
Dd	694	NDKQMSGYGLFPPLYLSSPEAKYDAFLTNNVMPYAFKRWAYFORVLVKYASERNGV	753
QY	744	NNVSGPIEDNYDGHDADDEITXHLANTDVPITPHYFVVLTSCKNKSHTPENCGLWDV	803
Dd	754	NVISGPIEDNYDGLURDEDEIKOYVGSGSIPTPHYSIIISCLDFTOPADKCDGPLSV	813
QY	804	LPFIIPHRTNVESCEGKPEALWVERFRTAHIARVDRVELLGLTFYOQKQVQPVSEILQ	863
Dd	814	SSFILPHRPDNDESCNSSDESQKVEBLMKMHARTVRDIEHLTGLODFYRKTSRYSEILT	873
QY	864	LKTYLPTFTTTI 875	
Dd	874	LKTYLHTYESEI 885	
RESULT 9			
YCR6_YEAST STANDARD; PRT; 742 AA.			
AC	P25353; Q8NIL9;		
DT	01-MAY-1992 (Rel. 22, Created)		
DT	10-OCT-2003 (Rel. 42, Last sequence update)		
DT	10-OCT-2003 (Rel. 42, Last annotation update)		
DE	Hypothetical protein YCR026C.		
GN	YCR026C OR YCR26C OR YCR246.		
OS	Saccharomyces cerevisiae (Baker's yeast).		
OC	Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;		
OC	Saccharomycetales; Saccharomycetaceae; Saccharomycetes.		
OX	NCBI_TaxID=4932;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=S288c;		
RX	MEDLINE=92244336; PubMed=1574125;		
RA	Oliver S.G., van der Aart Q.J.M., Agostoni-Carbone M.L., Aigle M.,		
RA	Alberghina L., Alexandraki D., Antoine G., Anwar R., Ballesta J.P.G.,		
RA	Benit P., Barben G., Bergantino E., Biteau N., Bolle P.-A.,		
RA	Bolotin-Fukuhara M., Brown A. J. P., Brown R., Buhler J.-M.,		
RA	Cargnani G., Chanet R., Contreras R., Crouzet M., Daiganan-Fornier B.,		
RA	De Haan M., Defoor E., Delgado M.D., Demolder J., Doira C., Dubois E.,		
RA	Dujon B., Duesterhoeft A., Erdmann D., Esterban M., Fabre F.,		

Matches 126; Conservative 72; Mismatches 154; Indels 95; Gaps 22;
QY 150 SQCEGFDLP-----VILPNDGFRAYL---VTWTLMPNINK 186
DB 47 SKCFKPDNGERTIANSTYFNGTHDFKTLTILISIDGPHPLIDAKYT--PFLYNLEN 104
QY 187 LKTCG---IHSKYMRYMTKTFPPNHYTIVTGLYPESHGIIIDNNMKNKTSLSK 242
DB 105 LRSFYDNIITAPYKPSFTQFPNHSWVTKYPIEHGIVSNIFWD-----NFTSEF 159
QY 243 EONY---PAWH-QOPW--LTAMYQG-LKAAFYWFGGEVAL--NGSPSPSYMP----- 288
DB 160 RPNLLDARIINSNTADPIWQLLOTESQGEYKVATHMFWGSEVYVDHGVPRERMPFYFGK 219
QY 289 YNGSVPPERISTLLKWLDPK-AERPRFYMTFEBPDGSGHAGG--PVSARVIALQV 345
DB 220 FNOEKLQDKLAQIFRIDFQPKDRPDLVISPNDVSGHSGFGYDLKDLKLIGEV 279
QY 346 DHAFGLMEGLKQRLNHCUNILLADHGDQYCNMWEYTDY-----FPR-----INFF 396
DB 280 DGFELDLIEGLQKLNKLSINVMIVSDHGMNSVANDGEHVWVERVFPADAMSAFISHL 339
QY 397 YMYEGPAPRIRAHNIPHDFFSFNSEETVRLNLSCKPKDQHPKPYLTPLDKRLH----- 449
DB 340 Y-NEGPMWVCLKN-PED-----KQWICOLIEAQLEKAYGEISRKHFVILKEDF 387
QY 450 -----YAKVRIDKVLHVDQQLAVRSKNTNCG-GGNHGYN-NEFRSMEA 494
DB 388 DPSKYPQYDNKRHYRDVGDVILADEYIAIVKEMGDVPIGIMTHGYNFNCSKAS 447
QY 495 IFLAHGSPFKEKTEVEFENIEVYNLM 521
DB 448 IFICGMPFNEV-VPFENIEVYNML 473

RESULT 11
PPD1_BOVIN STANDARD; PRT; 61 AA.
AC P15396;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Phosphodiesterase I (EC 3.1.4.1) (5'-exonuclease) (5'-nucleotide
phosphodiesterase) (Fragment).
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE.
RC TISSUE=Intestine; PubMed=2989287;
RX MEDLINE=85234541; PubMed=2989287;
RA Culp J.S., Blytt H.J., Hermodson M., Butler L.G.;
RT "Amino acid sequence of the active site peptide of bovine intestinal
5'-nucleotide phosphodiesterase and identification of the active
site residue as threonine.";
RT J. Biol. Chem. 260:8320-8324 (1985).
CC -I- CATALYTIC ACTIVITY: Hydrolytically removes 5'-nucleotides
successively from the 3'-hydroxy termini of 3'-hydroxy-terminated
oligo-nucleotides.
CC PIR: A25274; A25274.
DR InterPro: IPR02591; Phosphodiester.
DR Pfam: PF01663; Phosphodiester; 1.
KW Hydrolase.
FT NON TER 1
FT ACT SITE 39 39 PHOSPHOTHEONINE INTERMEDIATE.
SQ SEQUENCE 61 AA; 6999 MW; 580C8B4807A61C84 CRC64;

Query Match 6.3%; Score 301; DB 1; Length 61;
Best Local Similarity 86.7%; Pred No. 2.8e-15;
Matches 52; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 167 DGPRAEVLVTWDTLMBNINKLTCGHSKYMRYMTKTFPPNHYTIVTGLYPESHGIIIDN 226
DB 1 DGPRAEVLVTWDTLMBNINKLTCGHSKYMRYMTKTFPPNHYTIVTGLYPESHGIIIDN 60
RESULT 12
TNAG_HUMAN STANDARD; PRT; 476 AA.
AC Q9UW2; Q9UW1; Q9ULZ4;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Tubulointerstitial nephritis antigen (TIN-ag).
GN TINAG.
OS Homo sapiens (Human).
OC Eukaryota; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RC TISSUE=Kidney;
RX MEDLINE=20119130; PubMed=10652240;
RA Ikeda M., Takemura T., Hino S., Yoshioka K.;
RT "Molecular cloning, expression, and chromosomal localization of a
human tubulointerstitial nephritis antigen.";
RL Biochem. Biophys. Res. Commun. 268:225-230 (2000).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORMS TIN1 AND TIN2), TISSUE SPECIFICITY, AND
SUBCELLULAR LOCATION.
RC TISSUE=Kidney;
RX MEDLINE=20214190; PubMed=10752525;
RA Zhou B., Nelson T.R., Kashtan C., Gleason B., Michael A.F., Vlasi M.,
Charonis A.S.;
RT "Identification of two alternatively spliced forms of human
tubulointerstitial nephritis antigen (TIN-ag).";
RL J. Am. Soc. Nephrol. 11:658-668 (2000).
RN [3]
RP IDENTIFICATION, AND DISEASE.
RC TISSUE=Kidney;
RX MEDLINE=87199690; PubMed=3553704;
RA Fliger F.D., Wieslander J., Brentjens J.R., Andres G.A.,
Buckowski R.J.;
RT "Identification of a target antigen in human anti-tubular basement
membrane nephritis.";
RL Kidney Int. 31:800-887 (1987).
RN [4]
RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX MEDLINE=92106641; PubMed=1782287;
RA Buckowski R.J., Kleppel M.M., Katz A., Michael A.F., Fish A.J.;
RT "Distribution of tubulointerstitial nephritis antigen and evidence for
multiple forms.";
RL Kidney Int. 40:838-846 (1991).
RN [5]
RP DISEASE.
RX MEDLINE=93103006; PubMed=1456369;
RA Katz A., Fish A.J., Santamaria P., Nevins T.E., Kim Y.,
Buckowski R.J.;
RT "Role of antibodies to tubulointerstitial nephritis antigen in human
anti-tubular basement membrane nephritis associated with membranous
nephropathy.";
RL Am. J. Med. 93:691-698 (1992).
RN [6]
RP FUNCTION.
RX MEDLINE=96366847; PubMed=8770961;
RA Chen Y., Krishnamurti U., Wayner E.A., Michael A.F., Charonis A.S.;
RT "Receptors in proximal tubular epithelial cells for tubulointerstitial
nephritis antigen.";
RL Kidney Int. 49:153-157 (1996).
RN [7]
RP DEVELOPMENTAL STAGE.
RX MEDLINE=98305799; PubMed=9643646;
RA Nelson T.R., Kim Y., Michael A.F., Buckowski R.J., Charonis A.S.;
RT "Tubulointerstitial nephritis antigen (TIN-ag) is expressed in

DR	InterPro; IPR001212; Somatomedin_B.
DR	Pfam; PF01033; Somatomedin_B; 1.
DR	PRINTS; PR00022; SOMATOMEDINB.
DR	SMART; SM00201; SO; 1.
DR	PROSITE; PS00524; SOMATOMEDIN_B; 1.
KW	Hydrolase; Serine protease; Signal; Polymorphism.
FT	SIGNAL 1 18 PLACENTAL PROTEIN 11.
FT	CHAIN 19 369 SOMATOMEDIN-B LIKE
FT	DOMAIN 45 89 E -> Q (in dBSNP:6504).
FT	VARIANT 31 31 /FTIG=VAR_014793.
FT	E -> V (in dBSNP:6505).
FT	/FTIG=VAR_014794.
FT	VARIANT 31 31
FT	SEQUENCE 369 AA; 42121 MW; F5935AE12D7E924C CRC64;
QY	Query Match 2.7%; Score 129; DB 1; Length 369;
QY	Best Local Similarity 19.6%; Pred. No. 0.069;
MATCHES	Matches 71; Conservative 48; Mismatches 104; Indels 140; Gaps 17;
DB	53 SCRKCFDASFRGLENCRCDVACKRGDCGDMFDTCTVETRIWMCKNFCRGTRELASL 112
DB	48 SCGRCTEA-FDKHHCHCNARCQFGNGCKDFSLCSDEH----- 87
QY	113 CSCDDCLKQCCADYKSVCGETSLE-----DNCAQ-SQCPEGFDLP 159
DB	88 VSHSSDAITKEEQISSEKIYRADTNKAQKEDIVLSNQNCISPSSTRNQVDRCFKP---- 143
QY	160 PVILFSMDGFRAELYTWTLMPNTNKLTGCIHSKYRMAYPTTTFPHHTIVTGLYPE 219
DB	144 ---LFT---YVNKKLFSTPYAIFNL-----NNQRATG----- 173
QY	220 SHGIIDNNMYDVLNKNFSLSSKEQNPNAPWHGQPMLTAMYGKAAATYPWGSEVAIN 279
DB	174 -HG-----EHFSAQELAEODAF--REIMKTAVMKELY----- 203
QY	280 GSFPSIWPNVGVPFEERISTLLKWLDPKAEPRPFYTMYPEEPDSSGHAGGPVSARVI 339
DB	204 -SFLHNCRYSQSQEYFDLLKN--WFGL-----YSRGNEEGDSG----- 241
QY	340 KALQVVDHAFGMLEGLKQRLNHCNVNIILLADHGMDOYCNKMEYMTDYFFRPFFMY 399
DB	242 -----FHVFSGEVKKGVKTCFNWRP-----YLEKEGLVDYYSHI-----Y 280
QY	400 EGP 402
DB	281 DGP 283
RESULT 14	
YP73 YERP	STANDARD; PRT; 2004 AA.
ID	YP73 YERP
AC	O82DJ2;
DT	28-FEB-2003 (Rel. 41, Created)
DT	28-FEB-2003 (Rel. 41, Last sequence update)
DT	10-OCT-2003 (Rel. 42, Last annotation update)
DE	Hypothetical UP0192 protein YP02573/Y1143 precursor.
GN	YP02573 OR Y1143.
OS	Yersinia pestis.
OC	Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC	Enterobacteriaceae; Yersinia.
OX	NCBI_taxid=632;
RN	[1]
RC	SEQUENCE FROM N.A.
RC	STRAIN=CO-92 / Biovar Orientalis;
RX	MEDLINE=21470413; PubMed=11586360;
RX	Parkhill J., Wren B.W., Thomson N.R., Titball R.W., Holden M.T.G.,
RA	Prentice M.B., Sebahia M., James K.D., Churcher C., Mungall K.L.,
RA	Baker S., Basham D., Bentley S.D., Brooks K., Cerdeno-Haraga A.M.,
RA	Chillingworth T., Cronin A., Davies R.M., Davis P., Dougan G.,
RA	Feltwell T., Hamlin N., Hollroyd S., Jagels K., Karlyshev A.V.,
RA	Leather S., Moule S., Oyston P.C.F., Quail M.A., Rutherford K.,
RA	Simmonds M., Skelton J., Stevens K., Whitehead S., Barrall B.G.;
PT	"Genome sequence of Yersinia pestis."

QY 748 -----GPIFDYN-YDGHFADPDEITKILANTDVP-----PTHFVVLTSCKNKSHTPENC 797
 Db 801 TTGENSTGEWVLYLVGKNNETSMLLGHTTVNVKFEFEDRLKVL-----QLTPERQ 854
 QY 798 PGWL 801
 Db 855 QGWV 858
 RESULT 15
 LRPI_CHICK
 ID LRPI_CHICK STANDARD; PRT: 4543 AA.
 AC P98157;
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Low-density lipoprotein receptor-related protein 1 precursor (LRP)
 DE (Alpha-2-macroglobulin receptor) (A2MR).
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Actinoptera; Aves; Neognathae; Galliformes; Phasianidae;
 OC Gallus.
 OC NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
 RC STRAIN=White leghorn; TISSUE=Liver, and Ovary;
 RX MEDLINE=94103212; PubMed=7506255;
 RA Nimpf J., Scifani S., Bilous P.T., Schneider W.J.;
 RT "The somatic cell-specific low density lipoprotein receptor-related
 RT protein of the chicken. Close kinship to mammalian low density
 RT lipoprotein receptor gene family members.";
 RL J. Biol. Chem. 269:212-219(1994).
 CC -!- FUNCTION: Involved in the plasma clearance of chylomicron remnants
 CC and activated alpha 2-macroglobulin, as well as the local
 CC metabolism of complexes between plasminogen activators and their
 CC endogenous inhibitors. Binds vitellogenin, calcium and alpha 2-
 CC macroglobulin.
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event-Alternative splicing; Named isoforms=2;
 CC Name=1;
 CC IsoId=P98157-1; Sequence-Displayed;
 CC Name=2;
 CC IsoId=P98157-2; Sequence-VSP_004312;
 CC -!- TISSUE SPECIFICITY: Somatic.
 CC -!- PTM: Cleaved into a 85 kDa membrane-spanning subunit (LRP-85) and
 CC a 515 kDa large extracellular domain (LRP-515) that remains non-
 CC covalently associated.
 CC -!- SIMILARITY: Contains 22 EGF-like domains.
 CC -!- SIMILARITY: Contains 31 LDL-receptor Class A domains.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X74904; CAA52870.1; -;
 DR PIR; A53102; A53102.
 DR PDB; 1LPX; 29-DEC-99.
 DR InterPro; IPR000152; Asx hydroxyl_S.
 DR InterPro; IPR001881; EGF_Ca.
 DR InterPro; IPR006209; EGF-like.
 DR InterPro; IPR002172; LDL_receptor_A.
 DR InterPro; IPR000033; Ldl_receptor_rep.
 DR Pfam; PF00008; EGF; 14.
 DR Pfam; PF00057; ldl_recept_a; 31.
 DR PRINTS; PF00058; ldl_recept_b; 33.
 DR PRINTS; PF00261; LDLRECEPTOR.
 DR SMART; SM00179; EGF_CA; 3.
 DR SMART; SM00192; LDLg; 31.
 DR SMART; SM00135; LY; 34.
 DR PROSITE; PS00010; ASX HYDROXYL; 3.
 DR PROSITE; PS00022; EGF_1; 5.
 DR PROSITE; PS01186; EGF_2; 7.
 DR PROSITE; PS50026; EGF_3; 8.
 DR PROSITE; PS01187; EGF_CA; 2.
 DR PROSITE; PS01209; LDLRA_1; 27.
 DR PROSITE; PS00068; LDLRA_2; 31.
 KW Receptor; Transmembrane; Repeat; Endocytosis; Glycoprotein; Signal;
 KW Calcium-binding; EGF-like domain; Coated pits; Alternative splicing;
 KW 3D-structure.
 FT SIGNAL 1 21 POTENTIAL.
 FT CHAIN 22 4543 LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED
 FT PROTEIN 1. EXTRACELLULAR (POTENTIAL).
 FT POTENTIAL.
 FT CYTOPLASMIC (POTENTIAL).
 FT LDL-RECEPTOR CLASS A 1.
 FT LDL-RECEPTOR CLASS A 2.
 FT EGF-LIKE 1.
 FT EGF-LIKE 2. CALCIUM-BINDING (POTENTIAL).
 FT EGF-LIKE 3.
 FT EGF-LIKE 4.
 FT LDL-RECEPTOR CLASS A 3.
 FT LDL-RECEPTOR CLASS A 4.
 FT LDL-RECEPTOR CLASS A 5.
 FT LDL-RECEPTOR CLASS A 6.
 FT LDL-RECEPTOR CLASS A 7.
 FT LDL-RECEPTOR CLASS A 8.
 FT LDL-RECEPTOR CLASS A 9.
 FT LDL-RECEPTOR CLASS A 10.
 FT EGF-LIKE 5.
 FT EGF-LIKE 6.
 FT EGF-LIKE 7.
 FT EGF-LIKE 8.
 FT EGF-LIKE 9.
 FT EGF-LIKE 10.
 FT LDL-RECEPTOR CLASS A 11.
 FT LDL-RECEPTOR CLASS A 12.
 FT LDL-RECEPTOR CLASS A 13.
 FT LDL-RECEPTOR CLASS A 14.
 FT LDL-RECEPTOR CLASS A 15.
 FT LDL-RECEPTOR CLASS A 16.
 FT LDL-RECEPTOR CLASS A 17.
 FT LDL-RECEPTOR CLASS A 18.
 FT LDL-RECEPTOR CLASS A 19.
 FT LDL-RECEPTOR CLASS A 20.
 FT EGF-LIKE 11.
 FT EGF-LIKE 12. CALCIUM-BINDING (POTENTIAL).
 FT EGF-LIKE 13.
 FT LDL-RECEPTOR CLASS A 21.
 FT LDL-RECEPTOR CLASS A 22.
 FT LDL-RECEPTOR CLASS A 23.
 FT LDL-RECEPTOR CLASS A 24.
 FT LDL-RECEPTOR CLASS A 25.
 FT LDL-RECEPTOR CLASS A 26.
 FT LDL-RECEPTOR CLASS A 27.
 FT LDL-RECEPTOR CLASS A 28.
 FT LDL-RECEPTOR CLASS A 29.
 FT LDL-RECEPTOR CLASS A 30.
 FT LDL-RECEPTOR CLASS A 31.
 FT EGF-LIKE 14.
 FT EGF-LIKE 15.
 FT EGF-LIKE 16.
 FT EGF-LIKE 17.
 FT EGF-LIKE 18.
 FT EGF-LIKE 19.
 FT EGF-LIKE 20.
 FT EGF-LIKE 21.
 FT EGF-LIKE 22.
 FT RECOGNITION SITE FOR PROTEOLYTICAL
 FT PROCESSING (POTENTIAL).
 FT SITE 3939 3942

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 6, 2004, 12:45:12 ; Search time 64 Seconds
(without alignments)
3862.954 Million cell updates/sec

Title: US-10-005-480A-743
Perfect score: 4804
Sequence: 1 MESTLTLATQPVKXNTLKK.....QPVSEILQLKYLPTFTTTI 875

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : A Geneseq 29Jan04:*
- 1: Geneseqp1980s:*
 - 2: Geneseqp1990s:*
 - 3: Geneseqp2000s:*
 - 4: Geneseqp2001s:*
 - 5: Geneseqp2002s:*
 - 6: Geneseqp2003as:*
 - 7: Geneseqp2003bs:*
 - 8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	4804	100.0	875	7 ADE56099	Human Pro
2	4804	100.0	875	7 ADE56103	Human Pro
3	4804	100.0	875	7 ADE56891	Human 161
4	4804	100.0	875	7 ADE56904	Human 161
5	4804	100.0	875	7 ADE56969	Human 161
6	4804	100.0	875	7 ADE56899	Human 161
7	4804	100.0	875	7 ADE56983	Human 161
8	4804	100.0	875	7 ADE56982	Human 161
9	4804	100.0	875	7 ADE56909	Human 161
10	4804	100.0	875	7 ADE56984	Human 161
11	4804	100.0	875	7 ADE56991	Human 161
12	4801	99.9	875	7 ADE56910	Human 161
13	4801	99.9	875	7 ADE56905	Human 161
14	4801	99.9	875	7 ADE56897	Human 161
15	4798	99.9	875	7 ADE56907	Human 161
16	4798	99.9	875	7 ADE56907	Human 161
17	4797	99.9	875	7 ADE56906	Human 161
18	4797	99.9	875	7 ADE56895	Human 161
19	4796	99.8	875	7 ADE56901	Human 161
20	4795	99.8	875	6 ABG74664	Human ecc
21	4743	98.7	885	4 ABG10289	Novel hum
22	4642	96.6	841	7 ADE56989	Human 161
23	4642	96.6	841	7 ADE56903	Human 161
24	4634	96.5	841	7 ADE56990	Human 161
25	4634	96.5	841	7 ADE56988	Human 161

26	4634	96.5	841	7 ADE565908	Ades65908 Human 161
27	3953.5	82.3	876	7 ADE56097	Ades6097 Rat Prote
28	3953.5	82.3	876	7 ADE56101	Ades6101 Rat Prote
29	2498.5	52.0	873	3 AAY83620	Aay83620 Human PC-
30	2498.5	52.0	925	2 AAR79148	Aar79148 Human ins
31	2498.5	52.0	925	2 AAY39355	Aay39355 Insulin r
32	2498.5	52.0	925	3 AAB00195	Aab00195 Breast ca
33	2498.5	52.0	925	7 ADD46549	Add46549 Human Pro
34	2494.5	51.9	873	3 AAY83621	Aay83621 Variant h
35	2265	47.1	945	4 AAM25587	Aam25587 Human pro
36	2122.5	44.2	858	4 AAY71998	Aay71998 Rat autot
37	2120	44.1	862	5 ABG32516	Abg32516 Rat lysop
38	2119.5	44.1	858	4 AAY71986	Aay71986 Rat autot
39	2119.5	44.1	858	4 AAY71995	Aay71995 Rat autot
40	2118.5	44.1	858	4 AAY71997	Aay71997 Rat autot
41	2118.5	44.1	858	4 AAY71996	Aay71996 Rat autot
42	2116.5	44.1	858	4 AAY71988	Aay71988 Human ter
43	2094.5	43.6	863	7 ADC10214	Adc10214 Human NOV
44	2094.5	43.6	863	7 ADC10214	Adc10214 Human NOV
45	2091.5	43.5	870	7 ADC10224	Adc10224 Human NOV

ALIGNMENTS

RESULT 1
ADE56099
ID ADE56099 standard; protein; 875 AA.
XX

AC ADE56099;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human Protein AAC51813, SEQ ID NO 1940.
XX

KW Human; pain; neuronal tissue; gene therapy;
KW spinal segmental nerve injury; chronic constriction injury; CCI;
KW spared nerve injury; SNI; Chung.
XX

OS Homo sapiens.
XX
PN WO2003016475-A2.
XX

PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US025765.
XX

PR 14-AUG-2001; 2001US-0312147P.
PR 01-NOV-2001; 2001US-0346382P.
PR 26-NOV-2001; 2001US-0333347P.

PA (GSHO) GEN HOSPITAL CORP.
PA (FARB) BAYER AG.
XX

PI Woolf C, D'urso D, Befort K, Costigan M;
XX WPI; 2003-268312/26.
XX GENBANK; AAC51813.

DR New composition comprising two or more isolated polypeptides, useful for
XX preparing a medicament for treating pain in an animal.
XX Claim 1; Page; 1017pp; English.

CC The invention discloses a composition comprising two or more isolated rat
CC or human polynucleotides or a polynucleotide which represents a fragment,
CC derivative or allelic variation of the nucleic acid sequence. Also
CC claimed are a vector comprising the novel polynucleotide, a host cell
CC comprising the vector, a method for identifying a nucleotide sequence
CC which is differentially regulated in an animal subjected to pain and a
CC kit to perform the method, an array, a method for identifying an agent
CC that increases or decreases the expression of the polynucleotide sequence
CC that is differentially expressed in neuronal tissue of a first animal

CC subjected to pain, a method for identifying a compound which regulates
 CC the expression of a polynucleotide sequence which is differentially
 CC expressed in an animal subjected to pain, a method for identifying a
 CC compound that regulates the activity of one or more of the
 CC polynucleotides, a method for producing a pharmaceutical composition, a
 CC method for identifying a compound or small molecule that regulates the
 CC activity in an animal of one or more of the polypeptides given in the
 CC specification, a method for identifying a compound useful in treating
 CC pain and a pharmaceutical composition comprising the one or more
 CC polypeptides or their antibodies. The polynucleotide or the compound that
 CC modulates its activity is useful for preparing a medicament for treating
 CC pain (e.g. spinal segmental nerve injury (SNI), chronic constriction
 CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
 CC therapy). The sequence presented is a human protein (shown in Table 2 of
 CC the specification) which is differentially expressed during pain. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic form directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX
 SQ Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLAKYKTIACIVLALAVIMSLGLGLGLGRKLEKQSCRRKCFD 60
 Db 1 MESTLTATEQPVKNTLAKYKTIACIVLALAVIMSLGLGLGLGRKLEKQSCRRKCFD 60
 QY 61 ASFRGLENCRCVACKDRGDCWDEDTCTVCESTRIMCNKFCGTRLEASLCSGDDCL 120
 Db 61 ASFRGLENCRCVACKDRGDCWDEDTCTVCESTRIMCNKFCGTRLEASLCSGDDCL 120
 QY 121 QKDCCADYKSCQGETSLENCDTAQSQCPEGDLPPVLFSMDGFRAEYLYTWTDL 180
 Db 121 QKDCCADYKSCQGETSLENCDTAQSQCPEGDLPPVLFSMDGFRAEYLYTWTDL 180
 QY 181 MPNINKLKTGCIHSKYMRAMYTKTFPNHYITVTGLYPESHGIDNNMYDYNLKNFSL 240
 Db 181 MPNINKLKTGCIHSKYMRAMYTKTFPNHYITVTGLYPESHGIDNNMYDYNLKNFSL 240
 QY 241 SKEQNPAAWHQOPWMLTAMYQGLKAATYFPGSEVAINGSPPSIYMPYNGSVPFERIS 300
 Db 241 SKEQNPAAWHQOPWMLTAMYQGLKAATYFPGSEVAINGSPPSIYMPYNGSVPFERIS 300
 QY 301 TLLKWLDPKAEPRPFYMYPEEPDSSGHAGSPVSARVICALQVVDHAFGLMGLKORN 360
 Db 301 TLLKWLDPKAEPRPFYMYPEEPDSSGHAGSPVSARVICALQVVDHAFGLMGLKORN 360
 QY 361 LNCVNIILLADHGMDOQYCNKMEYTDYFPRINFFYMEGPAIRAHNIPHPDFFS 420
 Db 361 LNCVNIILLADHGMDOQYCNKMEYTDYFPRINFFYMEGPAIRAHNIPHPDFFS 420
 QY 421 EIVNLSCKRDEHKEVLTDPDLKRLHYAKNVRIDKVLHFDQOOLAVRSKNTCCG 480
 Db 421 EIVNLSCKRDEHKEVLTDPDLKRLHYAKNVRIDKVLHFDQOOLAVRSKNTCCG 480
 QY 481 GNHGYNNEFRSMEALFLAHGSPSFKTEVEPFENIEVYLNMLCDLLRIQAPNNGTHGSLN 540
 Db 481 GNHGYNNEFRSMEALFLAHGSPSFKTEVEPFENIEVYLNMLCDLLRIQAPNNGTHGSLN 540
 QY 541 HLLKVPFEPHSAEVSFSGPANPLPTESLDCFCPLHNSQLQEQVOMLNTQEEI 600
 Db 541 HLLKVPFEPHSAEVSFSGPANPLPTESLDCFCPLHNSQLQEQVOMLNTQEEI 600
 QY 601 TATVKVNLFPGRPRVLQKNVHCLLYHREYVSGFKAMRPMWSSYTVPOLGDTSPSPPT 660
 Db 601 TATVKVNLFPGRPRVLQKNVHCLLYHREYVSGFKAMRPMWSSYTVPOLGDTSPSPPT 660
 QY 661 VPDCLRADVRVPPESSQKCSYFLADKNITHTGFLYPPASNRTSDSQYDALITSNLVPMYEE 720
 Db 661 VPDCLRADVRVPPESSQKCSYFLADKNITHTGFLYPPASNRTSDSQYDALITSNLVPMYEE 720

QY 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDAPDEITGHANTDVPPIPHY 780
 Db 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDAPDEITGHANTDVPPIPHY 780
 QY 781 FVLTSCNKSHTPENCPCGWLVDLVPFIIPHRPTNVSCPEGKPEALWVERFTAARVR 840
 Db 781 FVLTSCNKSHTPENCPCGWLVDLVPFIIPHRPTNVSCPEGKPEALWVERFTAARVR 840
 QY 841 DVELLTGLDFVQDKVQVSVILQKLYLPTFETI 875
 Db 841 DVELLTGLDFVQDKVQVSVILQKLYLPTFETI 875

RESULT 2

AD56103

ID AD56103 standard; protein; 875 AA.

AC AD56103;

XX 29-JAN-2004 (first entry)

XX Human Protein AAC51813, SEQ ID NO 1944.

XX Human; pain; neuronal tissue; gene therapy;

XX spinal segmental nerve injury; chronic constriction injury; CCI;

XX spared nerve injury; SNI; Chung.

XX Homo sapiens.

XX WO2003016475-A2.

XX 27-FEB-2003.

XX 14-AUG-2002; 2002WO-US025765.

XX 14-AUG-2001; 2001US-0312147P.

XX 01-NOV-2001; 2001US-0346382P.

XX 26-NOV-2001; 2001US-0333347P.

XX (GEHO) GEN HOSPITAL CORP.

XX (FARB) BAYER AG.

XX Woolf C, D'urso D, Befort K, Costigan M;

XX WPI; 2003-268312/26.

XX GENBANK; AAC51813.

XX New composition comprising two or more isolated polypeptides, useful for preparing a medicament for treating pain in an animal.

XX Claim 1; Page; 1017pp; English.

XX The invention discloses a composition comprising two or more isolated rat or human polynucleotides or a polynucleotide which represents a fragment, derivative or allelic variation of the nucleic acid sequence. Also claimed are a vector comprising the novel polynucleotide, a host cell comprising the vector, a method for identifying a nucleotide sequence which is differentially regulated in an animal subjected to pain and a kit to perform the method, an array, a method for identifying an agent that increases or decreases the expression of the polynucleotide sequence that is differentially expressed in neuronal tissue of a first animal subjected to pain, a method for identifying a compound which regulates the expression of a polynucleotide sequence which is differentially expressed in an animal subjected to pain, a method for identifying a compound that regulates the activity of one or more of the polynucleotides, a method for producing a pharmaceutical composition, a method for identifying a compound or small molecule that regulates the activity in an animal of one or more of the polypeptides given in the specification, a method for identifying a compound useful in treating pain and a pharmaceutical composition comprising the one or more polypeptides or their antibodies. The polynucleotide or the compound that modulates its activity is useful for preparing a medicament for treating pain (e.g. spinal segmental nerve injury (Chung), chronic constriction

CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
CC therapy). The sequence presented is a human protein (shown in Table 2 of
CC the specification) which is differentially expressed during pain. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic form directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX	Sequence 875 AA;	
SQ	Query Match	100.0%; Score 4804; DB 7; Length 875;
	Best Local Similarity	100.0%; Pred. No. 0;
	Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1	MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLRKLKQSGCRKCFD 60
DB	1	MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLRKLKQSGCRKCFD 60
QY	61	ASFRGLENCRCVACKDRGCCWDFEDTCTVETRIWMCNKRFGCTRIEASLCSDDCL 120
DB	61	ASFRGLENCRCVACKDRGCCWDFEDTCTVETRIWMCNKRFGCTRIEASLCSDDCL 120
QY	121	QKQCCADYKSCQGETSWELENCDTAQOQCPGFDLPPVILFMSDGFRAEYLTYWDTL 180
DB	121	QKQCCADYKSCQGETSWELENCDTAQOQCPGFDLPPVILFMSDGFRAEYLTYWDTL 180
QY	181	MPNINKLKTGCIHSHKYNRMYPTKTFPNHYTIVTGLYPESHGIIIDNNYDVLNKNFSL 240
DB	181	MPNINKLKTGCIHSHKYNRMYPTKTFPNHYTIVTGLYPESHGIIIDNNYDVLNKNFSL 240
QY	241	SKEQNPANWHQOPMWTAMYQGLKAATYFPGSEVAINGSPPSYMPYNGSVPEERIS 300
DB	241	SKEQNPANWHQOPMWTAMYQGLKAATYFPGSEVAINGSPPSYMPYNGSVPEERIS 300
QY	301	TLLKWLDPKABRPRTYTYFEEPPSSGHAGGVSARVIALQVVDHAFGLMEGLKQRN 360
DB	301	TLLKWLDPKABRPRTYTYFEEPPSSGHAGGVSARVIALQVVDHAFGLMEGLKQRN 360
QY	361	LHNCVNIILLADHMDQTCNKMXYMTDYPRIINFPYMEGAPRIRAHNIHDSFENS 420
DB	361	LHNCVNIILLADHMDQTCNKMXYMTDYPRIINFPYMEGAPRIRAHNIHDSFENS 420
QY	421	BEIVRLNSCRKDPQHKPYLTPDLKRLHYAKNVRIDKVLHFDQQLAVRSKSTNCGG 480
DB	421	BEIVRLNSCRKDPQHKPYLTPDLKRLHYAKNVRIDKVLHFDQQLAVRSKSTNCGG 480
QY	481	GNHGYNNFRSMEAIPLAGPSFKETVEPEPENIEVYNLMCDLRIQAPANNTHGSLN 540
DB	481	GNHGYNNFRSMEAIPLAGPSFKETVEPEPENIEVYNLMCDLRIQAPANNTHGSLN 540
QY	541	HLKVPFYPSHAEVSKFSVCGFANPLPTESLDCFCPLHONSTOLEQVQMLNLTQBEI 600
DB	541	HLKVPFYPSHAEVSKFSVCGFANPLPTESLDCFCPLHONSTOLEQVQMLNLTQBEI 600
QY	601	TATVKYNLPFGRPVRLQKVDHCLLYHREYVSGFGKAMRMPWSSYTVPOLGDTSPLPPT 660
DB	601	TATVKYNLPFGRPVRLQKVDHCLLYHREYVSGFGKAMRMPWSSYTVPOLGDTSPLPPT 660
QY	661	VPDCLRADYVRPSESOKCSFYLDKNIITHGFLYPPASNRSDSQYDALITSNLVPMYEE 720
DB	661	VPDCLRADYVRPSESOKCSFYLDKNIITHGFLYPPASNRSDSQYDALITSNLVPMYEE 720
QY	721	FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNYDGHFDAPDEITKHLANTDVPITYH 780
DB	721	FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNYDGHFDAPDEITKHLANTDVPITYH 780
QY	781	FVVLTSCKNKSHTPENCPLWDLVLPFIIPHRPTNVESCEGKPEALWVEERTAHIAVR 840
DB	781	FVVLTSCKNKSHTPENCPLWDLVLPFIIPHRPTNVESCEGKPEALWVEERTAHIAVR 840
QY	841	DVELLGLDYPQDKVPVSEILQKTYLPTFTTI 875
DB	841	DVELLGLDYPQDKVPVSEILQKTYLPTFTTI 875

RESULT 3

ADE65891
ID ADE65891 standard; protein; 875 AA.

XX AC ADE65891;
XX DT 29-JAN-2004 (first entry)
XX DE Human 161P2F10B protein variant 1.
XX KW 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.

XX OS Homo sapiens.
XX PN WO2003040340-A2.

XX PD 15-MAY-2003.
XX PF 07-NOV-2002; 2002WO-US036002.

XX PR 07-NOV-2001; 2001US-00005480.
XX PR 31-JAN-2002; 2002US-00062109.

XX PA (AGEN-) AGENSYS INC.
XX PI Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KJM;
XX PI Morrison RK, Challita-Bid PM;

XX DR WPI; 2003-441560/41.
XX DR N-PSDB; ADE66890.

XX PT A composition for diagnosing, preventing and treating cancer (e.g.
XX PT prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
XX PT and polypeptides.

XX PS Claim 1; SEQ ID NO 3; 135pp; English.

XX CC This invention relates to a novel composition which comprises a substance
XX CC that modulates the status of a novel protein (161P2F10B) and its variants
XX CC having a sequence of 875 amino acids provided in the specification. The
XX CC protein of the invention is over-expressed in certain cancers. The
XX CC compounds of the invention may have cytostatic activity and the sequence
XX CC of the 161P2F10B protein, and the gene which encodes it, may be useful
XX CC for gene therapy or the development of a vaccine. The composition and
XX CC methods of the invention are useful in diagnosing, preventing and
XX CC treating cancer. The present sequence is the amino acid sequence of the
XX CC human 161P2F10B variant 1 protein of the invention.

SQ Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLRKLKQSGCRKCFD 60
DB 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLRKLKQSGCRKCFD 60

QY 61 ASFRGLENCRCVACKDRGCCWDFEDTCTVETRIWMCNKRFGCTRIEASLCSDDCL 120
DB 61 ASFRGLENCRCVACKDRGCCWDFEDTCTVETRIWMCNKRFGCTRIEASLCSDDCL 120

QY 121 QKQCCADYKSCQGETSWELENCDTAQOQCPGFDLPPVILFMSDGFRAEYLTYWDTL 180
DB 121 QKQCCADYKSCQGETSWELENCDTAQOQCPGFDLPPVILFMSDGFRAEYLTYWDTL 180

QY 181 MPNINKLKTGCIHSHKYNRMYPTKTFPNHYTIVTGLYPESHGIIIDNNYDVLNKNFSL 240
DB 181 MPNINKLKTGCIHSHKYNRMYPTKTFPNHYTIVTGLYPESHGIIIDNNYDVLNKNFSL 240

QY 241 SKEQNPANWHQOPMWTAMYQGLKAATYFPGSEVAINGSPPSYMPYNGSVPEERIS 300
DB 241 SKEQNPANWHQOPMWTAMYQGLKAATYFPGSEVAINGSPPSYMPYNGSVPEERIS 300

241	SK	E	Q	N	N	P	A	W	H	G	Q	P	M	W	L	T	A	M	Y	Q	G	L	K	A	A	Y	T	F	W	P	G	S	E	A	I	N	G	S	F	P	E	I	Y	M	P	N	G	S	V	P	F	F	E	R	I	S	300
301	T	L	L	K	W	L	D	L	F	K	A	E	R	P	R	F	Y	T	M	Y	E	E	P	D	S	S	G	H	A	G	G	P	S	A	R	V	I	K	A	L	Q	V	D	H	A	F	C	M	L	E	G	L	K	Q	R	N	360
301	T	L	L	K	W	L	D	L	F	K	A	E	R	P	R	F	Y	T	M	Y	E	E	P	D	S	S	G	H	A	G	G	P	S	A	R	V	I	K	A	L	Q	V	D	H	A	F	C	M	L	E	G	L	K	Q	R	N	360
361	L	H	N	C	V	N	I	I	L	L	A	D	H	G	M	D	Q	T	Y	C	N	K	M	E	Y	M	T	D	Y	P	P	R	I	N	F	F	Y	M	Y	G	P	A	P	R	A	H	N	I	P	H	D	F	S	F	N	S	420
361	L	H	N	C	V	N	I	I	L	L	A	D	H	G	M	D	Q	T	Y	C	N	K	M	E	Y	M	T	D	Y	P	P	R	I	N	F	F	Y	M	Y	G	P	A	P	R	A	H	N	I	P	H	D	F	S	F	N	S	420
421	E	E	I	V	R	N	L	S	C	R	K	P	D	Q	H	F	K	P	Y	L	T	P	D	L	P	K	R	L	H	Y	A	K	N	V	R	I	D	K	V	H	L	F	V	D	Q	W	L	A	V	R	S	K	N	T	C	G	480
421	E	E	I	V	R	N	L	S	C	R	K	P	D	Q	H	F	K	P	Y	L	T	P	D	L	P	K	R	L	H	Y	A	K	N	V	R	I	D	K	V	H	L	F	V	D	Q	W	L	A	V	R	S	K	N	T	C	G	480
481	G	N	H	G	Y	N	E	P	R	S	M	E	A	I	F	L	A	H	G	P	S	F	K	E	T	E	V	E	P	F	E	N	I	E	V	N	L	M	C	L	L	R	I	Q	A	P	A	N	N	G	T	H	G	S	L	N	540
481	G	N	H	G	Y	N	E	P	R	S	M	E	A	I	F	L	A	H	G	P	S	F	K	E	T	E	V	E	P	F	E	N	I	E	V	N	L	M	C	L	L	R	I	Q	A	P	A	N	N	G	T	H	G	S	L	N	540
541	H	L	L	K	V	P	F	E	S	A	E	B	V	S	K	F	S	C	G	F	A	N	P	L	P	T	S	L	D	C	F	C	H	L	Q	N	S	T	O	L	E	O	V	N	O	M	L	N	L	T	O	E	E	I	600		
541	H	L	L	K	V	P	F	E	S	A	E	B	V	S	K	F	S	C	G	F	A	N	P	L	P	T	S	L	D	C	F	C	H	L	Q	N	S	T	O	L	E	O	V	N	O	M	L	N	L	T	O	E	E	I	600		
601	T	A	T	K	V	N	L	F	G	R	P	R	V	L	Q	N	V	D	H	C	L	L	Y	H	R	E	Y	S	G	F	G	K	A	R	M	P	M	S	S	Y	T	V	P	O	L	G	T	S	P	L	P	T	660				
601	T	A	T	K	V	N	L	F	G	R	P	R	V	L	Q	N	V	D	H	C	L	L	Y	H	R	E	Y	S	G	F	G	K	A	R	M	P	M	S	S	Y	T	V	P	O	L	G	T	S	P	L	P	T	660				
661	V	P	D	C	L	R	A	D	V	R	V	P	P	S	S	Q	C	S	F	Y	L	A	D	K	N	I	T	H	G	F	L	Y	P	P	A	S	N																				

RESIST. T. A

RESULTS 4
ADECE904

ADE65904
ID ADE65904 standard; protein: 875 AA.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846

XX
AC
ADECE90A.

AC
yy
ADE65904;

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

DT 29-JAN-2004 (first entry)

XX

DE Human 161P2F10B

KW 161P2F10B: cancer: cytostatic

[illegible]

Home

US Homo sapiens.

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146.

PN WO2003040340-A2.

XX

PD 15-MAY-2003.

XX A composition for diagnosing, preventing and treating cancer (e.g.
PT prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
PT and polypeptides.
XX
XX
PS Example 1; SEQ ID NO 16; 135pp; English.
XX
CC This invention relates to a novel composition which comprises a substance
CC that modulates the status of a novel protein (161P2F10B) and its variants
CC having a sequence of 875 amino acids provided in the specification. The
CC protein of the invention is over-expressed in certain cancers. The
CC compounds of the invention may have cytostatic activity and the sequence
CC of the 161P2F10B protein, and the gene which encodes it, may be useful
CC for gene therapy or the development of a vaccine. The composition and
CC methods of the invention are useful in diagnosing, preventing and
CC treating cancer. The present sequence is the amino acid sequence of the
CC human 161P2F10B variant 1 protein of the invention.
CC

| | | | | |
|-----------------------|--------------|-------------|------------|------------|
| Query Match | 100.0% | Score 4804 | DE 7 | Length 875 |
| Best Local Similarity | 100.0% | Pred. NO. 0 | | |
| Matches 875 | Conservative | 0 | Mismatches | 0 |
| | | | Indels | 0 |
| | | | Gaps | 0 |

| | | | |
|----|-----|---|-----|
| Qy | 1 | MESTLLATLATEQPVKKNTLKKYKTIACIIVLLALLVIMSLGLGLGLGLKRLKQSGCRKKCFD | 60 |
| Db | 1 | MESTLLTATEQPVKKNTLKKYKTIACIIVLLALLVIMSLGLGLGLKRLKQSGCRKKCFD | 60 |
| Qy | 61 | ASFRGLENCRCDVACKDRGDCWDDEDTCVSESTRIMWCKNFKRCGETRLEASLCSGDDCL | 120 |
| Db | 61 | ASFRGLENCRCDVACKDRGDCWDDEDTCVSESTRIMWCKNFKRCGETRLEASLCSGDDCL | 120 |
| Qy | 121 | QKXDCADYKSVCOGGETSWLEENCDTAQOSQCPGFDLPVILFSDMGFRAEVLTYTWDTL | 180 |
| Db | 121 | QKXDCADYKSVCOGGETSWLEENCDTAQOSQCPGFDLPVILFSDMGFRAEVLTYTWDTL | 180 |
| Qy | 181 | MPNINKLKTGCHSKYKRAMYPKTKEPNHYITVGLYPESHGIIIDNNMYDVNLKNKFSLS | 240 |
| Db | 181 | MPNINKLKTGCHSKYKRAMYPKTKEPNHYITVGLYPESHGIIIDNNMYDVNLKNKFSLS | 240 |
| Qy | 241 | SKEQNNPAWHGQPMWLITAMYQGLKAATYFWPQSEVAINGSPFSIYMPYNGSVPPFERIS | 300 |
| Db | 241 | SKEQNNPAWHGQPMWLITAMYQGLKAATYFWPQSEVAINGSPFSIYMPYNGSVPPFERIS | 300 |
| Qy | 301 | TLLKLWLDLPAKEBPRFTYTWYFEEPDSSGHAGGPVSARVIKALQVDDHAFGLMEGLKORN | 360 |
| Db | 301 | TLLKLWLDLPAKEBPRFTYTWYFEEPDSSGHAGGPVSARVIKALQVDDHAFGLMEGLKORN | 360 |
| Qy | 361 | LHNCVNIILLADHGMDQTCYCNMEYMTDYFPRINFYMYEGPAPRIAHNIPHDFSFNS | 420 |
| Db | 361 | LHNCVNIILLADHGMDQTCYCNMEYMTDYFPRINFYMYEGPAPRIAHNIPHDFSFNS | 420 |
| Qy | 421 | EETVRNLSCRKPDQHKPYLTDPDKRLHYAKNVRIDKVHLFVDOQWLAVRSKSNNTCGS | 480 |
| Db | 421 | EETVRNLSCRKPDQHKPYLTDPDKRLHYAKNVRIDKVHLFVDOQWLAVRSKSNNTCGS | 480 |
| Qy | 481 | GNHGYNNEFRSMEAIFLAHGSPFKETEVPEPENIEVYNLMCDLLRIQAPNNGTHGSLN | 540 |
| Db | 481 | GNHGYNNEFRSMEAIFLAHGSPFKETEVPEPENIEVYNLMCDLLRIQAPNNGTHGSLN | 540 |
| Qy | 541 | HLLKVPFYPSPHAEBSVSKSVCGFANPLETESLDCCPHLQNSTOLEOVNOMLNTQBEI | 600 |
| Db | 541 | HLLKVPFYPSPHAEBSVSKSVCGFANPLETESLDCCPHLQNSTOLEOVNOMLNTQBEI | 600 |
| Qy | 601 | TATVKVNLFPGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPOLGDTSLPPT | 660 |
| Db | 601 | TATVKVNLFPGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPOLGDTSLPPT | 660 |
| Qy | 661 | VPDCLRADVRVPSESKCSFYLADKNITHGFLYPPASNRSTDSDQDALITSNLVPWYEE | 720 |
| Db | 661 | VPDCLRADVRVPSESKCSFYLADKNITHGFLYPPASNRSTDSDQDALITSNLVPWYEE | 720 |
| Qy | 721 | FRKMDYFHSVLLIKHATERNGVVYVSGIFDYNVDGDFHDADEIKTHLANDVPIPTHY | 780 |


```
Db 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNKSHTPENCPCGWLVDLPFIIPHRPTNVESCPGKPEALWVEERTAHIAVR 840
Db 781 FVVLTSCKNKSHTPENCPCGWLVDLPFIIPHRPTNVESCPGKPEALWVEERTAHIAVR 840
QY 841 DVELLTGLDFYQKQVPVSEILQLKTYLPTFTTI 875
Db 841 DVELLTGLDFYQKQVPVSEILQLKTYLPTFTTI 875

RESULT 5
ADE65969
ID ADE65969 standard; protein; 875 AA.
XX
AC ADE65969;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human 161P2F10B protein variant 1 #4.
XX
KW 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN WO2003040340-A2.
XX
PD 15-MAY-2003.
XX
PF 07-NOV-2002; 2002WO-US036002.
XX
PR 07-NOV-2001; 2001US-00005480.
XX
PR 31-JAN-2002; 2002US-00062109.
XX
XX (AGEN-) AGENSYS INC.
XX
XX Jakobovits A, Raitano AB, Farris M, Hubert RS, Ge W, Morrison KJM;
PI Morrison RK, Challita-Bid PM;
XX
XX WPI; 2003-441560/41.
XX
XX A composition for diagnosing, preventing and treating cancer (e.g.
PT prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
PT and polypeptides.
XX
XX Example 65; SEQ ID NO 81; 135pp; English.
XX
CC This invention relates to a novel composition which comprises a substance
CC that modulates the status of a novel protein (161P2F10B) and its variants
CC having a sequence of 875 amino acids provided in the specification. The
CC protein of the invention is over-expressed in certain cancers. The
CC compounds of the invention may have cytostatic activity and the sequence
CC of the 161P2F10B protein, and the gene which encodes it, may be useful
CC for gene therapy or the development of a vaccine. The composition and
CC methods of the invention are useful in diagnosing, preventing and
CC treating cancer. The present sequence is the amino acid sequence of the
CC human 161P2F10B variant 1 protein of the invention.
XX
SQ Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTLATEQPVKNTKKYKIACIVLLALVIMSLGGLGRLKLEKQGSCKKCFD 60
Db 1 MESTLTLATEQPVKNTKKYKIACIVLLALVIMSLGGLGRLKLEKQGSCKKCFD 60
QY 61 ASFRGLENCRCVACKDRGDCWDFEDTCVESTRIWMCNKRFCGTRLEASLCSDDCL 120
Db 61 ASFRGLENCRCVACKDRGDCWDFEDTCVESTRIWMCNKRFCGTRLEASLCSDDCL 120
```

```
QY 121 QKDCCADYKSVCOGETSWLEENCDDTAQSCCEGFDLPVILLFSMDGFAEVLTYWDTL 180
Db 121 QKDCCADYKSVCOGETSWLEENCDDTAQSCCEGFDLPVILLFSMDGFAEVLTYWDTL 180
QY 181 MPNINKLKTGCIHSHKYVRAMYPTKTFPNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSL 240
Db 181 MPNINKLKTGCIHSHKYVRAMYPTKTFPNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSL 240
QY 241 SKEQNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSFSPSIYMPYNGSVPFERIS 300
Db 241 SKEQNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSFSPSIYMPYNGSVPFERIS 300
QY 301 TLLKWLDPKAERPRFYTMVFEEDSSGHAGGPPSVARVICALQVVDHAFGLMGLKQRN 360
Db 301 TLLKWLDPKAERPRFYTMVFEEDSSGHAGGPPSVARVICALQVVDHAFGLMGLKQRN 360
QY 361 LHNCVNIILLADHGMDQTYCNKMEYMTDYPRINFFYNYEGPAPRIRAHNI PHDFFSFNS 420
Db 361 LHNCVNIILLADHGMDQTYCNKMEYMTDYPRINFFYNYEGPAPRIRAHNI PHDFFSFNS 420
QY 421 BEIVRNLSCKRPDQHFYKPYLTPDLPKLHYAKNVRIDKVLH FVDOQWLAVRSKNTNCGG 480
Db 421 BEIVRNLSCKRPDQHFYKPYLTPDLPKLHYAKNVRIDKVLH FVDOQWLAVRSKNTNCGG 480
QY 481 GNHCYNNEFRSMEAI FLAHGSPFKEKTEVEPFENIEVYNLMCDLLR QPAPNNGTHGSLN 540
Db 481 GNHCYNNEFRSMEAI FLAHGSPFKEKTEVEPFENIEVYNLMCDLLR QPAPNNGTHGSLN 540
QY 541 HLLKVPYFEPESHAEVSKFSVCGFANPLPTESLDCTCFPHLQNSTQLEQVQMLNLTQEEI 600
Db 541 HLLKVPYFEPESHAEVSKFSVCGFANPLPTESLDCTCFPHLQNSTQLEQVQMLNLTQEEI 600
QY 601 TATVKVNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRMKSSYTVPOLGDTSPLPPT 660
Db 601 TATVKVNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRMKSSYTVPOLGDTSPLPPT 660
QY 661 VPDCLRADVRVPPSESQKSFYLADKNITHGFLYPPASNRTSDSYDALITSNLVPMYEE 720
Db 661 VPDCLRADVRVPPSESQKSFYLADKNITHGFLYPPASNRTSDSYDALITSNLVPMYEE 720
QY 721 PRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITPHY 780
Db 721 PRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNKSHTPENCPCGWLVDLPFIIPHRPTNVESCPGKPEALWVEERTAHIAVR 840
Db 781 FVVLTSCKNKSHTPENCPCGWLVDLPFIIPHRPTNVESCPGKPEALWVEERTAHIAVR 840
QY 841 DVELLTGLDFYQKQVPVSEILQLKTYLPTFTTI 875
Db 841 DVELLTGLDFYQKQVPVSEILQLKTYLPTFTTI 875

RESULT 6
ADE65899
ID ADE65899 standard; protein; 875 AA.
XX
AC ADE65899;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human 161P2F10B protein variant 5.
XX
KW 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN WO2003040340-A2.
XX
PD 15-MAY-2003.
XX
PF 07-NOV-2002; 2002WO-US036002.
XX
```

```
PR 07-NOV-2001; 2001US-00005480.
PR 31-JAN-2002; 2002US-00062109.
XX (AGEN-) AGENSYS INC.
XX
PI Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KM;
PI Morrison RK, Challita-Eid PM;
XX
DR WPI: 2003-441560/41.
DR N-PSDB; ADE65983.
XX
PT A composition for diagnosing, preventing and treating cancer (e.g.
PT prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
PT and polypeptides.
XX
PS Claim 1; SEQ ID NO 11; 135pp; English.
XX
CC This invention relates to a novel composition which comprises a substance
CC that modulates the status of a novel protein (161P2F10B) and its variants
CC having a sequence of 875 amino acids provided in the specification. The
CC protein of the invention is over-expressed in certain cancers. The
CC compounds of the invention may have cytostatic activity and the sequence
CC of the 161P2F10B protein, and the gene which encodes it, may be useful
CC for gene therapy or the development of a vaccine. The composition and
CC methods of the invention are useful in diagnosing, preventing and
CC treating cancer. The present sequence is the amino acid sequence of the
CC human 161P2F10B variant 5 protein of the invention.
XX
SQ Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKYKTKLKKYKIACIVLLALLVINSIGLGLGLRKLKLEKQSCSKKCFD 60
DB 1 MESTLTATEQPVKYKTKLKKYKIACIVLLALLVINSIGLGLGLRKLKLEKQSCSKKCFD 60

QY 61 ASFRGLNCRCDVACDRGDCWDFDTCVETSTRIMCNKFRCGETRIEASLCSDDCL 120
DB 61 ASFRGLNCRCDVACDRGDCWDFDTCVETSTRIMCNKFRCGETRIEASLCSDDCL 120

QY 121 OKKDCADYKSCQGTSLWLENCDFTAQOSQCEGFDLPVILFSDMGFRAEYLTYDWTL 180
DB 121 OKKDCADYKSCQGTSLWLENCDFTAQOSQCEGFDLPVILFSDMGFRAEYLTYDWTL 180

QY 181 MPNINKLTCGIHSHKYNRAMPYPTKTPPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240
DB 181 MPNINKLTCGIHSHKYNRAMPYPTKTPPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240

QY 241 SKQNNPAMWHGQPMULTANYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPEERIS 300
DB 241 SKQNNPAMWHGQPMULTANYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPEERIS 300

QY 301 TLLKWLDPKAERPRFTYTYFPEPDSHGAGFVSARVIKALQVVDHAFGLMEGLKQRN 360
DB 301 TLLKWLDPKAERPRFTYTYFPEPDSHGAGFVSARVIKALQVVDHAFGLMEGLKQRN 360

QY 361 LHNVCNILLADHGMDOCTYCNMEYMTDYFPRINFEYVYEGAPRIRAHNIPHDFFSNS 420
DB 361 LHNVCNILLADHGMDOCTYCNMEYMTDYFPRINFEYVYEGAPRIRAHNIPHDFFSNS 420

QY 421 EEIVRLNLSCKRPDQHKPVLTPDLPRKLHYAKNVRIDKVLHFDQWLAVRSKSNTCGG 480
DB 421 EEIVRLNLSCKRPDQHKPVLTPDLPRKLHYAKNVRIDKVLHFDQWLAVRSKSNTCGG 480

QY 481 GNGYNNFRSMBAIFLAGHPSFKETEVPEPENIEVNLMDLLRIQAPNNGTHGSLN 540
DB 481 GNGYNNFRSMBAIFLAGHPSFKETEVPEPENIEVNLMDLLRIQAPNNGTHGSLN 540

QY 541 HLLKVPFYPSPSHAEVSKFSVCGFANFLPTESIDCFPHLQNSTOLEQVNMNLNLTQBEI 600
DB 541 HLLKVPFYPSPSHAEVSKFSVCGFANFLPTESIDCFPHLQNSTOLEQVNMNLNLTQBEI 600

QY 601 TATVKVNLPEGRPRVLQKXNDHCLLYHREYVSGFGKAMRMPMWSSYTVPLGDTSLPPT 660
DB 601 TATVKVNLPEGRPRVLQKXNDHCLLYHREYVSGFGKAMRMPMWSSYTVPLGDTSLPPT 660

QY 661 VPCLRADVRVPSPESQKCSFYLDKKNITHGFLYPPASNRTSDSQYDALITSNLVMYEE 720
DB 661 VPCLRADVRVPSPESQKCSFYLDKKNITHGFLYPPASNRTSDSQYDALITSNLVMYEE 720

QY 721 FRKWDYFHSVLLIKHATERGVNVVSGPIFDVNDGHFADPEITKHLANTDVPPIPTHY 780
DB 721 FRKWDYFHSVLLIKHATERGVNVVSGPIFDVNDGHFADPEITKHLANTDVPPIPTHY 780

QY 781 FVVLTSCKNKSHTPCNPGWLDVLPFIIPHRPNNVSCPEGKPEALWVEERTAHIAVR 840
DB 781 FVVLTSCKNKSHTPCNPGWLDVLPFIIPHRPNNVSCPEGKPEALWVEERTAHIAVR 840

QY 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFTTI 875
DB 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFTTI 875

RESULT 7
ADE65983
ID ADE65983 standard; protein; 875 AA.
XX
AC ADE65983;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human 161P2F10B protein variant 1 #5.
XX
KW 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN WO2003040340-A2.
XX
PD 15-MAY-2003.
XX
PF 07-NOV-2002; 2002WO-US036002.
XX
PR 07-NOV-2001; 2001US-00005480.
PR 31-JAN-2002; 2002US-00062109.
XX
XX (AGEN-) AGENSYS INC.
XX
PI Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KM;
PI Morrison RK, Challita-Eid PM;
XX
XX WPI; 2003-441560/41.
XX
PT A composition for diagnosing, preventing and treating cancer (e.g.
PT prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
PT and polypeptides.
XX
PS Example 5; SEQ ID NO 95; 135pp; English.
XX
CC This invention relates to a novel composition which comprises a substance
CC that modulates the status of a novel protein (161P2F10B) and its variants
CC having a sequence of 875 amino acids provided in the specification. The
CC protein of the invention is over-expressed in certain cancers. The
CC compounds of the invention may have cytostatic activity and the sequence
CC of the 161P2F10B protein, and the gene which encodes it, may be useful
CC for gene therapy or the development of a vaccine. The composition and
CC methods of the invention are useful in diagnosing, preventing and
CC treating cancer. The present sequence is the amino acid sequence of the
CC human 161P2F10B variant 1 protein of the invention.
XX
SQ Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKYKTKLKKYKIACIVLLALLVINSIGLGLGLRKLKLEKQSCSKKCFD 60
DB 1 MESTLTATEQPVKYKTKLKKYKIACIVLLALLVINSIGLGLGLRKLKLEKQSCSKKCFD 60

QY 61 ASFRGLNCRCDVACDRGDCWDFDTCVETSTRIMCNKFRCGETRIEASLCSDDCL 120
DB 61 ASFRGLNCRCDVACDRGDCWDFDTCVETSTRIMCNKFRCGETRIEASLCSDDCL 120

QY 121 OKKDCADYKSCQGTSLWLENCDFTAQOSQCEGFDLPVILFSDMGFRAEYLTYDWTL 180
DB 121 OKKDCADYKSCQGTSLWLENCDFTAQOSQCEGFDLPVILFSDMGFRAEYLTYDWTL 180

QY 181 MPNINKLTCGIHSHKYNRAMPYPTKTPPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240
DB 181 MPNINKLTCGIHSHKYNRAMPYPTKTPPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240

QY 241 SKQNNPAMWHGQPMULTANYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPEERIS 300
DB 241 SKQNNPAMWHGQPMULTANYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPEERIS 300

QY 301 TLLKWLDPKAERPRFTYTYFPEPDSHGAGFVSARVIKALQVVDHAFGLMEGLKQRN 360
DB 301 TLLKWLDPKAERPRFTYTYFPEPDSHGAGFVSARVIKALQVVDHAFGLMEGLKQRN 360

QY 361 LHNVCNILLADHGMDOCTYCNMEYMTDYFPRINFEYVYEGAPRIRAHNIPHDFFSNS 420
DB 361 LHNVCNILLADHGMDOCTYCNMEYMTDYFPRINFEYVYEGAPRIRAHNIPHDFFSNS 420

QY 421 EEIVRLNLSCKRPDQHKPVLTPDLPRKLHYAKNVRIDKVLHFDQWLAVRSKSNTCGG 480
DB 421 EEIVRLNLSCKRPDQHKPVLTPDLPRKLHYAKNVRIDKVLHFDQWLAVRSKSNTCGG 480

QY 481 GNGYNNFRSMBAIFLAGHPSFKETEVPEPENIEVNLMDLLRIQAPNNGTHGSLN 540
DB 481 GNGYNNFRSMBAIFLAGHPSFKETEVPEPENIEVNLMDLLRIQAPNNGTHGSLN 540

QY 541 HLLKVPFYPSPSHAEVSKFSVCGFANFLPTESIDCFPHLQNSTOLEQVNMNLNLTQBEI 600
DB 541 HLLKVPFYPSPSHAEVSKFSVCGFANFLPTESIDCFPHLQNSTOLEQVNMNLNLTQBEI 600
```

| | | Matches | 875; | Conservative | 0; | Mismatches | 0; | Indels | 0; | Gaps | 0; |
|--|-----|--|------|--------------|----|------------|----|--------|----|------|----|
| QY | 1 | MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQGSCKKCFD | 60 | | | | | | | | |
| Db | 1 | MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQGSCKKCFD | 60 | | | | | | | | |
| QY | 61 | ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWMCNKRFGCTREASLCSDDCL | 120 | | | | | | | | |
| Db | 61 | ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWMCNKRFGCTREASLCSDDCL | 120 | | | | | | | | |
| QY | 121 | QKDCADYKSVCOGETSWLENCDTAQOQCEGFDLPVILFSDGFRABYLTYWDTL | 180 | | | | | | | | |
| Db | 121 | QKDCADYKSVCOGETSWLENCDTAQOQCEGFDLPVILFSDGFRABYLTYWDTL | 180 | | | | | | | | |
| QY | 181 | MPNINKLTCGHSKYRMAMYPTKTPNNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSL | 240 | | | | | | | | |
| Db | 181 | MPNINKLTCGHSKYRMAMYPTKTPNNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSL | 240 | | | | | | | | |
| QY | 241 | SKEQNNPAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPERIS | 300 | | | | | | | | |
| Db | 241 | SKEQNNPAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPERIS | 300 | | | | | | | | |
| QY | 301 | TLLKWLDPKAEPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN | 360 | | | | | | | | |
| Db | 301 | TLLKWLDPKAEPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN | 360 | | | | | | | | |
| QY | 361 | LHNCVNIILLADHGMDQTCNKMEYMTDYPRINFYMYEGPAPRAHNIHDFFSFNS | 420 | | | | | | | | |
| Db | 361 | LHNCVNIILLADHGMDQTCNKMEYMTDYPRINFYMYEGPAPRAHNIHDFFSFNS | 420 | | | | | | | | |
| QY | 421 | BEIVRLNSCRKPDQHPKPYLTDPKRLHYAKNVRIDKVLHFDVQDQWLAVRSKNTCGG | 480 | | | | | | | | |
| Db | 421 | BEIVRLNSCRKPDQHPKPYLTDPKRLHYAKNVRIDKVLHFDVQDQWLAVRSKNTCGG | 480 | | | | | | | | |
| QY | 481 | GNHGYNNFRSMEAIPLAHGSPFKETVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN | 540 | | | | | | | | |
| Db | 481 | GNHGYNNFRSMEAIPLAHGSPFKETVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN | 540 | | | | | | | | |
| QY | 541 | HLLKVPFYPSPHABEVSKEFCGFANPLPTESLDCPCPLHNSLTQEQVNMNLNLTQBEI | 600 | | | | | | | | |
| Db | 541 | HLLKVPFYPSPHABEVSKEFCGFANPLPTESLDCPCPLHNSLTQEQVNMNLNLTQBEI | 600 | | | | | | | | |
| QY | 601 | TATVKYNLPFGPRVLQKNVDHCLLVHRYVSGFGKAMRMPMWSSYTPQLGDTSPLPPT | 660 | | | | | | | | |
| Db | 601 | TATVKYNLPFGPRVLQKNVDHCLLVHRYVSGFGKAMRMPMWSSYTPQLGDTSPLPPT | 660 | | | | | | | | |
| QY | 661 | VPDCLRADYRVPPSESKCSFYLDANKIITHGFLYPPASNRTSDSQYDALITSNLPMYEE | 720 | | | | | | | | |
| Db | 661 | VPDCLRADYRVPPSESKCSFYLDANKIITHGFLYPPASNRTSDSQYDALITSNLPMYEE | 720 | | | | | | | | |
| QY | 721 | FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDYDGHFDAPDEITKHLANTDVPITPHY | 780 | | | | | | | | |
| Db | 721 | FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDYDGHFDAPDEITKHLANTDVPITPHY | 780 | | | | | | | | |
| QY | 781 | FVVLTSCKNKSHTPENCPOWLDVLPPIIIPHRPTNVESCEGKPEALWVEERTTAHIAVR | 840 | | | | | | | | |
| Db | 781 | FVVLTSCKNKSHTPENCPOWLDVLPPIIIPHRPTNVESCEGKPEALWVEERTTAHIAVR | 840 | | | | | | | | |
| QY | 841 | DVELLGTGLFDYQDKQVPVSEILQLKTYLPTFETI | 875 | | | | | | | | |
| Db | 841 | DVELLGTGLFDYQDKQVPVSEILQLKTYLPTFETI | 875 | | | | | | | | |
| RESULT 8 | | | | | | | | | | | |
| AD265982 | | | | | | | | | | | |
| ADE65982 standard; protein; 875 AA. | | | | | | | | | | | |
| XX | | | | | | | | | | | |
| AC ADE65982; | | | | | | | | | | | |
| XX | | | | | | | | | | | |
| DT 29-JAN-2004 (first entry) | | | | | | | | | | | |
| XX | | | | | | | | | | | |
| DE Human 161P2F10B protein variant 6 #2. | | | | | | | | | | | |
| XX | | | | | | | | | | | |

| | |
|--|---|
| KW | 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human. |
| XX | |
| OS | Homo sapiens. |
| PN | WO2003040340-A2. |
| XX | |
| PD | 15-MAY-2003. |
| XX | |
| XX | 07-NOV-2002; 2002WO-US036002. |
| PR | 07-NOV-2001; 2001US-00005480. |
| PR | 31-JAN-2002; 2002US-00062109. |
| XX | |
| PA | (AGEN-) AGENSYS INC. |
| XX | |
| PI | Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KJM; |
| PI | Morrison RK, Challita-Eid PM; |
| XX | |
| XX | WPI; 2003-441560/41. |
| XX | |
| PT | A composition for diagnosing, preventing and treating cancer (e.g. |
| PT | prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides |
| PT | and polypeptides. |
| PS | Example 5; SEQ ID NO 94; 135bp; English. |
| XX | |
| CC | This invention relates to a novel composition which comprises a substance |
| CC | that modulates the status of a novel protein (161P2F10B) and its variants |
| CC | having a sequence of 875 amino acids provided in the specification. The |
| CC | protein of the invention is over-expressed in certain cancers. The |
| CC | compounds of the invention may have cytostatic activity and the sequence |
| CC | of the 161P2F10B protein, and the gene which encodes it, may be useful |
| CC | for gene therapy or the development of a vaccine. The composition and |
| CC | methods of the invention are useful in diagnosing, preventing and |
| CC | treating cancer. The present sequence is the amino acid sequence of the |
| CC | human 161P2F10B variant 6 protein of the invention. |
| XX | |
| SQ | Sequence 875 AA; |
| Query Match 100.0%; Score 4804; DB 7; Length 875; | |
| Best Local Similarity 100.0%; Pred. No. 0; | |
| Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0; | |
| QY | 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQGSCKKCFD 60 |
| Db | 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQGSCKKCFD 60 |
| QY | 61 ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWMCNKRFGCTREASLCSDDCL 120 |
| Db | 61 ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWMCNKRFGCTREASLCSDDCL 120 |
| QY | 121 QKDCADYKSVCOGETSWLENCDTAQOQCEGFDLPVILFSDGFRABYLTYWDTL 180 |
| Db | 121 QKDCADYKSVCOGETSWLENCDTAQOQCEGFDLPVILFSDGFRABYLTYWDTL 180 |
| QY | 181 MPNINKLTCGHSKYRMAMYPTKTPNNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSL 240 |
| Db | 181 MPNINKLTCGHSKYRMAMYPTKTPNNHYTIVTGLYPESHGIIIDNNMYDNLNKNFSL 240 |
| QY | 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPERIS 300 |
| Db | 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSYMPYNGSVFPERIS 300 |
| QY | 301 TLLKWLDPKAEPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360 |
| Db | 301 TLLKWLDPKAEPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360 |
| QY | 361 LHNCVNIILLADHGMDQTCNKMEYMTDYPRINFYMYEGPAPRAHNIHDFFSFNS 420 |
| Db | 361 LHNCVNIILLADHGMDQTCNKMEYMTDYPRINFYMYEGPAPRAHNIHDFFSFNS 420 |
| QY | 421 BEIVRLNSCRKPDQHPKPYLTDPKRLHYAKNVRIDKVLHFDVQDQWLAVRSKNTCGG 480 |

Db 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOVLAVRSKSNTCGG 480
QY 481 GNHGYNNFRSMEAI FLAHGSPFKETEVPEPENTIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNHGYNNFRSMEAI FLAHGSPFKETEVPEPENTIEVYNLMCDLLRIQAPNNGTHGSLN 540
QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDLFCPHLQNSTOLEQVQMLNLTQBEI 600
Db 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDLFCPHLQNSTOLEQVQMLNLTQBEI 600
QY 601 TATVKVNLPEGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTPQLGDTSPLPPT 660
Db 601 TATVKVNLPEGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTPQLGDTSPLPPT 660
QY 661 VPCLRADVRVPSESKFSFYLDKQNI THGFLYPPASNRTSDSQYDALITSNLVPMYEE 720
Db 661 VPCLRADVRVPSESKFSFYLDKQNI THGFLYPPASNRTSDSQYDALITSNLVPMYEE 720
QY 721 FRKMWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPPIPHY 780
Db 721 FRKMWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPPIPHY 780
QY 781 FVVLTSCKNKSHTPCNCPGMLDVLPII PHRTNVSCEPGKPEALWVEERFTHAIARVR 840
Db 781 FVVLTSCKNKSHTPCNCPGMLDVLPII PHRTNVSCEPGKPEALWVEERFTHAIARVR 840
QY 841 DVELLTGLDFYQDKVPQVSEILQKTYLPTFTTTI 875
Db 841 DVELLTGLDFYQDKVPQVSEILQKTYLPTFTTTI 875

RESULT 9

ID ADE65909 standard; protein; 875 AA.

XX AC ADE65909;

XX DT 29-JAN-2004 (first entry)

XX DE Human 161P2F10B protein variant 1 #3.

XX KW 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.

XX OS Homo sapiens.

XX PN WO2003040340-A2.

XX PD 15-MAY-2003.

XX PF 07-NOV-2002; 2002WO-US036002.

XX PR 07-NOV-2001; 2001US-00005480.

XX PR 31-JAN-2002; 2002US-00062109.

XX PA (AGEN-) AGENSYS INC.

XX PI Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KM;

XX PI Morrison RK, Chailita-Eid PM;

XX DR WPI; 2003-441560/41.

XX PT A composition for diagnosing, preventing and treating cancer (e.g.

XX PT prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides

XX PT and polypeptides.

XX PS Example 2; SEQ ID NO 21; 135pp; English.

XX CC This invention relates to a novel composition which comprises a substance
XX CC that modulates the status of a novel protein (161P2F10B) and its variants
XX CC having a sequence of 875 amino acids provided in the specification. The
XX CC protein of the invention is over-expressed in certain cancers. The
XX CC compounds of the invention may have cytostatic activity and the sequence
XX CC of the 161P2F10B protein, and the gene which encodes it, may be useful

CC for gene therapy or the development of a vaccine. The composition and
CC methods of the invention are useful in diagnosing, preventing and
CC treating cancer. The present sequence is the amino acid sequence of the
CC human 161P2F10B variant 1 protein of the invention.

XX Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTILATEQPVKNTLKYYKIACIVLLALLVIMSLGGLGLKRLKQKSCRKKCFD 60

Db 1 MESTLTILATEQPVKNTLKYYKIACIVLLALLVIMSLGGLGLKRLKQKSCRKKCFD 60

QY 61 ASFRGLENCRCDVACDRGDCWDFETCVESFRIWMCNKFRGCTRLBASLCSGSDCL 120

Db 61 ASFRGLENCRCDVACDRGDCWDFETCVESFRIWMCNKFRGCTRLBASLCSGSDCL 120

QY 121 QKXCCADYKSVCOGTSNLENCDTAQOSQCEGDLPPVILFSDMGFAEVLVTDLT 180

Db 121 QKXCCADYKSVCOGTSNLENCDTAQOSQCEGDLPPVILFSDMGFAEVLVTDLT 180

QY 181 MPNINKLKTGCIHSKYMRAWYPTKTFPNHYTIVTGLYPESHGIIIDNNMYDVLNKNFSL 240

Db 181 MPNINKLKTGCIHSKYMRAWYPTKTFPNHYTIVTGLYPESHGIIIDNNMYDVLNKNFSL 240

QY 241 SKQNNPAWHGQPMMLTAMYQGLKAATYFPGSEVAINGSPSIYMPYNGSVPPERIS 300

Db 241 SKQNNPAWHGQPMMLTAMYQGLKAATYFPGSEVAINGSPSIYMPYNGSVPPERIS 300

QY 301 TLLKWLDPKAEPRFYTMYFEBPDSGSHAGGSARVTKALQVVDHAFGLMEGLKQKN 360

Db 301 TLLKWLDPKAEPRFYTMYFEBPDSGSHAGGSARVTKALQVVDHAFGLMEGLKQKN 360

QY 361 LHCNVNIIILLADHGMDOQYCNKMEYMTDYPFRINFPYMEGAPAPRAINIPHDFFS 420

Db 361 LHCNVNIIILLADHGMDOQYCNKMEYMTDYPFRINFPYMEGAPAPRAINIPHDFFS 420

QY 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOVLAVRSKSNTCGG 480

Db 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOVLAVRSKSNTCGG 480

QY 481 GNHGYNNFRSMEAI FLAHGSPFKETEVPEPENTIEVYNLMCDLLRIQAPNNGTHGSLN 540

Db 481 GNHGYNNFRSMEAI FLAHGSPFKETEVPEPENTIEVYNLMCDLLRIQAPNNGTHGSLN 540

QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDLFCPHLQNSTOLEQVQMLNLTQBEI 600

Db 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDLFCPHLQNSTOLEQVQMLNLTQBEI 600

QY 601 TATVKVNLPEGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTPQLGDTSPLPPT 660

Db 601 TATVKVNLPEGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTPQLGDTSPLPPT 660

QY 661 VPCLRADVRVPSESKFSFYLDKQNI THGFLYPPASNRTSDSQYDALITSNLVPMYEE 720

Db 661 VPCLRADVRVPSESKFSFYLDKQNI THGFLYPPASNRTSDSQYDALITSNLVPMYEE 720

QY 721 FRKMWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPPIPHY 780

Db 721 FRKMWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPPIPHY 780

QY 781 FVVLTSCKNKSHTPCNCPGMLDVLPII PHRTNVSCEPGKPEALWVEERFTHAIARVR 840

Db 781 FVVLTSCKNKSHTPCNCPGMLDVLPII PHRTNVSCEPGKPEALWVEERFTHAIARVR 840

QY 841 DVELLTGLDFYQDKVPQVSEILQKTYLPTFTTTI 875

Db 841 DVELLTGLDFYQDKVPQVSEILQKTYLPTFTTTI 875

RESULT 10

```
AD65984
ID   AD65984 standard; protein; 875 AA.
AC   AD65984;
DT   29-JAN-2004 (first entry)
XX
DE   Human 161P2F10B protein variant 6 #3.
KW   161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.
OS   Homo sapiens.
PN   WO2003040340-A2.
XX
PD   15-MAY-2003.
XX
PR   07-NOV-2001; 2001US-00005480.
XX
PR   31-JAN-2002; 2002US-00062109.
XX
PA   (AGEN-) AGENSYS INC.
XX
PI   Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KJM;
PI   Morrison RK, Challita-Eid PM;
XX
DR   WPI; 2003-441560/41.
XX
PT   A composition for diagnosing, preventing and treating cancer (e.g.
PT   prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
PT   and polypeptides.
PS   Example 5; SEQ ID NO 96; 135pp; English.
XX
CC   This invention relates to a novel composition which comprises a substance
CC   that modulates the status of a novel protein (161P2F10B) and its variants
CC   having a sequence of 875 amino acids provided in the specification. The
CC   protein of the invention is over-expressed in certain cancers. The
CC   compounds of the invention may have cytostatic activity and the sequence
CC   of the 161P2F10B protein, and the gene which encodes it, may be useful
CC   for gene therapy or the development of a vaccine. The composition and
CC   methods of the invention are useful in diagnosing, preventing and
CC   treating cancer. The present sequence is the amino acid sequence of the
CC   human 161P2F10B variant 6 protein of the invention.
XX
SQ   Sequence 875 AA;
Query Match          100.0%; Score 4804; DB 7; Length 875;
Best Local Similarity 100.0%; Pred. NO. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY   1 MESTLTLEQEPVKKNTLKKYKIACIVLLALLVIMSLGLGLGRLKLEKQSGCRKKCFD 60
DB   1 MESTLTLEQEPVKKNTLKKYKIACIVLLALLVIMSLGLGLGRLKLEKQSGCRKKCFD 60
QY   61 ASFRGLENCRCVACKDRGDCWDFEDTCVESTRIWMCNKRFCGETRIEASLCSDDCDL 120
DB   61 ASFRGLENCRCVACKDRGDCWDFEDTCVESTRIWMCNKRFCGETRIEASLCSDDCDL 120
QY   121 OKKDCCADYKSVCGGTSWLENCDTAQOQCPEGFDLPPVILFSDGPRAEVLYTWDTL 180
DB   121 OKKDCCADYKSVCGGTSWLENCDTAQOQCPEGFDLPPVILFSDGPRAEVLYTWDTL 180
QY   181 MPNINKLKTGCIHSKYWRAMYPTKTPPNHYTIVTGLYPESHGIIIDNMVDMNKNFSL 240
DB   181 MPNINKLKTGCIHSKYWRAMYPTKTPPNHYTIVTGLYPESHGIIIDNMVDMNKNFSL 240
QY   241 SKQNNPAMWHGQPMMLTAMYQGLKAATYFWPGSEVAINGSPFSIYMPYNGSVPFEEIS 300
DB   241 SKQNNPAMWHGQPMMLTAMYQGLKAATYFWPGSEVAINGSPFSIYMPYNGSVPFEEIS 300
QY   301 TLLKWLDPKAERPRFYTWYFEEPDSSGHAGGVSARVIKALQVVDHAFGMLMEGLKQRN 360
DB   301 TLLKWLDPKAERPRFYTWYFEEPDSSGHAGGVSARVIKALQVVDHAFGMLMEGLKQRN 360
QY   361 LHCNVNIIILLADHGMQDYCNKMEYMTDYPFRINFFYMYEGPAPRIRAHNIPHDFFSFNS 420
DB   361 LHCNVNIIILLADHGMQDYCNKMEYMTDYPFRINFFYMYEGPAPRIRAHNIPHDFFSFNS 420
QY   421 EEIVRNLSCRKPDQCHFKPYLTPDLPKRLHYAKNVRIDKVLHFDVQOQWLAVRSKNTNCGG 480
DB   421 EEIVRNLSCRKPDQCHFKPYLTPDLPKRLHYAKNVRIDKVLHFDVQOQWLAVRSKNTNCGG 480
QY   481 GNEGYNNEFRSMEAI FLAHGPFSEKTEVEPFENIEVYNLMCDLLRIQPAPNNGTHGSLN 540
DB   481 GNEGYNNEFRSMEAI FLAHGPFSEKTEVEPFENIEVYNLMCDLLRIQPAPNNGTHGSLN 540
QY   541 HLLKVPPEYPSHAEVSKFSVCGFANPLPTESLDCFCPLHQLNSTOLEQVNMNLNLTQEEI 600
DB   541 HLLKVPPEYPSHAEVSKFSVCGFANPLPTESLDCFCPLHQLNSTOLEQVNMNLNLTQEEI 600
QY   601 TATVKVNLPRGRPRVLQKNVDHCLLYHREVYSGFGKAMRMPMKSSYTVPOLGDTSPLPPT 660
DB   601 TATVKVNLPRGRPRVLQKNVDHCLLYHREVYSGFGKAMRMPMKSSYTVPOLGDTSPLPPT 660
QY   661 VPDCLRADVRVPPSESQKCSFYLDXNITHGFYPPASNETSDSQYDALITSNLVPMYEE 720
DB   661 VPDCLRADVRVPPSESQKCSFYLDXNITHGFYPPASNETSDSQYDALITSNLVPMYEE 720
QY   721 FRKWMDYFHSVLLIKHATERNGVNVSGPIFDYNGDHFADPDEITKHLANTDVPIPTHY 780
DB   721 FRKWMDYFHSVLLIKHATERNGVNVSGPIFDYNGDHFADPDEITKHLANTDVPIPTHY 780
QY   781 FVVLTSCKNKSHTPENCPCGWLVDLVPFIIPHRPTNVESCPGKPEALWVEERFTHARVR 840
DB   781 FVVLTSCKNKSHTPENCPCGWLVDLVPFIIPHRPTNVESCPGKPEALWVEERFTHARVR 840
QY   841 DVELLTGLDFYQDKVQVPSHILQIKTYLPFTFTI 875
DB   841 DVELLTGLDFYQDKVQVPSHILQIKTYLPFTFTI 875
RESULT 11
ID   AD65991 standard; protein; 875 AA.
AC   AD65991;
XX
DT   29-JAN-2004 (first entry)
XX
DE   Human 161P2F10B protein variant 1 #6.
XX
KW   161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.
XX
OS   Homo sapiens.
XX
PN   WO2003040340-A2.
XX
PD   15-MAY-2003.
XX
PR   07-NOV-2002; 2002WO-US036002.
XX
PR   07-NOV-2001; 2001US-00005480.
XX
PR   31-JAN-2002; 2002US-00062109.
XX
PA   (AGEN-) AGENSYS INC.
XX
PI   Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KJM;
PI   Morrison RK, Challita-Eid PM;
XX
DR   WPI; 2003-441560/41.
XX
PT   A composition for diagnosing, preventing and treating cancer (e.g.
PT   prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
PT   and polypeptides.
```

XX Disclosure; Fig 13A; 135pp; English.

XX This invention relates to a novel composition which comprises a substance

CC that modulates the status of a novel protein (161P2F10B) and its variants

CC having a sequence of 875 amino acids provided in the specification. The

CC protein of the invention is over-expressed in certain cancers. The

CC compounds of the invention may have cytostatic activity and the sequence

CC of the 161P2F10B protein, and the gene which encodes it, may be useful

CC for gene therapy or the development of a vaccine. The composition and

CC methods of the invention are useful in diagnosing, preventing and

CC treating cancer. The present sequence is the amino acid sequence of the

CC human 161P2F10B variant 1 protein of the invention.

XX

SQ Sequence 875 AA;

Query Match 100.0%; Score 4804; DB 7; Length 875;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIALLVIMSLGLGLGRLKLEKQSCSRKCKCFD 60

DB 1 MESTLTATEQPVKNTLKKYKIACIALLVIMSLGLGLGRLKLEKQSCSRKCKCFD 60

QY 61 ASFRGLENCRCVACDRGDCWDEDTCTVESTRIMWCKNFKCGTRLEASI-CSSDDCL 120

DB 61 ASFRGLENCRCVACDRGDCWDEDTCTVESTRIMWCKNFKCGTRLEASLCSSDDCL 120

QY 121 QKDCADYKSCQGETSWLENCNTAQSCQCEGFDLPVILFMSMDGFRAEYLYTWDTL 180

DB 121 QKDCADYKSCQGETSWLENCNTAQSCQCEGFDLPVILFMSMDGFRAEYLYTWDTL 180

QY 181 MNINKLTCGHSKYRMYPTKFPNHYTIVTGLYPESHGIIIDNNYDYNLKNFSL 240

DB 181 MNINKLTCGHSKYRMYPTKFPNHYTIVTGLYPESHGIIIDNNYDYNLKNFSL 240

QY 241 SKEQNPANWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPFSIYMPYNGSVVPEERIS 300

DB 241 SKEQNPANWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPFSIYMPYNGSVVPEERIS 300

QY 301 TLLKWLDPKAEPRRYTYTFEEDSSHAGGFPVSARVICALQVVDHAFGLMGLKQRN 360

DB 301 TLLKWLDPKAEPRRYTYTFEEDSSHAGGFPVSARVICALQVVDHAFGLMGLKQRN 360

QY 361 LHCNVNIIILADHGMDOQTCNKMEYMTDYFRINFFYVYEGPAPRIAHNIPHDFSFNS 420

DB 361 LHCNVNIIILADHGMDOQTCNKMEYMTDYFRINFFYVYEGPAPRIAHNIPHDFSFNS 420

QY 421 EIVRLNLSCKRQDHPKPYLTDLPRKRLHYAKNRIDKVLHFDQOQWLAVRSKNTNCGG 480

DB 421 EIVRLNLSCKRQDHPKPYLTDLPRKRLHYAKNRIDKVLHFDQOQWLAVRSKNTNCGG 480

QY 481 GNHGYNNEFRSMEAFPLANGPSEKTEVEPENTEVNLMCDLRIOPAPNNGTHGSLN 540

DB 481 GNHGYNNEFRSMEAFPLANGPSEKTEVEPENTEVNLMCDLRIOPAPNNGTHGSLN 540

QY 541 HLLKVPFFYEPSSHAESVSKFSVCGFANPLPTESLDCFCPLHQLNSTOLEQVQMLNLTQBEI 600

DB 541 HLLKVPFFYEPSSHAESVSKFSVCGFANPLPTESLDCFCPLHQLNSTOLEQVQMLNLTQBEI 600

QY 601 TATVKNLDPGPRVLQKNVDHCLLYHREYVSGFGKAMRMPMSSYTYVQLGDTSPILPT 660

DB 601 TATVKNLDPGPRVLQKNVDHCLLYHREYVSGFGKAMRMPMSSYTYVQLGDTSPILPT 660

QY 661 VPDCLRADVRVPSSSKQCSFYLDKNTIHTGLYPASNRTSDSQYDALITSNLPVYEE 720

DB 661 VPDCLRADVRVPSSSKQCSFYLDKNTIHTGLYPASNRTSDSQYDALITSNLPVYEE 720

QY 721 FRKMDYFHSVLLIKHATERGNVNVSGPIFDYNDGHFDAPDEITKGLANTDVPITPHY 780

DB 721 FRKMDYFHSVLLIKHATERGNVNVSGPIFDYNDGHFDAPDEITKGLANTDVPITPHY 780

QY 781 FVVLTSCKNKSHTPENCPCGWLVDLPFIIPHRPTNVESCPGKPEALWVEERFTHAIAVR 840

DB 781 FVVLTSCKNKSHTPENCPCGWLVDLPFIIPHRPTNVESCPGKPEALWVEERFTHAIAVR 840

QY 841 DVELLTGLDFYQDKVQVPSVSILOLKYLYLPTFETI 875

DB 841 DVELLTGLDFYQDKVQVPSVSILOLKYLYLPTFETI 875

RESULT 12

AD65910

ID AD65910 standard; protein; 875 AA.

XX AC AD65910;

XX 29-JAN-2004 (first entry)

XX Human 161P2F10B protein K122R variant.

XX 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.

XX Homo sapiens.

XX WO2003040340-A2.

XX 15-MAY-2003.

XX 07-NOV-2002; 2002WO-US036002.

XX 07-NOV-2001; 2001US-00005480.

XX 31-JAN-2002; 2002US-00062109.

XX (AGEN-) AGENSYS INC.

XX Jakobovits A, Raitano AB, Paris M, Hubert RS, Ge W, Morrison KM;

XX Morrison RK, Challita-Eid PM;

XX WPI; 2003-441560/41.

XX A composition for diagnosing, preventing and treating cancer (e.g. prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides and polypeptides.

XX Example 2; SEQ ID NO 22; 135pp; English.

XX This invention relates to a novel composition which comprises a substance that modulates the status of a novel protein (161P2F10B) and its variants having a sequence of 875 amino acids provided in the specification. The protein of the invention is over-expressed in certain cancers. The compounds of the invention may have cytostatic activity and the sequence of the 161P2F10B protein, and the gene which encodes it, may be useful for gene therapy or the development of a vaccine. The composition and methods of the invention are useful in diagnosing, preventing and treating cancer. The present sequence is the amino acid sequence of the human 161P2F10B K122R variant protein which was used for homology purposes and is related to the invention.

XX

SQ Sequence 875 AA;

Query Match 99.9%; Score 4801; DB 7; Length 875;

Best Local Similarity 99.9%; Pred. No. 0;

Matches 874; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIALLVIMSLGLGLGRLKLEKQSCSRKCKCFD 60

DB 1 MESTLTATEQPVKNTLKKYKIACIALLVIMSLGLGLGRLKLEKQSCSRKCKCFD 60

QY 61 ASFRGLENCRCVACDRGDCWDEDTCTVESTRIMWCKNFKCGTRLEASI-CSSDDCL 120

DB 61 ASFRGLENCRCVACDRGDCWDEDTCTVESTRIMWCKNFKCGTRLEASLCSSDDCL 120

QY 121 QKDCADYKSCQGETSWLENCNTAQSCQCEGFDLPVILFMSMDGFRAEYLYTWDTL 180

DB 121 QKDCADYKSCQGETSWLENCNTAQSCQCEGFDLPVILFMSMDGFRAEYLYTWDTL 180

```
QY 181 MPNINKLKTGIIHSKYRMYPTKTPNNHYITVGLYPESHGIIIDNNMVDVNLKNFSL 240
Db 181 MENINKLKTGIIHSKYRMYPTKTPNNHYITVGLYPESHGIIIDNNMVDVNLKNFSL 240
QY 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSIYMPYNGSVPEERIS 300
Db 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSIYMPYNGSVPEERIS 300
QY 301 TLLKWLDPKAERPRFTYMTYFEPDSSGHAGGVPVSARVIALQVVDHAFGLMEGLKQ 360
Db 301 TLLKWLDPKAERPRFTYMTYFEPDSSGHAGGVPVSARVIALQVVDHAFGLMEGLKQ 360
QY 361 LHNVCNIIILLADHGMDQTYCNKMEYMTDYPFRINFFYMEGAPAPRAHNI PHDFFS 420
Db 361 LHNVCNIIILLADHGMDQTYCNKMEYMTDYPFRINFFYMEGAPAPRAHNI PHDFFS 420
QY 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQDQWLA VRKSN 480
Db 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQDQWLA VRKSN 480
QY 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTH 540
Db 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTH 540
QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCTCPHLQNSQLEQVNMNL 600
Db 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCTCPHLQNSQLEQVNMNL 600
QY 601 TATVKVNLPGFRVQLQNDHCLLYHREVSVGFGKAMPMPMSSYTVPLGDTSP 660
Db 601 TATVKVNLPGFRVQLQNDHCLLYHREVSVGFGKAMPMPMSSYTVPLGDTSP 660
QY 661 VPDCLRADVRVPSESKCSFYADKNITHGFLYPASNRTSDSYDALITSNLVPM 720
Db 661 VPDCLRADVRVPSESKCSFYADKNITHGFLYPASNRTSDSYDALITSNLVPM 720
QY 721 FRKMDYFHSVLLIKHATERGVNVSGPIFDYNDGHPDAPDEITKHLANTDV 780
Db 721 FRKMDYFHSVLLIKHATERGVNVSGPIFDYNDGHPDAPDEITKHLANTDV 780
QY 781 FVILTCKNKSHTPENCGLDVLPTIIPHRPTNVSCPEGKPEALWBERFTA 840
Db 781 FVILTCKNKSHTPENCGLDVLPTIIPHRPTNVSCPEGKPEALWBERFTA 840
QY 841 DVELLTGLDFQDKVQPVSEILQIKTLPFTETI 875
Db 841 DVELLTGLDFQDKVQPVSEILQIKTLPFTETI 875
```

RESULT 13

AD65905
ID AD65905 standard; protein; 875 AA.

AC AD65905;

XX 29-JAN-2004 (first entry)

DT Human 161P2F10B protein variant 2 #2.

DE 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.

KW Homo sapiens.

OS WO2003040340-A2.

PN 15-MAY-2003.

XX 07-NOV-2002; 2002WO-US036002.

XX 07-NOV-2001; 2001US-00005480.

PR 31-JAN-2002; 2002US-00062109.

XX

(AGEN-) AGENSYS INC.

Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KM;
Morrison RK, Challita-Eid PW;

WPI; 2003-441560/41.

DR N-PSDB; ADE65893.

XX A composition for diagnosing, preventing and treating cancer (e.g.
prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
and polypeptides.

PS Example 1; SEQ ID NO 17; 135pp; English.

XX This invention relates to a novel composition which comprises a substance
that modulates the status of a novel protein (161P2F10B) and its variants
having a sequence of 875 amino acids provided in the specification. The
protein of the invention is over-expressed in certain cancers. The
compounds of the invention may have cytostatic activity and the sequence
of the 161P2F10B protein, and the gene which encodes it, may be useful
for gene therapy or the development of a vaccine. The composition and
methods of the invention are useful in diagnosing, preventing and
treating cancer. The present sequence is the amino acid sequence of the
human 161P2F10B variant 2 protein of the invention.

XX Sequence 875 AA;

Query Match 99.9%; Score 4801; DB 7; Length 875;

Best Local Similarity 99.9%; Pred. No. 0;

Matches 874; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 MESTLTATQPKYKNTLKYKIACIVLLALLVMSLGLGLGLKLEKQSKCKKCFD 60
Db 1 MESTLTATQPKYKNTLKYKIACIVLLALLVMSLGLGLGLKLEKQSKCKKCFD 60
QY 61 ASFRGLENCDCVACDRGDCDCCDFEDTCTVETRIWCKNFKRCGETLEASLCSDDCL 120
Db 61 ASFRGLENCDCVACDRGDCDCCDFEDTCTVETRIWCKNFKRCGETLEASLCSDDCL 120
QY 121 QKDCADYKSVCGQETSWLENCDTAQSQCEGFDLPVILFSDMGFRAEYLYTWDTL 180
Db 121 QKDCADYKSVCGQETSWLENCDTAQSQCEGFDLPVILFSDMGFRAEYLYTWDTL 180
QY 181 MPNINKLKTGIIHSKYRMYPTKTPNNHYITVGLYPESHGIIIDNNMVDVNLKNFSL 240
Db 181 MPNINKLKTGIIHSKYRMYPTKTPNNHYITVGLYPESHGIIIDNNMVDVNLKNFSL 240
QY 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSIYMPYNGSVPEERIS 300
Db 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSIYMPYNGSVPEERIS 300
QY 301 TLLKWLDPKAERPRFTYMTYFEPDSSGHAGGVPVSARVIALQVVDHAFGLMEGLKQ 360
Db 301 TLLKWLDPKAERPRFTYMTYFEPDSSGHAGGVPVSARVIALQVVDHAFGLMEGLKQ 360
QY 361 LHNVCNIIILLADHGMDQTYCNKMEYMTDYPFRINFFYMEGAPAPRAHNI PHDFFS 420
Db 361 LHNVCNIIILLADHGMDQTYCNKMEYMTDYPFRINFFYMEGAPAPRAHNI PHDFFS 420
QY 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQDQWLA VRKSN 480
Db 421 BEIVRNLSCKRPDQHPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQDQWLA VRKSN 480
QY 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTH 540
Db 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTH 540
QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCTCPHLQNSQLEQVNMNL 600
Db 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCTCPHLQNSQLEQVNMNL 600
QY 601 TATVKVNLPGFRVQLQNDHCLLYHREVSVGFGKAMPMPMSSYTVPLGDTSP 660
Db 601 TATVKVNLPGFRVQLQNDHCLLYHREVSVGFGKAMPMPMSSYTVPLGDTSP 660
```

DB 601 TATVKNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRMPWSSYTVPOLGDTSPLPPT 660
 QY 661 VPDCLRADVRVPSESKCSFYLDKNIITHGFLYPPASNR7SDSDALITSNLVPYEE 720
 DB 661 VPDCLRADVRVPSESKCSFYLDKNIITHGFLYPPASNR7SDSDALITSNLVPYEE 720
 QY 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
 DB 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
 QY 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVSCPEGKPEALWVEERFTHIAVR 840
 DB 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVSCPEGKPEALWVEERFTHIAVR 840
 QY 841 DVELLTGLDFYQDKVQVPVSEILQLKTYLPTFTTI 875
 DB 841 DVELLTGLDFYQDKVQVPVSEILQLKTYLPTFTTI 875

RESULT 14

AD65893
 ID ADE65893 standard; protein; 875 AA.

AC ADE65893;
 DT 29-JAN-2004 (first entry)

XX Human 161P2F10B protein variant 2.

XX 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.

XX Homo sapiens.

XX NC0203040340-A2.

XX 15-MAY-2003.

XX 07-NOV-2002; 2002WO-US036002.

XX 07-NOV-2001; 2001US-00005480.

XX 31-JAN-2002; 2002US-00062109.

XX (AGEN-) AGENSYS INC.

XX Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KJM;

XX Morrison RK, Challita-Bid PM;

XX WPI; 2003-441560/41.

XX N-PSDB; AD565892.

XX A composition for diagnosing, preventing and treating cancer (e.g. prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides and polypeptides.

XX Claim 1; SEQ ID NO 5; 135pp; English.

XX This invention relates to a novel composition which comprises a substance that modulates the status of a novel protein (161P2F10B) and its variants having a sequence of 875 amino acids provided in the specification. The protein of the invention is over-expressed in certain cancers. The compounds of the invention may have cytostatic activity and the sequence of the 161P2F10B protein, and the gene which encodes it, may be useful for gene therapy or the development of a vaccine. The composition and methods of the invention are useful in diagnosing, preventing and treating cancer. The present sequence is the amino acid sequence of the human 161P2F10B variant 2 protein of the invention.

XX Sequence 875 AA;

XX Query Match 99.9%; Score 4801; DB 7; Length 875;

XX Best Local Similarity 99.9%; Pred. No. 0;

XX Matches 874; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTLTATEQPVKQNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQGSCKKCFD 60
 DB 1 MESTLTLTATEQPVKQNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQGSCKKCFD 60
 QY 61 ASFGLENCRCDVACKDGGCCWDPEDTCVESTETIWNKFRCGETRELASLCSDDCL 120
 DB 61 ASFGLENCRCDVACKDGGCCWDPEDTCVESTETIWNKFRCGETRELASLCSDDCL 120
 QY 121 QKDCADYKSVCCOGETSWLEENCDTAQQSCPEGFDLPVILFSDMGFRAEYLYTWDTL 180
 DB 121 QKDCADYKSVCCOGETSWLEENCDTAQQSCPEGFDLPVILFSDMGFRAEYLYTWDTL 180
 QY 181 MPNTNKLKTCGIHSHKYNRAMPYPTKTFPNHYTIVTGLYPESHGIIIDNNMYOVNKNQPSLS 240
 DB 181 MPNTNKLKTCGIHSHKYNRAMPYPTKTFPNHYTIVTGLYPESHGIIIDNNMYOVNKNQPSLS 240
 QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSPFSIYMPYNGSVPFEEIS 300
 DB 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSPFSIYMPYNGSVPFEEIS 300
 QY 301 TLLKWLDPKAERPRFTMYFEPPDSSGHAGGVPVSARVIKALQVDFHAFOMLMEGLKQRN 360
 DB 301 TLLKWLDPKAERPRFTMYFEPPDSSGHAGGVPVSARVIKALQVDFHAFOMLMEGLKQRN 360
 QY 361 LHCNVNIIILLADHGMDOCTYCNKMEYMTDYPFRINFFYMEGAPAPRAHNIIPHDFSFS 420
 DB 361 LHCNVNIIILLADHGMDOCTYCNKMEYMTDYPFRINFFYMEGAPAPRAHNIIPHDFSFS 420
 QY 421 BEIVRNLSCKRPDQHFEPYITDLPKRLHYAKNVRIDKVHLFVDQOQWLAVRSKNTNCG 480
 DB 421 BEIVRNLSCKRPDQHFEPYITDLPKRLHYAKNVRIDKVHLFVDQOQWLAVRSKNTNCG 480
 QY 481 GNEGYNNPESMEAI FLAHPSPFKEKTEVEPENIEVNLKCDLRIOPAPNNGTHGSLN 540
 DB 481 GNEGYNNPESMEAI FLAHPSPFKEKTEVEPENIEVNLKCDLRIOPAPNNGTHGSLN 540
 QY 541 HLLKVPFYPFSAEVSKEFSVCGFANPLPTESLDGFCPHLQNSTOLEQVNMNLTOEBI 600
 DB 541 HLLKVPFYPFSAEVSKEFSVCGFANPLPTESLDGFCPHLQNSTOLEQVNMNLTOEBI 600
 QY 601 TATVKVNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRMPWSSYTVPOLGDTSPLPPT 660
 DB 601 TATVKVNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRMPWSSYTVPOLGDTSPLPPT 660
 QY 661 VPDCLRADVRVPSESKCSFYLDKNIITHGFLYPPASNR7SDSDALITSNLVPYEE 720
 DB 661 VPDCLRADVRVPSESKCSFYLDKNIITHGFLYPPASNR7SDSDALITSNLVPYEE 720
 QY 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
 DB 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
 QY 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVSCPEGKPEALWVEERFTHIAVR 840
 DB 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVSCPEGKPEALWVEERFTHIAVR 840
 QY 841 DVELLTGLDFYQDKVQVPVSEILQLKTYLPTFTTI 875
 DB 841 DVELLTGLDFYQDKVQVPVSEILQLKTYLPTFTTI 875

RESULT 15

AD65897

ID ADE65897 standard; protein; 875 AA.

XX ADE65897;

XX 29-JAN-2004 (first entry)

XX Human 161P2F10B protein variant 4.

XX 161P2F10B; cancer; cytostatic; gene therapy; vaccine; human.

OS Homo sapiens.
XX WO2003040340-A2.
XX 15-MAY-2003.
XX 07-NOV-2002; 2002WO-US036002.
XX 07-NOV-2001; 2001US-00005480.
XX 31-JAN-2002; 2002US-00062109.
XX (AGEN-) AGENSYS INC.
XX Jakobovits A, Raitano AB, Faris M, Hubert RS, Ge W, Morrison KJM;
XX Morrison RK, Challita-Eid PM;
XX WPI: 2003-441560/41.
XX N-PSDB; ADE65896.
XX
XX A composition for diagnosing, preventing and treating cancer (e.g.
XX prostatic, renal or uterine cancer) comprises 161P2F10B polynucleotides
XX and polypeptides.
XX Claim 1; SEQ ID NO 9; 135pp; English.
XX
XX This invention relates to a novel composition which comprises a substance
XX that modulates the status of a novel protein (161P2F10B) and its variants
XX having a sequence of 875 amino acids provided in the specification. The
XX protein of the invention is over-expressed in certain cancers. The
XX compounds of the invention may have cytostatic activity and the sequence
XX of the 161P2F10B protein, and the gene which encodes it, may be useful
XX for gene therapy or the development of a vaccine. The composition and
XX methods of the invention are useful in diagnosing, preventing and
XX treating cancer. The present sequence is the amino acid sequence of the
XX human 161P2F10B variant 4 protein of the invention.
XX
XX Sequence 875 AA;
SQ
Query Match 99.9%; Score 4798; DB 7; Length 875;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 874; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MESTLTATEQPVKNTLKKYKIACIVLIALVIMSLGILGLGLKLEKQSGCRKKCFD 60
Db 1 MESTLTATEQPVKNTLKKYKIACIVLIALVIMSLGILGLGLKLEKQSGCRKKCFD 60
QY 61 ASFRGLENCRCVACKDRGDCWDPEDTCTVESTRIWMCNFKRCGETRLEASLCSDCL 120
Db 61 ASFRGLENCRCVACKDRGDCWDPEDTCTVESTRIWMCNFKRCGETRLEASLCSDCL 120
QY 121 QKDCADYKSVCCQGETSWELENCDTAQSCQCEGFDLPVILFSGMDGFAEYLYTWDTL 180
Db 121 QKDCADYKSVCCQGETSWELENCDTAQSCQCEGFDLPVILFSGMDGFAEYLYTWDTL 180
QY 181 MPNINKLKTGHIHSKYNRAMYPTKTPPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240
Db 181 MPNINKLKTGHIHSKYNRAMYPTKTPPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240
QY 241 SKQNNPAWHGQPMWLTAMYQGLKAATYFPCSEVAINGSPSIYMPYNGSVPPFEERIS 300
Db 241 SKQNNPAWHGQPMWLTAMYQGLKAATYFPCSEVAINGSPSIYMPYNGSVPPFEERIS 300
QY 301 TLLKWLDPKAEPRFVTMYFEEDPSGSHAGGVPVSARVICALQVVDHAFGLMEGLKORN 360
Db 301 TLLKWLDPKAEPRFVTMYFEEDPSGSHAGGVPVSARVICALQVVDHAFGLMEGLKORN 360
QY 361 LHCNVNIIILLADHGMQTCYCNKMEYMTDYPPIRINFFYMEGAPRIAHNI PHDFFSFS 420
Db 361 LHCNVNIIILLADHGMQTCYCNKMEYMTDYPPIRINFFYMEGAPRIAHNI PHDFFSFS 420
QY 421 EETVRNLSCRPQDQHFKPYLTDPKRLHYAKNVRIDKVLHFVDQOQWLAVRSKSNNTCCG 480
Db 421 EETVRNLSCRPQDQHFKPYLTDPKRLHYAKNVRIDKVLHFVDQOQWLAVRSKSNNTCCG 480

QY 481 GNGHYNNEFRSMEAIFLAHGSPFKEKTEVEPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNGHYNNEFRSMEAIFLAHGSPFKEKTEVEPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
QY 541 HLLKVPFYBPSHAEEVSKSVCGFANPLPTESLDCFCPLQNSLTQLEQVQMLNLTQEEI 600
Db 541 HLLKVPFYBPSHAEEVSKSVCGFANPLPTESLDCFCPLQNSLTQLEQVQMLNLTQEEI 600
QY 601 TATVKVNLFPGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPLGDTSLPPT 660
Db 601 TATVKVNLFPGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPLGDTSLPPT 660
QY 661 VPDCLRADVRVPSESKCSFYLLADKNITGHFLYPPASNRTSDSOYDALITSNLVPMYEE 720
Db 661 VPDCLRADVRVPSESKCSFYLLADKNITGHFLYPPASNRTSDSOYDALITSNLVPMYEE 720
QY 721 FRKWDYFHSVLIIKHATERNGVNVVSGPIFDYNYDGHFDAPDEITKHLANTDVPITPHY 780
Db 721 FRKWDYFHSVLIIKHATERNGVNVVSGPIFDYNYDGHFDAPDEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNKSHTPENCPCGWL DVLPIIIPHRPTNVESCPGKDEALWBERFTHIARVR 840
Db 781 FVVLTSCKNKSHTPENCPCGWL DVLPIIIPHRPTNVESCPGKDEALWBERFTHIARVR 840
QY 841 DVELLTGLDFYQDKVQPVSEILQKTYLPTFTTI 875
Db 841 DVELLTGLDFYQDKVQPVSEILQKTYLPTFTTI 875

Search completed: July 6, 2004, 13:18:17
Job time : 68 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 6, 2004, 13:17:02 ; Search time 23 Seconds
(without alignments)
1964.032 Million cell updates/sec

Title: US-10-005-480A-743

Perfect score: 4804

Sequence: 1 MESTLTLATEQPVKNTLKK.....QPVSEILQKLYLPTFTTI 875

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*
1: /cgn2_6/prodata/2/iaa/5A COMB.pap:*
2: /cgn2_6/prodata/2/iaa/5B COMB.pap:*
3: /cgn2_6/prodata/2/iaa/5A COMB.pap:*
4: /cgn2_6/prodata/2/iaa/5B COMB.pap:*
5: /cgn2_6/prodata/2/iaa/5A COMB.pap:*
6: /cgn2_6/prodata/2/iaa/5B COMB.pap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|--------|-------------|--------|----|-------------------|
| 1 | 2498.5 | 52.0 | 873 | 3 | US-09-187-331-6 |
| 2 | 2498.5 | 52.0 | 873 | 4 | US-09-470-946-6 |
| 3 | 2498.5 | 52.0 | 873 | 4 | US-09-438-908-2 |
| 4 | 2498.5 | 52.0 | 925 | 2 | US-08-392-946-1 |
| 5 | 2498.5 | 52.0 | 925 | 2 | US-08-504-169-1 |
| 6 | 2498.5 | 52.0 | 925 | 5 | PCT-US94-14893-1 |
| 7 | 2494.5 | 51.9 | 873 | 4 | US-09-438-906-4 |
| 8 | 2040.5 | 42.5 | 915 | 1 | US-08-346-455B-69 |
| 9 | 2040.5 | 42.5 | 915 | 3 | US-08-977-221-69 |
| 10 | 2040.5 | 42.5 | 915 | 4 | US-09-483-831B-69 |
| 11 | 2040.5 | 42.5 | 915 | 5 | PCT-US95-06613-69 |
| 12 | 1964.5 | 40.9 | 829 | 1 | US-08-346-455B-34 |
| 13 | 1964.5 | 40.9 | 829 | 3 | US-08-977-221-34 |
| 14 | 1964.5 | 40.9 | 829 | 4 | US-09-483-831B-34 |
| 15 | 1964.5 | 40.9 | 829 | 5 | PCT-US95-06613-34 |
| 16 | 1923.5 | 40.0 | 861 | 1 | US-08-346-455B-67 |
| 17 | 1923.5 | 40.0 | 861 | 3 | US-08-977-221-67 |
| 18 | 1923.5 | 40.0 | 861 | 4 | US-09-483-831B-67 |
| 19 | 1923.5 | 40.0 | 861 | 5 | PCT-US95-06613-67 |
| 20 | 1838.5 | 38.3 | 979 | 1 | US-08-346-455B-38 |
| 21 | 1838.5 | 38.3 | 979 | 3 | US-08-977-221-38 |
| 22 | 1838.5 | 38.3 | 979 | 4 | US-09-483-831B-70 |
| 23 | 1838.5 | 38.3 | 979 | 5 | PCT-US95-06613-38 |
| 24 | 1761.5 | 36.7 | 788 | 1 | US-08-346-455B-36 |
| 25 | 1761.5 | 36.7 | 788 | 3 | US-08-977-221-36 |
| 26 | 1761.5 | 36.7 | 788 | 4 | US-09-483-831B-36 |
| 27 | 1761.5 | 36.7 | 788 | 5 | PCT-US95-06613-36 |

28 641 13.3 452 4 US-09-800-729-83 Sequence 83, Appl
29 503 10.5 355 2 US-09-014-969-19 Sequence 19, Appl
30 432.5 9.0 438 3 US-09-187-331-2 Sequence 2, Appl
31 432.5 9.0 438 4 US-09-470-946-2 Sequence 2, Appl
32 227.5 4.7 136 4 US-09-621-976-3913 Sequence 3913, Ap
33 210.5 4.4 151 4 US-09-621-976-3991 Sequence 3991, Ap
34 144.5 3.0 1354 4 US-07-757-022B-48 Sequence 48, Appl
35 143 3.0 1022 4 US-07-757-022B-84 Sequence 84, Appl
36 140.5 2.9 937 4 US-07-757-022B-72 Sequence 72, Appl
37 139.5 2.9 1311 4 US-07-757-022B-42 Sequence 42, Appl
38 139 2.9 463 4 US-07-757-022B-54 Sequence 54, Appl
39 136.5 2.8 157 4 US-07-757-022B-102 Sequence 102, App
40 136.5 2.8 157 4 US-07-757-022B-114 Sequence 114, App
41 134 2.8 106 4 US-07-757-022B-56 Sequence 56, Appl
42 134 2.8 130 4 US-07-757-022B-78 Sequence 78, Appl
43 134 2.8 130 4 US-07-757-022B-86 Sequence 86, Appl
44 134 2.8 138 4 US-07-757-022B-34 Sequence 34, Appl
45 134 2.8 141 4 US-07-757-022B-80 Sequence 80, Appl

ALIGNMENTS

RESULT 1
US-09-187-331-6

; Sequence 6, Application US/09187331

; Patent No. 6043056

; GENERAL INFORMATION:

; APPLICANT: Yue, Henry

; APPLICANT: Corley, Neil C.

; APPLICANT: Guegler, Karl J.

; APPLICANT: Gorgone, Gira A.

; APPLICANT: Baughn, Mariah R.

; TITLE OF INVENTION: CELL SURFACE GLYCOPROTEINS

; FILE REFERENCE: PF-0631 US

; CURRENT APPLICATION NUMBER: US/09/187,331

; CURRENT FILING DATE: 1998-11-06

; NUMBER OF SEQ ID NOS: 6

; SOFTWARE: PERL Program

; SEQ ID NO 6

; LENGTH: 873

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE: -

; OTHER INFORMATION: g189650

US-09-187-331-6

Query Match 52.0%; Score 2498.5; DB 3; Length 873;

Best Local Similarity 53.1%; Pred. No. 86-235;

Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;

Qy 10 EQPVKK---NTLK---KYKIACIVLLALLVIMSLGLGLGLKLEKQSGCRKKCFDAS 62

Db 5 EEPLKAAARTAKDFTYKVLVSLVSVLTLILGCIIFGLKPKSCAKEVKSGRCFERT 64

Qy 63 FRGLENCRDVACKDCCWPFEDTCVETRIWCKNFRGCTRLASLCSDDCLQK 122

Db 65 F--GNCRCDAACVELGNCCLDYQETCEPEPHIWTCKNFRGCKRRLTSLCACSDCKDK 121

Qy 123 KDCADYKSVCCQGETSWLEENCDDTAQQCCQCEGDFLPVILFSPMDGFRAEYLYTMDTLM 182

Db 122 GDCCINYSVCCQKSWVEEPCESEINEPCQAPAGFTPTLLFSLDGFRAEYLTWGLLP 181

Qy 183 NINKLTCGHIHKKYRAMYPTKTFNNHTITVGLYPESHGIIIDNNMYDNLNKPFLSSK 242

Db 182 VTSKLKCCYTKNNRPPVPTKTFNNHYSIVTGLYPESHGIDNNMYDNLNKPFLSSK 241

Qy 243 EQNPAWEGQPMWLTAMYQGLKAATYFWPGSEVAINGSFPTSIYMPYNGSVPFPERISTL 302

Db 242 EKFNPEWYKGEIWTAKYQGLKSCGTFWPGSDVNEINGIFPDYKMYNGSVPFPERILAV 301

Qy 303 LKWLDPKAEPRFTYMTYFPEPDSGSHAGGPPVSARVIALQVDFHAFQMLMEGLKQRLH 362

Db 303 LKWLDPKAEPRFTYMTYFPEPDSGSHAGGPPVSARVIALQVDFHAFQMLMEGLKQRLH 362

Db 302 LQWLQJPKDRPHFYTLYLEEPSSGHSYGVSVSEVVKALQKRVDMVGMMLDGLKSLNLH 361
Qy 363 NCNVIILLADHGMDOQVYCNKMEYMTDYPRINFFYMEGPAIRAHNIPHPDFFSSE 422
Db 362 RCLNLILISDHGMEQSGCKKYIYLNKYLGDVKNIKVIYGAARLRPSDVPDXYSFNYEG 421
Qy 423 IVNLSCKRKHQKPKVLTDLKRLHYAKNVRIDKVLHFDVQW-LAVRSKNTNCGG 481
Db 422 IARNLSREPNQHFPLKHLFKRLHFAKSDRIEPLTFYLDPPQWOLALNPSERYKCGSG 481
Qy 482 NHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
Db 482 FHGSDNVFSNQALFVGYGPGFKHGEADTFENIEVYNLMCDLLNLTAPNNGTHGSLNH 541
Qy 542 LLKVPYFESHAEVSKFSVCGFANPLPTESLDQFC-PHLQNSTOLEQVNMQLTQBEI 600
Db 542 LLKXNVYTPKHPKEVHPLVQCPPTRN-PRDNLGSCNPSI---LPTEDPQTOFNLTVAEE 597
Qy 601 TATVKVNLPGPRVRLQKNDHCLLYHREYVSGFGKAMPMWSSVYVLPQDGTSPLPPT 660
Db 598 KLIKHTLPYGRPRVLQKENTICLLSQHOFMGSYQDILMPLWTSTVD--NDSFSTED 655
Qy 661 VPCLRADVRVPSSQKSFYLADKNITHGFLYPPASNRTSDSY-DALITSNLVPMYE 719
Db 656 FSNCLYQDFRIPLSPVHKSFYKNTKVSYGLSPQLNKNSSGYSEALLTNIVPMYQ 715
Qy 720 EPRKMDYFHSVLLIKHATERGVNVSGPIFDYNDVGHDFADPDEITKH---LANTDVI 776
Db 716 SFQVIRYFHDLLRKYAERGVNVSGVDFDYDGRCDSENLROKRRVIRNQEILI 775
Qy 777 PTHYFVLTSCNKSHTPCNCPWLDVLPFIIPHRPTNVESCEPKPEALWVEERFTHI 836
Db 776 PTHFFVLTSCKDTSTPLHCEN-LDTLAFILPHRTDNSESCHGKHDSWVEELLMLHR 834
Qy 837 ASVRDVELLTGLDFYQDKVQPVSEILQKTYLPTF 871
Db 835 ARITDVEHITGLSFYQORKEPVSDILKTLHPTF 869

RESULT 2

US-09-470-946-6
; Sequence 6, Application US/09470946
; Patent No. 6358923
; GENERAL INFORMATION:
; APPLICANT: Yue, Henry
; APPLICANT: Corley, Neil C.
; APPLICANT: Guegier, Karl J.
; APPLICANT: Gorgone, Gina A.
; APPLICANT: Baughn, Mariah R.
; TITLE OF INVENTION: CELL SURFACE GLYCOPROTEINS
; FILE REFERENCE: PF-0631 US
; CURRENT APPLICATION NUMBER: US/09/470,946
; EARLIER FILING DATE: 1999-12-22
; EARLIER APPLICATION NUMBER: US 09/187,331
; EARLIER FILING DATE: 1998-11-06
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PERL Program
; SEQ ID NO 6
; LENGTH: 873
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: g189650
US-09-470-946-5

Query Match 52.0%; Score 2498.5; DB 4; Length 873;
Best Local Similarity 53.1%; Pred. No. 8e-235;
Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;
Qy 10 BOPVKK---NTLK---KYKTIACIVLALLVIMSLGLGLGURKLEKQSCRKCFDAS 62
Db 5 BEPLEKAAARTAKDPNTYKVLISLVSVCLTTLTGICIFGLKPSCAKEVSKRCRCFERT 64

Qy 63 FRGLENCRCVACKDRGCCWDFEDTCTVETRIWNCNKRFCGETRLEASICSDDCLQK 122
Db 65 F---GNCRCDAAACVELGNCCLDYQETCIEPEHIWTKNCRGKXKLRSLCACSSDDCKK 121
Qy 123 KCCADYKSVCCGTSWLENCDDTAQSQCPGFDLPVILFSDVGFRABYLTWDTLMP 182
Db 122 GDCICINTSSVCCQSKSWVEEPCESINEPQCPAGFETPTLLFSLDGFRABYLTWCGLLP 181
Qy 183 NINKLKCGIHSKVMRAMYPTKTPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNPSLSK 242
Db 182 VISLKKCGTYTKMRRPVYPTKTFPNHYSIVTGLYPESHGIIIDNNMYDPKONASFSLKSK 241
Qy 243 EONPAMWQHOPMWTAMYOGLKAATYVFGSEVALNGSPFSIYMPYNGSVPFEEIRISTL 302
Db 242 EKNPEWYKGEPIWVTAQYQGLKSGTFFWPGSDVEINGIFPDYIKMYNGSVPFEEIRILAV 301
Qy 303 LKMLDLKPAERPRFYTMYPFEEDSSGHAGGVSARVVKALQVVDHAFGLMEGLKORNLIH 362
Db 302 LQWLQJPKDRPHFYTLYLEEPSSGHSYGVSVSEVVKALQKRVDMVGMMLDGLKSLNLH 361
Qy 363 NCNVIILLADHGMDOQVYCNKMEYMTDYPRINFFYMEGPAIRAHNIPHPDFFSSE 422
Db 362 RCLNLILISDHGMEQSGCKKYIYLNKYLGDVKNIKVIYGAARLRPSDVPDXYSFNYEG 421
Qy 423 IVNLSCKRKHQKPKVLTDLKRLHYAKNVRIDKVLHFDVQW-LAVRSKNTNCGG 481
Db 422 IARNLSREPNQHFPLKHLFKRLHFAKSDRIEPLTFYLDPPQWOLALNPSERYKCGSG 481
Qy 482 NHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
Db 482 FHGSDNVFSNQALFVGYGPGFKHGEADTFENIEVYNLMCDLLNLTAPNNGTHGSLNH 541
Qy 542 LLKVPYFESHAEVSKFSVCGFANPLPTESLDQFC-PHLQNSTOLEQVNMQLTQBEI 600
Db 542 LLKXNVYTPKHPKEVHPLVQCPPTRN-PRDNLGSCNPSI---LPTEDPQTOFNLTVAEE 597
Qy 601 TATVKVNLPGPRVRLQKNDHCLLYHREYVSGFGKAMPMWSSVYVLPQDGTSPLPPT 660
Db 598 KLIKHTLPYGRPRVLQKENTICLLSQHOFMGSYQDILMPLWTSTVD--NDSFSTED 655
Qy 661 VPCLRADVRVPSSQKSFYLADKNITHGFLYPPASNRTSDSY-DALITSNLVPMYE 719
Db 656 FSNCLYQDFRIPLSPVHKSFYKNTKVSYGLSPQLNKNSSGYSEALLTNIVPMYQ 715
Qy 720 EPRKMDYFHSVLLIKHATERGVNVSGPIFDYNDVGHDFADPDEITKH---LANTDVI 776
Db 716 SFQVIRYFHDLLRKYAERGVNVSGVDFDYDGRCDSENLROKRRVIRNQEILI 775
Qy 777 PTHYFVLTSCNKSHTPCNCPWLDVLPFIIPHRPTNVESCEPKPEALWVEERFTHI 836
Db 776 PTHFFVLTSCKDTSTPLHCEN-LDTLAFILPHRTDNSESCHGKHDSWVEELLMLHR 834
Qy 837 ASVRDVELLTGLDFYQDKVQPVSEILQKTYLPTF 871
Db 835 ARITDVEHITGLSFYQORKEPVSDILKTLHPTF 869

RESULT 3

US-09-438-906-2
; Sequence 2, Application US/09438906
; Patent No. 6465185
; GENERAL INFORMATION:
; APPLICANT: Goldfine, Ira
; APPLICANT: Trischitta, Vincenzo
; APPLICANT: Pizzuti, Antonio
; APPLICANT: Vigneri, Riccardo
; APPLICANT: Frittitta, Lucia
; TITLE OF INVENTION: Polymorphic Human PC-1 Sequences
; FILE REFERENCE: 9076-089
; CURRENT APPLICATION NUMBER: US/09/438,906
; CURRENT FILING DATE: 1999-11-18
; PRIOR APPLICATION NUMBER: 60/108,853
; PRIOR FILING DATE: 1998-11-18

```

; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 873
; TYPE: PRT
; ORGANISM: H. sapiens
; US-09-438-906-2

Query Match          52.0%; Score 2498.5; DB 4; Length 873;
Best Local Similarity 53.1%; Pred. No. 8.8e-235;
Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;

QY 10 EQPVKK----NTLK---KYKIACIVLLALLVIMSLGLGLGRKLEKOGSKCKCFDAS 62
Db 5 EEPLKAAARATKADPNTYKVLVSLVSVCLVTILGCI FGLKPSCAKEVSKGRCFERT 64

QY 63 FRGLENCRCDVACKDRGDCWPFDCVSTRIMCNKFRCEGTRELEASLCSDDCLOK 122
Db 65 F---GNCRDCAACVBLGNCCLDYQETCIEPHIWTCKNRCGEKRLTRSLCACSDCKDK 121

QY 123 KDCADYKVCQGETSWLENCNTAQOQCEGDFLPVILFSDMGFRAEYLYTWDTLMP 182
Db 122 GDCINYSVCOGEKSWVEEPCESINEPQCPAGFETPTLLFSLDGFRAEYLYHTWGLLP 181

QY 183 NINKLKTGTHSKYKAMVPTKTFPNHYTIVTGLYPESHGIDNNYDVNKNKFSLSK 242
Db 182 VISLKKKCGTYTKNMRPVPTKTFPNHYTIVTGLYPESHGIDNNYDVNKNKFSLSK 241

QY 243 EQNNPAWHGQPMWTAMVGLKAATYFPGSEVAINSGFPIYMPYNGSVFFEBRISTL 302
Db 242 EKNPEWYKGEPIWVTAKYQGLKSGTFFPGSDVEINGIFPDYIKYNGSVFFEBRILAV 301

QY 303 LKWLDLPKRAERPRFTYMTYFEEPDSSGHAGGVSARVICALQVVDHAFGLMEGLKQRLN 362
Db 302 LQWLQPKDRPHFTLYLEEDPSGHSYGPVSSEVIKALQVVDHAFGLMEGLKQRLN 361

QY 363 NCNVIILLADHGDQVYCNKMEYTDYFPRINFFYMEGPAPRAIRAHNIPHDFFSNSE 422
Db 362 RCLNLLISDHGMEQSCKKYIYLNKYLGVKNIKVYGPAAFLRSDVPDKYVSFNYEG 421

QY 423 IVNLSCKRDPQHKPKYLTLPDLKRLHYAKNVIDKHVFDQW--LAVRSKNTNCGG 481
Db 422 IARNLSCEENQHFKEPLKHLFKRLHFAKSDRIEPLTFYLDQWQALNPEERKYCGSG 481

QY 482 NHGVNNEFRSWEAIFLAHGSFPEKTEVEPEFENIENVNLMCDLRIQAPNNGTHGSLNH 541
Db 482 FHGSDNVFSNQALFVGYGFGFKHGEADTFENIENVNLMCDLNLTPAPNNGTHGSLNH 541

QY 542 LLKVPFYPGSHAEVSKFSCVGFANPLFTBSLDFC--PHLQNSTQLEQVNMNLTOBEI 600
Db 542 LLKNPVYTPKPKVEHPLVQCPETRN--PRDNLGSCNPSI---LP-EDFQTNLTVAEE 597

QY 601 TATVKNLPRGRPRVLQKNVDHCLLYHREYVSGFKAMRPMWSSYTVPLGDTSPLPPT 660
Db 598 KIHKETLPYGRPRVLQKENTICLLSQHFMGYSQDILMPLMTSTVTDK--NDSPSTED 655

QY 661 VPCDLRADVRPPSESKCFYLADKNIITHGFIYPPASNRITSQY--DALITSNLVPMYE 719
Db 656 FSNCLYQDFRPLSPVHKCFYKNTKVSYGFLSPQNLNKNSSGIYSEALLTNIVPMYQ 715

QY 720 EFRKQWDFYSVLLIKHATERNGVNVSGIFDYNDGHFADDEITKH---LANTDVPI 776
Db 716 SFQWIRYFHTLLRKYAEERNGVNVSGIFDYNDGRCDLSLENFRQKRVIRNOEILI 775

QY 777 PTHVFVLTSCNKSHTPENCPGLDVLPIIHRPTNVSCPEGKPEALWBERTAHI 836
Db 776 PTHFVILTCKDTSQIPLHCEN--LDTLAFILPHRTDNSESCVHGKSDSWBELWLHR 834

QY 837 ARVEDVELLTGLDFYQDKQVPSIQLKTLPTTF 871
Db 835 ARITDVEHITGLSFYQKQKPSVDILKTLPTTF 869

RESULT 4
US-08-392-946-1
; Sequence 1, Application US/08392946
; Patent No. 5939269
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: The Regents of the University of California
; APPLICANT: Goldfine, Ira D.
; APPLICANT: Grupe, Andrew
; APPLICANT: Maddux, Betty A.
; APPLICANT: Spencer, Steven
; APPLICANT: Stewart, Timothy A.
; TITLE OF INVENTION: Antagonists to Insulin Receptor Tyrosine
; TITLE OF INVENTION: Kinase inhibitor
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA: US/08/392,946
; APPLICATION NUMBER: US/08/392,946
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182241
; FILING DATE: 14-JAN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0875P1PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-8228
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 925 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; US-08-392-946-1

Query Match          52.0%; Score 2498.5; DB 2; Length 925;
Best Local Similarity 53.1%; Pred. No. 8.8e-235;
Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;

QY 10 EQPVKK----NTLK---KYKIACIVLLALLVIMSLGLGLGRKLEKOGSKCKCFDAS 62
Db 57 EEPLKAAARATKADPNTYKVLVSLVSVCLVTILGCI FGLKPSCAKEVSKGRCFERT 116

QY 63 FRGLENCRCDVACKDRGDCWPFDCVSTRIMCNKFRCEGTRELEASLCSDDCLOK 122
Db 117 F---GNCRDCAACVBLGNCCLDYQETCIEPHIWTCKNRCGEKRLTRSLCACSDCKDK 173

QY 123 KDCADYKVCQGETSWLENCNTAQOQCEGDFLPVILFSDMGFRAEYLYTWDTLMP 182
Db 174 GDCINYSVCOGEKSWVEEPCESINEPQCPAGFETPTLLFSLDGFRAEYLYHTWGLLP 233

QY 183 NINKLKTGTHSKYKAMVPTKTFPNHYTIVTGLYPESHGIDNNYDVNKNKFSLSK 242
Db 234 VISLKKKCGTYTKNMRPVPTKTFPNHYTIVTGLYPESHGIDNNYDVNKNKFSLSK 293

QY 243 EQNNPAWHGQPMWTAMVGLKAATYFPGSEVAINSGFPIYMPYNGSVFFEBRISTL 302
Db 294 EKNPEWYKGEPIWVTAKYQGLKSGTFFPGSDVEINGIFPDYIKYNGSVFFEBRILAV 353

QY 303 LKWLDLPKRAERPRFTYMTYFEEPDSSGHAGGVSARVICALQVVDHAFGLMEGLKQRLN 362
```

Db 354 LQWLQPKDERPHFYTLLEPDSGSHSYGVSSEVIALQORVDGMVGLMDGLKELNLH 413
Qy 363 NCVNILLADHGMDOYCNKWEYMTDYPFRINFFYVYEGPAPRIARHNPHDFPSNSE 422
Db 414 RCLNLLISDHGMEQGGCKYIYLKYLGDVKNIKVIYGPAAALRSDVPDKYYSFNYEG 473
Qy 423 IVRNLSCKPDQHPKPYLTDLPRKRLHYAKNRVIDKVLHFDVDOQW-LAVRSKNTNCGG 481
Db 474 IARNLSCKREPNOHPKPYLKHFLPKRLHFAKSDRIEPLTFYLDQWQALNPSERKCYGSG 533
Qy 482 NHGYNNEFRSMEALFLAHGSPFKEKTEVEFFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
Db 534 FHGSDNVFSNQALFVGYGPGFKHGEADTFENIEVYNLMCDLLNLTAPNNGTHGSLNH 593
Qy 542 LLKVPFYPSPHAEVSKFSVCGFANPLPTEBSLDFCFC-PHLQNSTQLEQVNMNLTOEII 600
Db 594 LLKNPVYTPKHPKEVHPLVQCPFTRN-PRDNLGSCNPSI---LPIDFQTOENLTVAEE 649
Qy 601 TATVKVNLPRGRPRVLQKXNDHCLLYHREYVSGFGKAMRPMWSSYTVPOLGDTSPLPPT 660
Db 650 KIHKHETLPYGRPRVLQKENTICLLSQHOFMSGYSDILMPLWTSYTVDR--NDSESTED 707
Qy 661 VPDCLRADVVPSESKFSYFADKNITHGFLYPPASNRTSDSY-DALITSNLVPMYE 719
Db 708 FSNCLYQDFRIPLSPVHKCSFYKNTKVSYGFLSPPOLNKNSSGIYSEALLTNIIVPMYQ 767
Qy 720 EFRKMDYFHSVLLIKHATERNGVNVVSGPIFDYNDYDGHFADPEITKH---LANTDVI 776
Db 768 SFQVIRWYFHTLLRKYABERNGVNVVSGPVPDFDYDGRCDLSLENLRQKRRVIRNQEII 827
Qy 777 PTHFVVLTSCKNKSHPENCPLWDLVPEIIPHRPTNVSECEGKPEALWEEFTAH 836
Db 828 PTHFFVLTSCKTSQTLPHCN-LDTLAPILPHRTDNSESVHGHKDSWVEELMLHR 886
Qy 837 ARVDVELLTGLDFYQDKQVDFVSEIILQKLYLPTF 871
Db 887 ARITDVEHITGLSFYQORKEPVSILKTLHPTF 921

RESULT 5

US-08-504-169-1
; Sequence 1, Application US/08504169
; Patent No. 5968508
; GENERAL INFORMATION:
; APPLICANT: Goldfine, Ira
; APPLICANT: Grupe, Andrew
; APPLICANT: Henzel, William
; APPLICANT: Maddox, Betty
; APPLICANT: Spencer, Steven
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Harrison, Denise M.
; TITLE OF INVENTION: Antibodies to Insulin Receptor Tyrosine Kinase Activation Inhi
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/504,169
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/14893
; FILING DATE: 28-Dec-1994

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182241
; FILING DATE: 14-Jan-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0875P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 925 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-504-169-1

Query Match 52.0%; Score 2498.5; DB 2; Length 925;
Best Local Similarity 53.1%; Pred. No. 8.8e-235;
Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;

Qy 10 BOPVKK---NTLK---KYXIACIVLLALLVINSGLGLGLGLRLEKQSKCKKCFDAS 62
Db 57 EEPLEKARARTAKDPNTYKLSVLVSVCVLTITLIGCIFGLKPKSCAKEVSKRCRCERT 116
Qy 63 FRGLENCRCDVACDRGDCCDFEDTCTVSTRIMCMKFKRCGETRLEASLCSGDDCLOK 122
Db 117 F---GNCRCDAAACVELGNCCLDQETCIEPEHIWTCNKFKCGEKRLTRSLCACSDCKDK 173
Qy 123 KDCADYKSVCOGTSWLENCDTAQQSCPEGFDPVILFSDGFRAPRIYLTWTLMP 182
Db 174 GDCINYSVCCQGEKSWVEBPCEINPEPQCPAGFETPTLLFLSDGFRAPRIYLTWGLLP 233
Qy 183 NINKLTCGHSKVMRAMYPTKTPNHYITVTGLYPESHGIIIDNNYDVNLNKNFSLSSK 242
Db 234 VISKLKCGIYTKMRPVYPTKTPNHYISVTGLYPESHGIIIDNKMYDPKKNASFLSKSK 293
Qy 243 EONNPANWHGQPMWLTAMYQGLKAATYFPGSEVANGSPSPSYMPYNGSVPEERISTL 302
Db 294 EKFNPEWYKGEPIVWTAKYQGLSGTFFWPGSGVEINGIFPDYIKMYNGSVPEERILAV 353
Qy 303 LKWLDPKAPRPFTYTWYFPEPDSGSHAGGVSARVIALQVVDHAFGLMEGLKORNHL 362
Db 354 LOWLQPKDERPHFYTLLEPDSGSHSYGVSSEVIALQORVDGMVGLMDGLKELNLH 413
Qy 363 NCVNILLADHGMDOYCNKWEYMTDYPFRINFFYVYEGPAPRIARHNPHDFPSNSE 422
Db 414 RCLNLLISDHGMEQGGCKYIYLKYLGDVKNIKVIYGPAAALRSDVPDKYYSFNYEG 473
Qy 423 IVRNLSCKPDQHPKPYLTDLPRKRLHYAKNRVIDKVLHFDVDOQW-LAVRSKNTNCGG 481
Db 474 IARNLSCKREPNOHPKPYLKHFLPKRLHFAKSDRIEPLTFYLDQWQALNPSERKCYGSG 533
Qy 482 NHGYNNEFRSMEALFLAHGSPFKEKTEVEFFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
Db 534 FHGSDNVFSNQALFVGYGPGFKHGEADTFENIEVYNLMCDLLNLTAPNNGTHGSLNH 593
Qy 542 LLKVPFYPSPHAEVSKFSVCGFANPLPTEBSLDFCFC-PHLQNSTQLEQVNMNLTOEII 600
Db 594 LLKNPVYTPKHPKEVHPLVQCPFTRN-PRDNLGSCNPSI---LPIDFQTOENLTVAEE 649
Qy 601 TATVKVNLPRGRPRVLQKXNDHCLLYHREYVSGFGKAMRPMWSSYTVPOLGDTSPLPPT 660
Db 650 KIHKHETLPYGRPRVLQKENTICLLSQHOFMSGYSDILMPLWTSYTVDR--NDSESTED 707
Qy 661 VPDCLRADVVPSESKFSYFADKNITHGFLYPPASNRTSDSY-DALITSNLVPMYE 719
Db 708 FSNCLYQDFRIPLSPVHKCSFYKNTKVSYGFLSPPOLNKNSSGIYSEALLTNIIVPMYQ 767
Qy 720 EFRKMDYFHSVLLIKHATERNGVNVVSGPIFDYNDYDGHFADPEITKH---LANTDVI 776
Db 768 SFQVIRWYFHTLLRKYABERNGVNVVSGPVPDFDYDGRCDLSLENLRQKRRVIRNQEII 827

QY 777 PTHYFVVLTSCKNKSHTPENCQWLDVLPFIIPHRPTNVSCEPGKEALWVEERFAHI 836
DB 828 PTHFFIVLTSCKDTSTPLHCEN-LDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHR 886
QY 837 ARVRDVELLTGLDFYQDKVQPVSEIQLKTYLPTF 871
DB 887 ARITDVEHITGLSFYQORKEPVSDILKXTHLPTF 921

RESULT 6

PCT-US94-14893-1
; Sequence 1, Application PC/TUS9414893
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: The Regents of the University of California
; APPLICANT: Goldfine, Ira D.
; APPLICANT: Grupe, Andrew
; APPLICANT: Maddux, Betty A.
; APPLICANT: Spencer, Steven
; APPLICANT: Stewart, Timothy A.
; TITLE OF INVENTION: Antagonists to Insulin Receptor Tyrosine Kinase Inhibitor
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/14893
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; FILING DATE: 08/182241
; FILING DATE: 14-JAN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: 875P1PCT

; TELECOMMUNICATION INFORMATION:
; TELEPHONE:
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 925 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
PCT-US94-14893-1

Query Match 52.0%; Score 2498.5; DB 5; Length 925;
Best Local Similarity 53.1%; Pred. No. 8.8e-235;
Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;

QY 10 EQPVKK---NTLK---KYIACIATVLLALVIMSLGLGLGLGLKLEKOGSCRKCKCFDAS 62
DB 57 EEPLKAAARTADPNTRYKLSLVSVCLTILGCIPLGKPSCAKVKSKRCGRFERT 116
QY 63 FRGLENCRCDVACDRGDCCWDEDTCTVSTRIMCNKFRCGFTRLEASLCSCSDDCLOK 122
DB 117 F---GNCRDAACVGLNCCLDYQETCTEPEHIWTCNKPFCGEKRLTRSLCACSDCKDX 173
QY 123 KCCADYKSVCGGTSLWLENCDTAQSCPEGFDPVILFMSDGFRAEYLYTWDTLMP 182
DB 174 GDCCINYSVCCQGEKSWBPCESINBPQCPAGFETPTLLFSLDGFRAEYLIHTWGLLP 233

QY 183 NINKLTCGIHSHKMYRMYPTTKTFNNHYTIVTGLYPESHGIIIDNNYVDNINKNPFSLSK 242
DB 234 VISKLKCCGTYTQNRVPVYPTTKTFNNHYSIVTGLYPESHGIIIDNNYDPKKNASFSLSK 293
QY 243 EQNNPAWMEGQPMWLTAMTQGLKAATYFWPGSEVAINSGFSPSIYMPYNGSVPPFERSTL 302
DB 294 EKENPEWYKGEIIVWTAKYQGLKSGTFFWPGSDVEINGIFPDYIYKMYNGSVPPFERILAV 353
QY 303 LKWLDPKAEPRFYTMPEEPDSSGHAGGPPVSAVIALQVVDHAFGLMEGLKQRLVH 362
DB 354 LOWLQPKDERPHERFYTLYLEEPDSSGHSYGPVSSSVIKALQVDMGVMDGKELNLH 413
QY 363 NCVNIILLADHGMDOQYCNKMEYMTDYFPRINFFYMWEGPAPRIARAHNI PHDFFSFNSE 422
DB 414 RCLNLLISDHGMEQSCCKYIYLNKYLGDVKNIKVIYGPAAALRPSDVPDKYISFNYEG 473
QY 423 IVNLSCRKPDQHFKPYLTPDLPKLHYAKNVRIDKVLH FVDQQW-LAVRSKSNNTCCGG 481
DB 474 IAEMLSCREFNQHFYKHLFKLHFAKSDRIEPLTFYLDPOWQALALNFSERYKCGSG 533
QY 482 NHGYNNEFRSMEALFLAHGSPFKEKTEVEPPFENIYVYMLMCDLLRIQAPNNGTHGSLNH 541
DB 534 FHGSDNVFSNQALFVGYPGFKGIEADTFENIEVYMLMCDLLNLTPAPNNGTHGSLNH 593
QY 542 LLKVPYEPHSHAEVSKSVCGFANPLPTESLDCCF-PHLQNSTOLEQVOMNLNLTQEEI 600
DB 594 LLKNPVYTPKPKVHPLVQCPFTRN-PEDNIGCCSNFSI---LPIDFQTFQNLTVAAE 649
QY 601 TATVKVNLPGRPVLQKNVDHCLLVHRYEVSFGKAMRPMWSSYTPQLCDTSPLEPT 660
DB 650 KIITHETLPYGRPVLOKENTICLLSOHQFMSYQDILMPLMTSYTVDR--NDSFSTED 707
QY 661 VPDCLRADVRVPPSPESQKSVFLADKNITHGFLYPPASNRSDSOY-DALTSNLVPMYE 719
DB 708 FSNCLYQDFRIPLSPVHKCSFYKNTKVSGLFSPQLNKNSSGYSBALLTNI-VPMYQ 767
QY 720 EFRKMDYTHSVLLIKHATERGVNVVSGPIEDYNDVGHFADPEITKH--LANTDVEPI 776
DB 768 SFQVIWRYFHDLLRKYAEERGVNVVSGPVDFDYDGRCSLENLQRKQVRINQETLI 827
QY 777 PTHYFVVLTSCKNKSHTPENCQWLDVLPFIIPHRPTNVSCEPGKEALWVEERFAHI 836
DB 828 PTHFFIVLTSCKDTSTPLHCEN-LDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHR 886
QY 837 ARVRDVELLTGLDFYQDKVQPVSEIQLKTYLPTF 871
DB 887 ARITDVEHITGLSFYQORKEPVSDILKXTHLPTF 921

RESULT 7

US-09-438-906-4
; Sequence 4, Application US/09438906
; Patent No. 6465185
; GENERAL INFORMATION:
; APPLICANT: Goldfine, Ira
; APPLICANT: Trischitta, Vincenzo
; APPLICANT: Pizzuti, Antonio
; APPLICANT: Vigneri, Riccardo
; APPLICANT: Frittitta, Lucia
; TITLE OF INVENTION: Polymorphic Human PC-1 Sequences
; FILE REFERENCE: 9076-089
; CURRENT APPLICATION NUMBER: US/09/438,906
; CURRENT FILING DATE: 1999-11-18
; PRIOR APPLICATION NUMBER: 60/108,853
; PRIOR FILING DATE: 1998-11-18
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 873
; TYPE: PRT
; ORGANISM: H. sapiens
US-09-438-906-4

304 KWLDPKAEPRFRFTMYFEEDSSGSHAGGPVSA----- 336
351 PVAPPKRRKRIHRMDHYAAETQDKVTNPLREIDKIVGLQMDGLKQLRLRCVNVIFVG 410
372 DHGMDQTYCNKMEYMTDYPRINFFMYEGPAPRIR---AHNIPDFFPSNSEEIVRLNS 428
411 DHGMDQTYCNKMEYMTDYPRINFFMYEGPAPRIR---AHNIPDFFPSNSEEIVRLNS 465
429 CRKPDQHFKEPFLTPDLKRLHYAKNVRIDKVLHFLVDQW-----LAVRSKNTNC-GGG 481
466 CKPDQHFKEPFLTPDLKRLHYAKNVRIDKVLHFLVDQW-----LAVRSKNTNC-GGG 525
482 NHGYNNEFRSWEAIFLAHGPSFKEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
526 DHGMDQTYCNKMEYMTDYPRINFFMYEGPAPRIR---AHNIPDFFPSNSEEIVRLNS 585
542 LKVPFFYEPHAEVSFVSFGFANPLPTESLDFCF- PHLQNSTOLEQVNMNLNLTQBEI 600
586 LRTNTRPTWPEBVTREPNVPGIMYLQSDFDLCTCDDKVEPKNKLDELNKLRLTK--- 641
601 TATVKNLPGRRPVLQKNDVHCLLHREYVSGFGKMRMPWSSYTVPLQDGTSLPPT 660
642 GSTEERHLLYGRPAVLYR-TRYDILXHTDFESYSEIFLMLLWTSYTSVKQAEVSSVDPH 700
661 VPDCLRADVRVPPSESQKCSFYLAADKNITHGFLYPPASNRITSDSQYDALITNLNVPYEE 720
701 LTSCVRPDRVSPFSQCLAYKNDKQMSYGLFPVPLSSPEAKYDAVLTVNVMYPYA 760
721 FRKWDYFHSVLLIKHATERNUNVSGPIFDYNYDGHDPADDEITKHLANTDVIPHY 780
761 FRYVNTYFORVLVKYASERGNVNIASGPIFDYDPLGHDTEKIKQYVEGSSIPVPHY 820
781 FVWLTCKNSKSHTPENCGWLDVLPFIIPHRPTNVSCPEGKPEALWVEERTFAHARVR 840
821 YSIITSLDFTQPADKCGPLSVSSFLPHRPDNESSCNSDESKWVELMKWHTARVR 880
841 DVELLTGLDFVQDKVQVPSILQIKYLPFTFETI 875
881 DIEHLTSLDFRKTSSRSPYELTLKTYLHTYSEI 915

RESULT 9
US-08-977-221-69
; Sequence 69, Application US/08977221
; Patent No. 6084069
; GENERAL INFORMATION:
; APPLICANT: UNITED STATES OF AMERICA; DEPT.
; APPLICANT: OF HEALTH AND HUMAN SERVICES
; TITLE OF INVENTION: MOTILITY STIMULATING
; TITLE OF INVENTION: MOTILITY STIMULATING
; TITLE OF INVENTION: PROTEIN USEFUL IN CANCER DIAGNOSIS AND
; TITLE OF INVENTION: THERAPY
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/977,221
; FILING DATE:
; CLASSIFICATION:

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/346,455
; FILING DATE: 28-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/249,182
; FILING DATE: 25-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/822,043
; FILING DATE: 17-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: DOROTHY R. AUTH
; REGISTRATION NUMBER: 36,434
; REFERENCE/DOCKET NUMBER: 2026-4149US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 69:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 915
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: Unknown
; MOLECULE TYPE: CDNA
; HYPOTHEetical: No
; FEATURE:
; NAME/KEY: A2058 ATX protein
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION:
US-08-977-221-69

Query Match 42.5%; Score 2040.5; DB 3; Length 915;
Best Local similarity 40.5%; Pred. No. 5.2e-190;
Matches 379; Conservative 177; Mismatches 268; Indels 111; Gaps 11;
QY 24 ACIVLALLVIMSLGLGLGLRLKLBK-----QSCRRKKCFDASF 63
DB 9 SCQIISLFTAVGVSICLQFTAHRIKRAEGWBEPPPTVLSDSPWTNISGCKRCGFELQE 68
QY 64 RGLNCRCDVACDRGDCCKWEDTCTVETRIWMCKKFCGTRLEASI-CSCDDCLOKK 123
DB 69 AGPPDCRCNWLCKSYSCCHDFDELCLKTARWECYKRCGEVRNEENACHSECLARG 128
QY 124 DCCADYKVCQGETSWLENCDDTAQSQCPGDFLPPVILFSDMGDFRABLYLTWTLMPN 183
DB 129 DCCNTYQVCKGSHWDDCEIKAAECFAGFVRPPLIIFSVGDFRASYMKKSKWPN 188
QY 184 INKLKTCGHSKYRWAMYPTKTFPNHYTIVTGLYPESHGIIIDNMVDYLNKNFSLSSKE 243
DB 189 IEKLRSCGTHSPYRNPVPTKTFPNHYTIVTGLYPESHGIIIDNMVDYLNKNFSLSSKE 248
QY 244 QNNPAMWGHQPMWLTAMYQGLKAATYFWPGSEVAINGSPFSIYMPYNGSVPEERISTIL 303
DB 249 KFNHRWGGQPLWITATKQGVKAGTFW-----SVVIPH-----ERRILITL 290
QY 304 KWLDPKAEPRFRFTMYFEEDSSGSHAGGPVSA----- 336
DB 291 RWLTLPDHERPSVAFYSSQDPFSGHKYGFPGPESSYSGSPPTPAKPRKRVAPKRQBR 350
QY 337 -----RVIKALQVVDHAFGLMEGLKQRLNHCNVNIIILA 371
DB 351 PVAPPKRRKRIHRMDHYAAETQDKVTNPLREIDKIVGLQMDGLKQLRLRCVNVIFVG 410
QY 372 DHGMDQTYCNKMEYMTDYPRINFFMYEGPAPRIR---AHNIPDFFPSNSEEIVRLNS 428
DB 411 DHGMDQTYCNKMEYMTDYPRINFFMYEGPAPRIR---AHNIPDFFPSNSEEIVRLNS 465
QY 429 CRKPDQHFKEPFLTPDLKRLHYAKNVRIDKVLHFLVDQW-----LAVRSKNTNC-GGG 481
DB 466 CKPDQHFKEPFLTPDLKRLHYAKNVRIDKVLHFLVDQW-----LAVRSKNTNC-GGG 525
QY 482 NHGYNNEFRSWEAIFLAHGPSFKEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLNH 541

Db 526 DHGPNKVNMQTVFVGYPFKYKTKVPPFENIELVNMWCDLLGLKAPNNGTHGSLNH 585
Qy 542 LLKVPFPEPSHAEVSEKESVCGFANPLPTESLQFCF-PHLQNSTQLEQVNMNLNLTQEEI 600
Db 586 LLRTNTRFTMPESEVTRPNVPGIMYLOSDFDLGCTDDKVEPKNKLDELKHLTK- 641
Qy 601 TATVKNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDGTSPPLPT 660
Db 642 GSTEERHLLYGRPAVLVYR-TRYDILYHTDFESGVSEIFLMLLWTSYTVSKQAEVSSVDPH 700
Qy 661 VPDCLRADVRVPSSEKSCFYLADKNITHGFLYPPASNRTSDSYDALITSNLVPMEYEE 720
Db 701 LTSCVRPDRVPSFQSNCLAYKNDKQMSYGLFPPYLSSEPEAKYDAFLVNMVMPYA 760
Qy 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDFADPEIKHLANTDVPITPHY 780
Db 761 FKRVMNYFORVLVKYASERNGVNVISGPIFDYDGLHDTEDKIQYVEGSSIFVPTHY 820
Qy 781 FVLTCKNKSHTPENCPCGMLDVLFPFIIPHRPTNVESCEPGKPAALWVEERTAHARVR 840
Db 821 YSIITSLDFTQPADKCDGLSVSSFLPHRPDNESSCNSEDESKWVELMKHTARVR 880
Qy 841 DVELLTGLDFYQDKVQVSEIQLKTYLPTFTTI 875
Db 881 DIEHLTSLDFFPKTSRSPYELTLTKYLHTYSEI 915

RESULT 10

US-09-483-831B-69
; Sequence 69, Application US/09483831B
; Patent No. 6417338
; GENERAL INFORMATION:
; APPLICANT: STRACKE, MARY
; APPLICANT: LIOTTA, LANCE
; APPLICANT: SCHIFFMANN, ELLIOTT
; APPLICANT: KRUTZCH, HENRY
; APPLICANT: MURATA, JUN
; TITLE OF INVENTION: AUTOTAXIN: MOTILITY STIMULATING PROTEIN USEFUL IN
; TITLE OF INVENTION: CANCER DIAGNOSIS AND THERAPY
; FILE REFERENCE: 2026-4149S4
; CURRENT APPLICATION NUMBER: US/09/483,831B
; CURRENT FILING DATE: 2000-01-17
; PRIOR APPLICATION NUMBER: 07/822,043
; PRIOR FILING DATE: 1992-01-17
; PRIOR APPLICATION NUMBER: 08/249,182
; PRIOR FILING DATE: 1994-05-25
; PRIOR APPLICATION NUMBER: 08/346,455
; PRIOR FILING DATE: 1994-11-28
; PRIOR APPLICATION NUMBER: 08/977,221
; PRIOR FILING DATE: 1997-11-24
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 69
; LENGTH: 915
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Polypeptide
US-09-483-831B-69

Query Match 42.5%; Score 2040.5; DB 4; Length 915;
Best Local Similarity 40.5%; Pred. No. 5.2e-190;
Matches 379; Conservative 177; Mismatches 268; Indels 111; Gaps 11;
Qy 24 ACIVLLALLVMSLGLGGLGRLEK- 63
Db 9 SCQIISLFTFVAGVSCICLGTAKIRKAEWGEGPTVLSDSPWNISCKGRCFLEQ 68
Qy 64 RGLNCRCDVACDRGDCDDPDTVCVESTRIWMCKNFKCGETRLFASLCSCSDCLQKX 123
Db 69 AGPPDCRCDNLKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHGSEDCLARG 128

Qy 124 DCCADYKSCOGTSLWLEBNCDTAQOSQCEGFDLPPVILFSMDGFRAEYLYTWTDLMPN 183
Db 129 DCCNTQVQVCKGESHVWDDDEIKAACECPAGFVPPPLIIISVDGFRASYMKKSKVMPN 188
Qy 184 INKLKTCGHSKYMRAMYPTKTFPNHVTITGLYPESHGIIDNNMYDNLNKNFSLSKSE 243
Db 189 IEKLRSCGTHSPVMPRVYPTKTFPNLTATGLYPESHGIVGNSMYDFVDFATHLRGRE 248
Qy 244 QNPPAWHGGQPMWLTAMYQGLKAATVFWPGSEVAINGSPSPSYMPYNGSVFPEERISTLL 303
Db 249 KFHRWGWGQPLWITATKQGVKAGTFW- 336
Qy 304 KWLDLKABRPPRYTMYFEPDSSSHAGGPVSA- 336
Db 291 RWLTLDPHERPSVYAFYSQDPFSGHKYGFPGPESSYSGSPFPKRPKRVAPKRQER 350
Qy 337 - 371
Db 351 PVAPPKRRRKTHRMHYAAETROQKMTNPLREIDKIVGQMDGLKQLKLRQNVIFVG 410
Qy 372 DHGMDQTYCNKMEYMTDYPFRINFFYMEGAPRIR- 428
Db 411 DHGMDVTCDRTEFLSNLTNVDITLVEGTIGRIRSKFSNNAKYD- 465
Qy 429 CRKPDQHFKPYLTPDLKPLHYAKXVRIDKVLHFVDOOM- 481
Db 466 CKPDDQHFKPYLQKPLKELHYANNRIED IHLVRRHHVARKDLYVKFSGKCPQG 525
Qy 482 NHGYNNEFRSMEAFILAHGSPKETEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLNH 541
Db 526 DHGFDNKVNSMOTVFGYGFTEKYTKVPPFENIELVNMWCDLLGLKAPNNGTHGSLNH 585
Qy 542 LLKVPFPEPSHAEVSEKESVCGFANPLPTESLQFCF-PHLQNSTQLEQVNMNLNLTQEEI 600
Db 586 LLRTNTRFTMPESEVTRPNVPGIMYLOSDFDLGCTDDKVEPKNKLDELKHLTK- 641
Qy 601 TATVKNLPGFRPRVLQKNDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDGTSPPLPT 660
Db 642 GSTEERHLLYGRPAVLVYR-TRYDILYHTDFESGVSEIFLMLLWTSYTVSKQAEVSSVDPH 700
Qy 661 VPDCLRADVRVPSSEKSCFYLADKNITHGFLYPPASNRTSDSYDALITSNLVPMEYEE 720
Db 701 LTSCVRPDRVPSFQSNCLAYKNDKQMSYGLFPPYLSSEPEAKYDAFLVNMVMPYA 760
Qy 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHDFADPEIKHLANTDVPITPHY 780
Db 761 FKRVMNYFORVLVKYASERNGVNVISGPIFDYDGLHDTEDKIQYVEGSSIFVPTHY 820
Qy 781 FVLTCKNKSHTPENCPCGMLDVLFPFIIPHRPTNVESCEPGKPAALWVEERTAHARVR 840
Db 821 YSIITSLDFTQPADKCDGLSVSSFLPHRPDNESSCNSEDESKWVELMKHTARVR 880
Qy 841 DVELLTGLDFYQDKVQVSEIQLKTYLPTFTTI 875
Db 881 DIEHLTSLDFFPKTSRSPYELTLTKYLHTYSEI 915

RESULT 11

PCT-US95-06613-69
; Sequence 69, Application PC/TUS9506613
; GENERAL INFORMATION:
; APPLICANT: STRACKE, MARY; LIOTTA, LANCE;
; APPLICANT: SCHIFFMANN, ELLIOTT; KRUTZSCH,
; APPLICANT: HENRY; MURATA, JUN
; TITLE OF INVENTION: MOTILITY STIMULATING
; TITLE OF INVENTION: PROTEIN USEFUL IN CANCER DIAGNOSIS AND
; TITLE OF INVENTION: THERAPY
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK

FILING DATE: 17-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: DOROTHY R. AUTH
REGISTRATION NUMBER: 36,434
REFERENCE/DOCKET NUMBER: 2026-4149PCT
TELEPHONE: (212) 751-4800
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 829
TYPE: amino acid
STRAINEDNESS: single
TOPOLOGY: Unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Human
STRAIN:
INDIVIDUAL ISOLATE:
DEVELOPMENTAL STAGE:
HAPLOTYPE:
TISSUE TYPE:
CELL TYPE: Melanoma
CELL LINE: A2058
ORGANELLE:
FEATURE:
NAME/KEY:
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION: Putative protein
OTHER INFORMATION: sequence of A2058 Autotaxin
US-08-346-455B-34

Query Match 40.9%; Score 1964.5; DB.1; Length 829;
Best Local Similarity 42.4%; Pred. No. 1.2e-182;
Matches 363; Conservative 164; Mismatches 239; Indels 91; Gaps 10;

QY 82 CWDPEDTGVETRIWMCKNFKRCGTRLEASLCSDCLQKDCADYKSVCCGTSWLE 141
DB 1 CHDFDELCLTKARGWECTKDRGVEVNEENACHSEDCCLARGDCCTNYQVCKGESHWD 60
QY 142 ENCDTAQSQSQCEGFDLPVILFSDGGERAYLYTWTMPNINKLTCGIHKSRYRAMY 201
DB 61 DCESEIKAAECAPAGVRPLIFSDGFRASYMKGKSKWENIEKLRSCGTHSPYMRPY 120
QY 202 PKTTPFNHYTIVGLYPESHGIIIDNNYVDMNKNFSLSSKEQNNPAAWHGQPMILTAMY 261
DB 121 PKTTPFNLYTLATGLYPESHGIVGNSMYDVPVDFATFHLRGREKFNHRWGGQPLWITATK 180
QY 262 QGLKAATYFWGSEVAINGPSFSPYIMYNGSVPEERISILLKWLDPKAEERFRFTWTF 321
DB 181 QGVKAGTFFW-----SVVIPH-----ERRILTLRLWLTLPDHERPSVYAFYS 222
QY 322 BEPDSGSHAGGPVSA----- 336
DB 223 EQPDSGHKYGFPGEBSYSGPPTPAKPKRVAPKRRQERFVAPPKERRKIHMDHY 282
QY 337 -----RVIALQVDFHAFGLMEGLKORNLHNCVNIILLADHGMGDTYCNKMEYWTY 389
DB 283 AAEATQDQNTNPLREIDKIVQQLMDGLKQLKRCVNVIFVGHGMEDVTCDSFELS 342
QY 390 FPRINFFNYGAPAPRI--AHNIPDFFSSEIIVNLSCRKPDQHFQKPYLTDPLEK 446
DB 343 LTNVDDITLVPTGLRIRSKFSNAKYD-----PKAIANLTCKKPDQHFQKPYLKHLPK 397
QY 447 RLHAKVNRIDKIVHLFYDQW-----LAVRSKNTNC-CGGNHGYNNEFRSNEALFLAH 499
DB 398 RLHANNRRIEDIHLLVRRHWHVARKPLDYVKPFGKCFQGGHGDENKVNNGMTVFVGY 457
QY 500 GPSFKETEVFFENIEVYNLMCDLLRIQAPNNGTHGSLMHLKVFYFPEPSHAEVSF 559
DB 458 GPTFKYTKVPPFENIELYNVCMCLGLKAPNNGTHGSLNHLRTNTRFTMPPEVTRP 517

QY 560 SVCGFANPLPTESLDCEFC-PHLQNSTCLEQVQMLNLTQEEITATVKNLPGRRPVLOK 618
DB 518 NYPGIMYLOSDDDIGCTCDDKVKPKKLDLNLRLHTK-----GSTERHLLYGRPAVLRY 573
QY 619 NVDHCLLYHREYVSGFGKAMRMWMSYVTPQLGDTSPPLPPTVPCDLRADVRVPSESO 678
DB 574 -TRYDILYHTDFESGYSEIFLMLLWTSYVSKQAEVSSVPDHLTSCVRPDVAVSPFSQ 632
QY 679 CSFYLADKNITHGFLYPPASNRISDSQYDALITSNLVNMVSEFRKMWDFHSLVLLIKHT 738
DB 633 CLAYKNDKQSYGFLFPYLSUSSPEAKYDAFLVNNVMYPAKRVNMYFORVLVKKVAS 692
QY 739 ERNGVNVSGPIFDYNDYDGHFADPEITIKHLANTDVPITPHYFVVLTSCKNSKHTPENC 798
DB 693 ERNGVNVISGPIFDYDYLGLHDTEDKIKQVGESSIPVPTHYVSIITSLDFTQPADKCD 752
QY 799 GWLDVLPFLPHRPTNVESCEGKPEALWVEERPTAHIAVRDVELLTGLDFYQKQVQV 858
DB 753 GPLSVSSFLPHRPNDESSCSSEDESKWVEELMGMHTARVDRDIEHLTSLDFFRKT 812
QY 859 SEILQLKTYLPTFTTTI 875
DB 813 PEILTKLYLTYESEI 829

RESULT 13
US-08-977-221-34
; Sequence 34, Application US/08977221
; Patent No. 6084069
; GENERAL INFORMATION:
; APPLICANT: UNITED STATES OF AMERICA: DEPT.
; APPLICANT: OF HEALTH AND HUMAN SERVICES
; TITLE OF INVENTION: MOTILITY STIMULATING
; TITLE OF INVENTION: PROTEIN USEFUL IN CANCER DIAGNOSIS AND
; TITLE OF INVENTION: THERAPY
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESS: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/977,221
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/346,455
; FILING DATE: 28-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/249,182
; FILING DATE: 25-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/822,043
; FILING DATE: 17-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: DOROTHY R. AUTH
; REGISTRATION NUMBER: 36,434
; REFERENCE/DOCKET NUMBER: 2026-4149US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 751-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 829
; TYPE: amino acid

```

; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; STRAIN:
; INDIVIDUAL ISOLATE:
; DEVELOPMENTAL STAGE:
; HARLOT TYPE:
; TISSUE TYPE:
; CELL TYPE: Melanoma
; CELL LINE: A2058
; ORGANELLE:
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION: Putative protein
; OTHER INFORMATION: sequence of A2058 Autotaxin
US-08-977-221-34.

Query Match 40.9%; Score 1964.5; DB 3; Length 829;
Best Local Similarity 42.4%; Pred. No. 1.2e-182;
Matches 363; Conservative 164; Mismatches 239; Indels 91; Gaps 10;

QY 82 CWDEDTCVESTRIWMCNKFRGCTRLASLCSDDCLQKCCADYKSCOGTSLWLE 141
Db 1 CHDFDELCKTARGWECTKDRGCEVRNEENACHSEDCIARGDCCTNYQVCKGESHWD 60
QY 142 ENCCTAQOQCEGFDLPVILFMSDGFRAEYLYTWTMLPNINKLTCGIHSKYNAMY 201
Db 61 DCCEIKAAECPCAGFVRPPLIIFSVDFGRASYMKKGSKVMPNTEKLRSCGTHSPYMRPV 120
QY 202 PKTFPNHYTIVTGLYPESHGIIIDNNMVDVNLKNFSLSSKEONNPAWHGQPMWLTAMY 261
Db 121 PKTFPNLYTLATGLYPESHGIVGNSMYPVDFATFHLRGREKFNHRWGGQPLWITATK 180
QY 262 QGLKAATYFWPGEVAINGSPFSIYWPYNGSVFFPERISTLLKWLDPKAEPRFYTMVF 321
Db 181 QGVKAGTFW-----SVVIPH-----ERRILITLRLWLTLPDHERPSVYAFYS 222
QY 322 EEPDSSGHAGGPVSA----- 336
Db 223 EQPDFSGHKYGFPGPESSYSGPFTPAKPKRVPKARQREPVPAPKKRRKIRHMDHY 282
QY 337 -----RVIKALQVVDHAFGLMMEGLKORNHLNCUNILLADHGMDOOTYCNKMEYMTDY 389
Db 633 CLAYNDKQMSYGLFFPPLSSSPKAYDAFLVTNMVPMYPAFKRVNMYFQRLVVKYAS 692

; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; STRAIN:
; INDIVIDUAL ISOLATE:
; DEVELOPMENTAL STAGE:
; HARLOT TYPE:
; TISSUE TYPE:
; CELL TYPE: Melanoma
; CELL LINE: A2058
; ORGANELLE:
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION: Putative protein
; OTHER INFORMATION: sequence of A2058 Autotaxin
US-09-483-831B-34
; Sequence 34, Application US/09483831B
; Patent No. 6417338
; GENERAL INFORMATION:
; APPLICANT: STRACKE, MARY
; APPLICANT: LIOTTA, LANCE
; APPLICANT: SCHIFFMANN, ELLIOTT
; APPLICANT: KRUTZCH, HENRY
; APPLICANT: MURATA, JUN
; TITLE OF INVENTION: AUTOTAXIN: MOTILITY STIMULATING PROTEIN USEFUL IN
; FILE REFERENCE: 2026-4149S4
; CURRENT APPLICATION NUMBER: US/09/483,831B
; CURRENT FILING DATE: 2000-01-17
; PRIOR APPLICATION NUMBER: 07/822,043
; PRIOR FILING DATE: 1992-01-17
; PRIOR APPLICATION NUMBER: 08/249,182
; PRIOR FILING DATE: 1994-05-25
; PRIOR APPLICATION NUMBER: 08/346,455
; PRIOR FILING DATE: 1994-11-28
; PRIOR APPLICATION NUMBER: 08/977,221
; PRIOR FILING DATE: 1997-11-24
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 34
; LENGTH: 829
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative protein sequence of A2058 Autotaxin
US-09-483-831B-34

Query Match 40.9%; Score 1964.5; DB 4; Length 829;
Best Local Similarity 42.4%; Pred. No. 1.2e-182;
Matches 363; Conservative 164; Mismatches 239; Indels 91; Gaps 10;

QY 82 CWDEDTCVESTRIWMCNKFRGCTRLASLCSDDCLQKCCADYKSCOGTSLWLE 141
Db 1 CHDFDELCKTARGWECTKDRGCEVRNEENACHSEDCIARGDCCTNYQVCKGESHWD 60
QY 142 ENCCTAQOQCEGFDLPVILFMSDGFRAEYLYTWTMLPNINKLTCGIHSKYNAMY 201
Db 61 DCCEIKAAECPCAGFVRPPLIIFSVDFGRASYMKKGSKVMPNTEKLRSCGTHSPYMRPV 120
QY 202 PKTFPNHYTIVTGLYPESHGIIIDNNMVDVNLKNFSLSSKEONNPAWHGQPMWLTAMY 261
Db 121 PKTFPNLYTLATGLYPESHGIVGNSMYPVDFATFHLRGREKFNHRWGGQPLWITATK 180
QY 262 QGLKAATYFWPGEVAINGSPFSIYWPYNGSVFFPERISTLLKWLDPKAEPRFYTMVF 321
Db 181 QGVKAGTFW-----SVVIPH-----ERRILITLRLWLTLPDHERPSVYAFYS 222
QY 322 EEPDSSGHAGGPVSA----- 336
Db 223 EQPDFSGHKYGFPGPESSYSGPFTPAKPKRVPKARQREPVPAPKKRRKIRHMDHY 282
QY 337 -----RVIKALQVVDHAFGLMMEGLKORNHLNCUNILLADHGMDOOTYCNKMEYMTDY 389
Db 633 CLAYNDKQMSYGLFFPPLSSSPKAYDAFLVTNMVPMYPAFKRVNMYFQRLVVKYAS 692
```

Db 283 AAEATQDKMTNPLREIDKIVGQMDGLKQLKLRRCVNVIFVGDHGMEDVTCDRTEFLSN 342
Qy 390 FPRINFFMYEGPAPRIR---AHNIPDFFSFNSEEIVRNLSCKKPDQHPKPYLTDPLEK 446
Db 343 LTNVDDITLVPGLGRIKSKFSNAKYD-----PKAIIANLTCKKPDQHPKPYLKQHLKP 397
Qy 447 RLHYAKNVRIDKVLHFDVQW-----LAVRSKNTNC-GGGNHGYNNEFRSMEALFLAH 499
Db 398 RLHYANNRRIEDIHLVRRHVARKPLDVYKPSGKCFQGDHGFNDKNSMTVFVGY 457
Qy 500 GPSFEXEKEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLNHLKYPFVEPGBHAEVSKF 559
Db 458 GTTFYKTKVFPFENIELYNMCDLLGLKAPNNGTHGSLNHLRTNTPFTMPEEIVRP 517
Qy 560 SVCGFANPLFTESLDFCF-PHLQNSTOLEQVQNMNLNTOBEITATVKVNLFPGRPRVLQK 618
Db 518 NYEGIMYLSQDDDLGCTCDDVEPRKNLDELNKLHTK---GSTBERHLLYGRPAVLYR 573
Qy 619 NVDHCLLYHREYVSGFGKAMPMWSSYTVLPQDGTSPDPTVDDCLRADVRVPPSESOK 678
Db 574 -TRYDILVHTDPSGYSIFPLMLTWSYTSVKQEVSSVPDHLTSCURPDVRVSPFSQ 632
Qy 679 CSFYADKNITHFLYPPASNRTSDSQYDALITSNLYPMYEBFRKWDYFHSVLLIKHAT 738
Db 633 CLAYKNDKQMSYGFPPYLSSEPAKYDAFLVTNVMYVPAKRVWNYFORLVKKVAS 692
Qy 739 ERNGVNVSGPIFDYNDGHFADPEITKHLANTDVPITHYFVLTSCNKSHTPENC 798
Db 693 ERNGVNVISGPIFDYDGLHDTEDKIQVYESSIPVTHYYSILTSCLDFTQADKCD 752
Qy 799 GMDVLPFIIPHRPTNVESCEGPBALWVEERTAHIAVRVVELLTGLDFTYQDKVQV 858
Db 753 GFLSVSSFILHRPNDEESSNDESKWVEELMOMHTARVDIEHLTSLDFRKTSSY 812
Qy 859 SEILOKTYLPTFTT 875
Db 813 PELILKTYLHTYSEI 829

RESULT 15

PCT-US95-06613-34

Sequence 34, Application PC/TUS9506613

GENERAL INFORMATION:

APPLICANT: STRACKE, MARY; LIOTTA, LANCE;

APPLICANT: SCHIFFMANN, ELLIOTT; KRUTZSCH,

APPLICANT: HENRY; MURATA, JUN

TITLE OF INVENTION: MOTILITY STIMULATING

TITLE OF INVENTION: PROTEIN USEFUL IN CANCER DIAGNOSIS AND

TITLE OF INVENTION: THERAPY

NUMBER OF SEQUENCES: 69

CORRESPONDENCE ADDRESS:

ADDRESSES: MORGAN & FINNEGAN

STREET: 345 PARK AVENUE

CITY: NEW YORK

STATE: NEW YORK

COUNTRY: U.S.A.

ZIP: 10154

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Wordperfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/06613

FILING DATE: 24-MAY-1995

CLASSIFICATION:

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: 08/346,455

FILING DATE: 28-NOV-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/249,182

FILING DATE: 25-MAY-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/822,043
FILING DATE: 17-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: DOROTHY R. AUTH
REGISTRATION NUMBER: 36,434
REFERENCE/DOCKET NUMBER: 2026-4149US2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 829
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: Unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Human
STRAIN:
INDIVIDUAL ISOLATE:
DEVELOPMENTAL STAGE:
HAPLOTYPE:
TISSUE TYPE:
CELL TYPE: Melanoma
CELL LINE: A2058
ORGANELLE:
FEATURE:
NAME/KEY:
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION: Putative protein
OTHER INFORMATION: sequence of A2058 Autotaxin
PCT-US95-06613-34

Query Match 40.9%; Score 1964.5; DB 5; Length 829;

Best Local Similarity 42.4%; Pred. No. 1-2e-182;

Matches 363; Conservative 164; Mismatches 239; Indels 91; Gaps 10;

Qy 82 CWFDETCVETRIWKNKPCGCTRLASLCSDDCLQKCCADYKSVCGGETSWLE 141
Db 1 CHDFDELCLKTARGWECTKDRGVEVRNEENACHSEDCLAGDCCTNYQVVCGESHW 60
Qy 142 ENCDTAQSQCEGFDLPPLVLFSDMGPRARYLYTWTLMNPINKLKTGCIHSHKWEAMY 201
Db 61 DCEEBKAAECAPAGVRPPLIFSVDFRASYMKKSKWMPNIEKLSCGTHSPYKRPVY 120
Qy 202 PTKTFPNHYTIVTGLYPESHGIIIDNNYDNLNKNFSLSSKEQNNPAWHGQPMWLTAMY 261
Db 121 PTKTFPNLYTLATGLYPESHGIVGNSYDVPVDFATFHLRGREKFNHRWGWGQPLW 180
Qy 262 QGLKAATVFWPGSEVAINGSPSPYMPYNGSVPPPEERISTLLKWLDPKAEPRFTMYF 321
Db 181 QGVKAGTFW-----SVVIPH-----ERRILILRWLTLPDHERSVAFYS 222
Qy 322 EEPDSSCHAGGPVSA----- 336
Db 223 EQPDFSGHKYGFGEPESSYSGPFTPAKPKRVAPKRQERPVAPPKRRRIHRMDHY 282
Qy 337 -----RVIKALQVVDHAFGLMEGLKQRLNHCNVIILLADHGMDOQTCNRYEYMTDY 389
Db 283 AAETRQDKMTNPLREIDKIVGQMDGLKQLKLRRCVNVIFVGDHGMEDVTCDRTEFLSN 342
Qy 390 FPRINFFMYEGPAPRIR---AHNIPDFFSFNSEEIVRNLSCKKPDQHPKPYLTDPLEK 446
Db 343 LTNVDDITLVPGLGRIKSKFSNAKYD-----PKAIIANLTCKKPDQHPKPYLKQHLKP 397
Qy 447 RLHYAKNVRIDKVLHFDVQW-----LAVRSKNTNC-GGGNHGYNNEFRSMEALFLAH 499
Db 398 RLHYANNRRIEDIHLVRRHVARKPLDVYKPSGKCFQGDHGFNDKNSMTVFVGY 457
Qy 500 GPSFEXEKEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLNHLKYPFVEPGBHAEVSKF 559

Db 458 GPTFKYKTVPPFENIELYNNVCDLLGLKPAPNNGTHGSLNHLRLTNTFRPTMPEEVRTP 517
QY 560 SVCGFANPLPTESLQFC-PHLQNSTOLEQVNOMLNLTQBEITATVKNVLPFGSPRYLOK 618
Db 518 NYFGIMYLOSDDLQCTCDDKVEPKKLDLNLKRLHTK----GSTERHLLYGRPAVLYR 573
QY 619 NVDHCLLYHREYVSGFGKAMRMPMWSYVPQLGDTSELPETVPDCLRADVRVPPSSQK 678
Db 574 -TRYDILYHTDFESGYSEIFLMLLWTSYVSKQAEVSSVPDHLTSCVRPDRVRSPPSQN 632
QY 679 CSFYLADKNITGFLYPPASNETSDOYDALITSNLVPMYEEFERKMDYHSHVLLIKHAT 738
Db 633 CLAYKNDKQMSYGLFFPYLSSPEAKYDAFLVNNWPMYPAFRVWNYFORVLVKKYAS 692
QY 739 ERNGNVVSGPIFDYNDYGHFDAPDEITKHLANTDVPITPHYFVVLTSCKNKSHTPENCP 798
Db 693 ERNGNVVSGPIFDYNDYGLHDTEDKIKQYVEGSIPTVTHYSIITSCLDFTQPADKCD 752
QY 799 GWLDVLPFIIPHRPTNVESCPGKPEALWVEERFTHARTARDVDELLTGLDFYQDKVQPV 858
Db 753 GPLSVSSFILHRPDNEESCNSDESKWVELMKOHTARVDIEHLTSLDFFKTSRSY 812
QY 859 SEILQKTYLPTFTTI 875
Db 813 PEILTLKTYLHTYSEI 829

Search completed: July 6, 2004, 13:21:04
Job time : 27 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 6, 2004, 13:19:53 ; Search time 56 Seconds
(without alignments)
4863.810 Million cell updates/sec

Title: US-10-005-480A-743
Perfect score: 4804
Sequence: 1 MESTLTATLQEPVKNTLKK.....QPVSEILQKTYLPTPEITI 875

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1276540 seqs, 311283816 residues

Total number of hits satisfying chosen parameters: 1276540

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/prodata/2/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/prodata/2/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/prodata/2/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/prodata/2/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/prodata/2/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/prodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/prodata/2/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/prodata/2/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/prodata/2/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/prodata/2/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/prodata/2/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/prodata/2/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/prodata/2/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/prodata/2/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/prodata/2/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/prodata/2/pubpaa/US10_NEW_PUB.pep.*
- 17: /cgn2_6/prodata/2/pubpaa/US60_NEW_PUB.pep.*
- 18: /cgn2_6/prodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|--------------------|
| 1 | 4804 | 100.0 | 875 | 14 | US-10-062-109A-743 |
| 2 | 4804 | 100.0 | 875 | 14 | US-10-062-109A-743 |
| 3 | 4804 | 100.0 | 875 | 14 | US-10-062-109A-743 |
| 4 | 4804 | 100.0 | 875 | 14 | US-10-005-480A-743 |
| 5 | 4804 | 100.0 | 875 | 14 | US-10-005-480A-743 |
| 6 | 4804 | 100.0 | 875 | 14 | US-10-005-480A-751 |
| 7 | 4804 | 100.0 | 875 | 15 | US-10-291-241-3 |
| 8 | 4804 | 100.0 | 875 | 15 | US-10-291-241-11 |
| 9 | 4804 | 100.0 | 875 | 15 | US-10-291-241-16 |
| 10 | 4804 | 100.0 | 875 | 15 | US-10-291-241-21 |
| 11 | 4804 | 100.0 | 875 | 15 | US-10-291-241-22 |
| 12 | 4804 | 100.0 | 875 | 15 | US-10-291-241-81 |
| 13 | 4804 | 100.0 | 875 | 15 | US-10-291-241-94 |
| 14 | 4804 | 100.0 | 875 | 15 | US-10-291-241-95 |
| 15 | 4804 | 100.0 | 875 | 15 | US-10-291-241-96 |

| | | | | | |
|----|--------|-------|-----|----|--------------------|
| 16 | 4804 | 100.0 | 875 | 15 | US-10-291-241-103 |
| 17 | 4801 | 99.9 | 875 | 14 | US-10-062-109A-745 |
| 18 | 4801 | 99.9 | 875 | 14 | US-10-062-109A-748 |
| 19 | 4801 | 99.9 | 875 | 14 | US-10-005-480A-745 |
| 20 | 4801 | 99.9 | 875 | 14 | US-10-005-480A-748 |
| 21 | 4801 | 99.9 | 875 | 15 | US-10-291-241-5 |
| 22 | 4801 | 99.9 | 875 | 15 | US-10-291-241-17 |
| 23 | 4798 | 99.9 | 875 | 15 | US-10-291-241-9 |
| 24 | 4798 | 99.9 | 875 | 15 | US-10-291-241-19 |
| 25 | 4797 | 99.9 | 875 | 15 | US-10-291-241-7 |
| 26 | 4797 | 99.9 | 875 | 15 | US-10-291-241-18 |
| 27 | 4796 | 99.8 | 875 | 15 | US-10-291-241-13 |
| 28 | 4704 | 97.9 | 871 | 14 | US-10-062-109A-765 |
| 29 | 4704 | 97.9 | 871 | 14 | US-10-005-480A-765 |
| 30 | 4642 | 96.6 | 841 | 15 | US-10-291-241-15 |
| 31 | 4642 | 96.6 | 841 | 15 | US-10-291-241-101 |
| 32 | 4634 | 96.5 | 841 | 15 | US-10-291-241-20 |
| 33 | 4634 | 96.5 | 841 | 15 | US-10-291-241-100 |
| 34 | 4634 | 96.5 | 841 | 15 | US-10-291-241-102 |
| 35 | 2498.5 | 52.0 | 873 | 9 | US-09-997-701-6 |
| 36 | 2265 | 47.1 | 945 | 12 | US-10-296-115-1102 |
| 37 | 2120 | 44.1 | 862 | 12 | US-10-250-342-2 |
| 38 | 2108 | 43.9 | 862 | 12 | US-10-307-817-603 |
| 39 | 2094.5 | 43.6 | 863 | 12 | US-10-307-817-278 |
| 40 | 2094.5 | 43.6 | 863 | 12 | US-10-307-817-604 |
| 41 | 2094.5 | 43.6 | 863 | 12 | US-10-307-817-605 |
| 42 | 2094.5 | 43.6 | 863 | 12 | US-10-307-817-610 |
| 43 | 2091.5 | 43.5 | 870 | 12 | US-10-307-817-286 |
| 44 | 2091.5 | 43.5 | 871 | 12 | US-10-307-817-276 |
| 45 | 2084 | 43.4 | 384 | 14 | US-10-062-109A-749 |

ALIGNMENTS

RESULT 1

US-10-062-109A-743
Sequence 743, Application US/10062109A
Publication No. US20030165505A1
GENERAL INFORMATION:
APPLICANT: Ageneys
APPLICANT: Chaltica-Bid, Pia M.
APPLICANT: Raitano, Arthur B.
APPLICANT: Paris, Mary
APPLICANT: Hubert, Rene S.
APPLICANT: Morrison, Karen Jane Meyrick
APPLICANT: Jakobovits, Ava
TITLE OF INVENTION: Nucleic Acid and Corresponding Protein
TITLE OF INVENTION: Entitled 161P2F10B Useful in Treatment and Detection of
TITLE OF INVENTION: Cancer
FILE REFERENCE: 51158-20062.01
CURRENT APPLICATION NUMBER: US/10/062,109A
CURRENT FILING DATE: 2002-01-31
PRIOR APPLICATION NUMBER: US 10/005,480
PRIOR FILING DATE: 2001-11-07
NUMBER OF SEQ ID NOS: 765
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 743
LENGTH: 875
TYPE: PRT
ORGANISM: Homo sapiens
US-10-062-109A-743

Query Match 100.0%; Score 4804; DB 14; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

| | | | |
|----|----|--|-----|
| Qy | 1 | MESTLTATLQEPVKNTLKKYKIACIVLLALLVIMSLGVLGLRKLKQSCRRKCFD | 60 |
| Db | 1 | MESTLTATLQEPVKNTLKKYKIACIVLLALLVIMSLGVLGLRKLKQSCRRKCFD | 60 |
| Qy | 61 | ASPRGLNCRDVCADKRGDCWDPEDTCEVSTRIMCNKFCGCTRLRASI | 120 |

Db 61 ASFRGLENCRCVACKDRCDCWDFEDTCTVETSTRIWNCNKRFCGETRLEASLCSDDCL 120
 QY 121 OKKCCADYKSVCOGETSWLEENDCTAQOOCPEGFDLPVILFSDMGFRAEYLTYWDTL 180
 Db 121 OKKCCADYKSVCOGETSWLEENDCTAQOOCPEGFDLPVILFSDMGFRAEYLTYWDTL 180
 QY 181 MPNINKLTCGHSKYRAMPYPTKTFNHYTIVTGLYPESHGIIDNNMYDVLNKNFSL 240
 Db 181 MPNINKLTCGHSKYRAMPYPTKTFNHYTIVTGLYPESHGIIDNNMYDVLNKNFSL 240
 QY 241 SKEQNNPAWHGQPMWLTAMTQGLKAATYFWPGEVAINGSFPIYMPYNGSVPFPERIS 300
 Db 241 SKEQNNPAWHGQPMWLTAMTQGLKAATYFWPGEVAINGSFPIYMPYNGSVPFPERIS 300
 QY 301 TLLKWLDPKRAERPRFYTMFEEPDSSGHAGGPPVSARVICALQVDFHAFGLMEGLKQRN 360
 Db 301 TLLKWLDPKRAERPRFYTMFEEPDSSGHAGGPPVSARVICALQVDFHAFGLMEGLKQRN 360
 QY 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPFRINFFYMEGPAAPRAHNI PHDFFSFS 420
 Db 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPFRINFFYMEGPAAPRAHNI PHDFFSFS 420
 QY 421 EIVRNLSCKRPOHFKPYLTDPDLPKELHYAKNVRIDKVLHFDVQOQLAVRSKSNNTCCG 480
 Db 421 EIVRNLSCKRPOHFKPYLTDPDLPKELHYAKNVRIDKVLHFDVQOQLAVRSKSNNTCCG 480
 QY 481 GNGYNNFPRSMBAIFLAHGPSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
 Db 481 GNGYNNFPRSMBAIFLAHGPSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
 QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVQMLNTQBEI 600
 Db 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVQMLNTQBEI 600
 QY 601 TATVKNLPGRRVLOKQNVHCLLYHREYVSGFGKAMPMPWSSYTPVQLGDTSPLPPT 660
 Db 601 TATVKNLPGRRVLOKQNVHCLLYHREYVSGFGKAMPMPWSSYTPVQLGDTSPLPPT 660
 QY 661 VPCLRADVRVPSESKFSYLAADKNITHGLYPASNRTSDSQYDALITSNLPMVEE 720
 Db 661 VPCLRADVRVPSESKFSYLAADKNITHGLYPASNRTSDSQYDALITSNLPMVEE 720
 QY 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPITPHY 780
 Db 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPITPHY 780
 QY 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVESCEGKPEALWVEERTAHIAVR 840
 Db 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVESCEGKPEALWVEERTAHIAVR 840
 QY 841 DVELLTGLDFYQDKQVPVSEILQLKTYLPTFTTI 875
 Db 841 DVELLTGLDFYQDKQVPVSEILQLKTYLPTFTTI 875

RESULT 2

US-10-062-109A-747
 ; Sequence 747, Application US/10062109A
 ; Publication No. US20030165505A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Agensys
 ; APPLICANT: Challita-Bid, Pia M.
 ; APPLICANT: Raitano, Arthur B.
 ; APPLICANT: Paris, Mary
 ; APPLICANT: Hubert, Rene S.
 ; APPLICANT: Morrison, Karen Jane Meyrick
 ; APPLICANT: Jakobovits, Aya
 ; TITLE OF INVENTION: Nucleic Acid and Corresponding Protein
 ; TITLE OF INVENTION: Entitled 161P2F10B Useful in Treatment and Detection of
 ; TITLE OF INVENTION: Cancer
 ; FILE REFERENCE: 51158-20062.01
 ; CURRENT APPLICATION NUMBER: US/10/062,109A
 ; CURRENT FILING DATE: 2002-01-31

; PRIOR APPLICATION NUMBER: US 10/005,480
 ; PRIOR FILING DATE: 2001-11-07
 ; NUMBER OF SEQ ID NOS: 765
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 747
 ; LENGTH: 875
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-062-109A-747

Query Match 100.0%; Score 4804; DB 14; Length 875;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTLATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQSGCRKCCFD 60
 Db 1 MESTLTLATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGRKLEKQSGCRKCCFD 60
 QY 61 ASFRGLENCRCVACKDRCDCWDFEDTCTVETSTRIWNCNKRFCGETRLEASLCSDDCL 120
 Db 61 ASFRGLENCRCVACKDRCDCWDFEDTCTVETSTRIWNCNKRFCGETRLEASLCSDDCL 120
 QY 121 OKKCCADYKSVCOGETSWLEENDCTAQOOCPEGFDLPVILFSDMGFRAEYLTYWDTL 180
 Db 121 OKKCCADYKSVCOGETSWLEENDCTAQOOCPEGFDLPVILFSDMGFRAEYLTYWDTL 180
 QY 181 MPNINKLTCGHSKYRAMPYPTKTFNHYTIVTGLYPESHGIIDNNMYDVLNKNFSL 240
 Db 181 MPNINKLTCGHSKYRAMPYPTKTFNHYTIVTGLYPESHGIIDNNMYDVLNKNFSL 240
 QY 241 SKEQNNPAWHGQPMWLTAMTQGLKAATYFWPGEVAINGSFPIYMPYNGSVPFPERIS 300
 Db 241 SKEQNNPAWHGQPMWLTAMTQGLKAATYFWPGEVAINGSFPIYMPYNGSVPFPERIS 300
 QY 301 TLLKWLDPKRAERPRFYTMFEEPDSSGHAGGPPVSARVICALQVDFHAFGLMEGLKQRN 360
 Db 301 TLLKWLDPKRAERPRFYTMFEEPDSSGHAGGPPVSARVICALQVDFHAFGLMEGLKQRN 360
 QY 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPFRINFFYMEGPAAPRAHNI PHDFFSFS 420
 Db 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPFRINFFYMEGPAAPRAHNI PHDFFSFS 420
 QY 421 EIVRNLSCKRPOHFKPYLTDPDLPKELHYAKNVRIDKVLHFDVQOQLAVRSKSNNTCCG 480
 Db 421 EIVRNLSCKRPOHFKPYLTDPDLPKELHYAKNVRIDKVLHFDVQOQLAVRSKSNNTCCG 480
 QY 481 GNGYNNFPRSMBAIFLAHGPSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
 Db 481 GNGYNNFPRSMBAIFLAHGPSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
 QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVQMLNTQBEI 600
 Db 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVQMLNTQBEI 600
 QY 601 TATVKNLPGRRVLOKQNVHCLLYHREYVSGFGKAMPMPWSSYTPVQLGDTSPLPPT 660
 Db 601 TATVKNLPGRRVLOKQNVHCLLYHREYVSGFGKAMPMPWSSYTPVQLGDTSPLPPT 660
 QY 661 VPCLRADVRVPSESKFSYLAADKNITHGLYPASNRTSDSQYDALITSNLPMVEE 720
 Db 661 VPCLRADVRVPSESKFSYLAADKNITHGLYPASNRTSDSQYDALITSNLPMVEE 720
 QY 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPITPHY 780
 Db 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADDEITKHLANTDVPITPHY 780
 QY 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVESCEGKPEALWVEERTAHIAVR 840
 Db 781 FVVLTSCKNKSHTPENCPCWLDVLPFIIPHRPTNVESCEGKPEALWVEERTAHIAVR 840
 QY 841 DVELLTGLDFYQDKQVPVSEILQLKTYLPTFTTI 875
 Db 841 DVELLTGLDFYQDKQVPVSEILQLKTYLPTFTTI 875

RESULT 3

US-10-062-109A-751
 ; Sequence 751, Application US/10062109A
 ; Publication No. US20030165505A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Agensys
 ; APPLICANT: Challita-Bid, Pia M.
 ; APPLICANT: Raitano, Arthur B.
 ; APPLICANT: Faris, Mary
 ; APPLICANT: Hubert, Rene S.
 ; APPLICANT: Morrison, Karen Jane Meyrick
 ; APPLICANT: Jakobovits, Aya
 ; TITLE OF INVENTION: Nucleic Acid and Corresponding Protein
 ; TITLE OF INVENTION: Entitled 161P2F108 Useful in Treatment and Detection of
 ; TITLE OF INVENTION: Cancer
 ; FILE REFERENCE: 51158-20062.01
 ; CURRENT APPLICATION NUMBER: US/10/062.109A
 ; CURRENT FILING DATE: 2002-01-31
 ; PRIOR APPLICATION NUMBER: US 10/005,480
 ; PRIOR FILING DATE: 2001-11-07
 ; NUMBER OF SEQ ID NOS: 765
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 751
 ; LENGTH: 875
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-062-109A-751

Query Match 100.0%; Score 4804; DB 14; Length 875;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEOPVKKNTLKKYKACIVLLALLVIMSLGLGLGRLEKQSGCRKKCFD 60
 DB 1 MESTLTATEOPVKKNTLKKYKACIVLLALLVIMSLGLGLGRLEKQSGCRKKCFD 60

QY 61 ASFRGLENCRCVAKRGDCDCCWDFEDTCVESTRIWNCNFRGCTREASLCSDDCL 120
 DB 61 ASFRGLENCRCVAKRGDCDCCWDFEDTCVESTRIWNCNFRGCTREASLCSDDCL 120

QY 121 QKCCADYKSVCOGETSWLEENCDTAQSCQCEGFDLPVILFSDMGFAEYLYTWDTL 180
 DB 121 QKCCADYKSVCOGETSWLEENCDTAQSCQCEGFDLPVILFSDMGFAEYLYTWDTL 180

QY 181 MENINKLKTGCIHSHKYRMYPTKTFPHNYTIVTGLYPESHGIIIDNNMYDVNLKNFSL 240
 DB 181 MENINKLKTGCIHSHKYRMYPTKTFPHNYTIVTGLYPESHGIIIDNNMYDVNLKNFSL 240

QY 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSFPSIYMPYNGSVFPERIS 300
 DB 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSFPSIYMPYNGSVFPERIS 300

QY 301 TLLKWLDPKAEPRFRFTMYFEEDSSGHAGGPVSARVIALQVVDHAFGLMEGLKQRN 360
 DB 301 TLLKWLDPKAEPRFRFTMYFEEDSSGHAGGPVSARVIALQVVDHAFGLMEGLKQRN 360

QY 361 LNCVNIILLADHNDQTYCNKMEYMTDYPFRINFFYMGAPRAHNI PHDFPSNS 420
 DB 361 LNCVNIILLADHNDQTYCNKMEYMTDYPFRINFFYMGAPRAHNI PHDFPSNS 420

QY 421 BEIVNLSCKRPDQHFKEPILTPDLPKRLHYAKNVRIDKVLFDVQOWLA VRSKSNINCGG 480
 DB 421 BEIVNLSCKRPDQHFKEPILTPDLPKRLHYAKNVRIDKVLFDVQOWLA VRSKSNINCGG 480

QY 481 GNHGYNNEFRSWEAIFLAHGSFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLN 540
 DB 481 GNHGYNNEFRSWEAIFLAHGSFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLN 540

QY 541 HLLKVPFEPHABEVSFSCGPNPLPESLDCFCPLQNSQLQVQNMNLNLTQEEI 600
 DB 541 HLLKVPFEPHABEVSFSCGPNPLPESLDCFCPLQNSQLQVQNMNLNLTQEEI 600

RESULT 4

US-10-005-480A-743
 ; Sequence 743, Application US/10005480A
 ; Publication No. US20030191073A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Agensys
 ; APPLICANT: Challita-Bid, Pia M.
 ; APPLICANT: Raitano, Arthur B.
 ; APPLICANT: Faris, Mary
 ; APPLICANT: Hubert, Rene S.
 ; APPLICANT: Morrison, Karen Jane Meyrick
 ; APPLICANT: Jakobovits, Aya
 ; TITLE OF INVENTION: Nucleic Acid and Corresponding Protein
 ; TITLE OF INVENTION: Entitled 161P2F108 Useful in Treatment and Detection of
 ; TITLE OF INVENTION: Cancer
 ; FILE REFERENCE: 51158-20062.00
 ; CURRENT APPLICATION NUMBER: US/10/005,480A
 ; CURRENT FILING DATE: 2001-11-07
 ; NUMBER OF SEQ ID NOS: 765
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 743
 ; LENGTH: 875
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien
 US-10-005-480A-743

Query Match 100.0%; Score 4804; DB 14; Length 875;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEOPVKKNTLKKYKACIVLLALLVIMSLGLGLGRLEKQSGCRKKCFD 60
 DB 1 MESTLTATEOPVKKNTLKKYKACIVLLALLVIMSLGLGLGRLEKQSGCRKKCFD 60

QY 61 ASFRGLENCRCVAKRGDCDCCWDFEDTCVESTRIWNCNFRGCTREASLCSDDCL 120
 DB 61 ASFRGLENCRCVAKRGDCDCCWDFEDTCVESTRIWNCNFRGCTREASLCSDDCL 120

QY 121 QKCCADYKSVCOGETSWLEENCDTAQSCQCEGFDLPVILFSDMGFAEYLYTWDTL 180
 DB 121 QKCCADYKSVCOGETSWLEENCDTAQSCQCEGFDLPVILFSDMGFAEYLYTWDTL 180

QY 181 MENINKLKTGCIHSHKYRMYPTKTFPHNYTIVTGLYPESHGIIIDNNMYDVNLKNFSL 240
 DB 181 MENINKLKTGCIHSHKYRMYPTKTFPHNYTIVTGLYPESHGIIIDNNMYDVNLKNFSL 240

QY 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSFPSIYMPYNGSVFPERIS 300
 DB 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSFPSIYMPYNGSVFPERIS 300

QY 301 TLLKWLDPKAEPRFRFTMYFEEDSSGHAGGPVSARVIALQVVDHAFGLMEGLKQRN 360

```

Db 301 TLLKWLDPKAEPRFYMTYFEEPDSSGHAGGVSARVIALQVVDHAFGLMEGLKQKN 360
Qy 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPRINFFYMEGPAPIRAHNI PHDFFSFS 420
Db 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPRINFFYMEGPAPIRAHNI PHDFFSFS 420
Qy 421 BEIVRNLSCKRPDQHFEPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOQLAVRSKNTNCGG 480
Db 421 BEIVRNLSCKRPDQHFEPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOQLAVRSKNTNCGG 480
Qy 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Qy 541 HLLKVPFEPESHAEVSKFSVCGFANPLPTESLDCCPHLQNSTOLEQVNMNLNLTQBEI 600
Db 541 HLLKVPFEPESHAEVSKFSVCGFANPLPTESLDCCPHLQNSTOLEQVNMNLNLTQBEI 600
Qy 601 TATVKVNLPGFRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSSYTVPLGDTSPLPPT 660
Db 601 TATVKVNLPGFRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSSYTVPLGDTSPLPPT 660
Qy 661 VPDCLRADVRVPPESSQKCSFYLDKNI THGFLYPPASNETSDSQYDALITSNLVPMEY 720
Db 661 VPDCLRADVRVPPESSQKCSFYLDKNI THGFLYPPASNETSDSQYDALITSNLVPMEY 720
Qy 721 FRKWDYFHSVLLIKHATERGNVNVSGPIFDYNDGHFDAPDEITKHLANTDVPPIPHY 780
Db 721 FRKWDYFHSVLLIKHATERGNVNVSGPIFDYNDGHFDAPDEITKHLANTDVPPIPHY 780
Qy 781 FVLTSCNKSHTPENCPCWGLDVLFPFIIPHRPTNVESCEPGKPEALWVEERFTHARVR 840
Db 781 FVLTSCNKSHTPENCPCWGLDVLFPFIIPHRPTNVESCEPGKPEALWVEERFTHARVR 840
Qy 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFETI 875
Db 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFETI 875

RESULT 5
US-10-005-480A-747
; Sequence 747, Application US/10005480A
; Publication No. US20030191073A1
; GENERAL INFORMATION:
; APPLICANT: Agensys
; APPLICANT: Challita-Bid, Pia M.
; APPLICANT: Raitano, Arthur B.
; APPLICANT: Paris, Mary
; APPLICANT: Hubert, Rene S.
; APPLICANT: Morrison, Karen Jane Meyrick
; APPLICANT: Jakobovits, Aya
; TITLE OF INVENTION: Nucleic Acid and Corresponding Protein
; TITLE OF INVENTION: Entitled 161P2F10B Useful in Treatment and Detection of
; TITLE OF INVENTION: Cancer
; FILE REFERENCE: 51158-20062.00
; CURRENT APPLICATION NUMBER: US/10/005,480A
; CURRENT FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 765
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 747
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-005-480A-747

Query Match 100.0%; Score 4804; DB 14; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESTLTATGEPVKKNTLKKYKACIVLLALLVIMSLGGLGKLEKQSCCKKCFD 60
Db 1 MESTLTATGEPVKKNTLKKYKACIVLLALLVIMSLGGLGKLEKQSCCKKCFD 60

```

```

Qy 61 ASFRGLENCRCVACKDRGDCWDFEDTCVSESTRIMCNKFRCGETRLBASLCSDDCL 120
Db 61 ASFRGLENCRCVACKDRGDCWDFEDTCVSESTRIMCNKFRCGETRLBASLCSDDCL 120
Qy 121 QKXCCADYKSVCCGETSWLEENCDTAQOSQCEGFDLPVILFSDMGFRAEVLVYTWDTL 180
Db 121 QKXCCADYKSVCCGETSWLEENCDTAQOSQCEGFDLPVILFSDMGFRAEVLVYTWDTL 180
Qy 181 MPNINKLKTGCIHISKYKRAMYPTKTPNNHYTIVTGLYPESHGIIIDNNMYDVNLMNFSLS 240
Db 181 MPNINKLKTGCIHISKYKRAMYPTKTPNNHYTIVTGLYPESHGIIIDNNMYDVNLMNFSLS 240
Qy 241 SKEONNPAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPPSIYMPYNGSVPEERIS 300
Db 241 SKEONNPAWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPPSIYMPYNGSVPEERIS 300
Qy 301 TLLKWLDPKAEPRFYMTYFEEPDSSGHAGGVSARVIALQVVDHAFGLMEGLKQKN 360
Db 301 TLLKWLDPKAEPRFYMTYFEEPDSSGHAGGVSARVIALQVVDHAFGLMEGLKQKN 360
Qy 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPRINFFYMEGPAPIRAHNI PHDFFSFS 420
Db 361 LHNCVNIILLADHGMDOQTCNKMEYMTDYPRINFFYMEGPAPIRAHNI PHDFFSFS 420
Qy 421 BEIVRNLSCKRPDQHFEPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOQLAVRSKNTNCGG 480
Db 421 BEIVRNLSCKRPDQHFEPKPYLTDPDLKRLHYAKNVRIDKVLHFDVQOQLAVRSKNTNCGG 480
Qy 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Qy 541 HLLKVPFEPESHAEVSKFSVCGFANPLPTESLDCCPHLQNSTOLEQVNMNLNLTQBEI 600
Db 541 HLLKVPFEPESHAEVSKFSVCGFANPLPTESLDCCPHLQNSTOLEQVNMNLNLTQBEI 600
Qy 601 TATVKVNLPGFRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSSYTVPLGDTSPLPPT 660
Db 601 TATVKVNLPGFRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSSYTVPLGDTSPLPPT 660
Qy 661 VPDCLRADVRVPPESSQKCSFYLDKNI THGFLYPPASNETSDSQYDALITSNLVPMEY 720
Db 661 VPDCLRADVRVPPESSQKCSFYLDKNI THGFLYPPASNETSDSQYDALITSNLVPMEY 720
Qy 721 FRKWDYFHSVLLIKHATERGNVNVSGPIFDYNDGHFDAPDEITKHLANTDVPPIPHY 780
Db 721 FRKWDYFHSVLLIKHATERGNVNVSGPIFDYNDGHFDAPDEITKHLANTDVPPIPHY 780
Qy 781 FVLTSCNKSHTPENCPCWGLDVLFPFIIPHRPTNVESCEPGKPEALWVEERFTHARVR 840
Db 781 FVLTSCNKSHTPENCPCWGLDVLFPFIIPHRPTNVESCEPGKPEALWVEERFTHARVR 840
Qy 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFETI 875
Db 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFETI 875

RESULT 6
US-10-005-480A-751
; Sequence 751, Application US/10005480A
; Publication No. US20030191073A1
; GENERAL INFORMATION:
; APPLICANT: Agensys
; APPLICANT: Challita-Bid, Pia M.
; APPLICANT: Raitano, Arthur B.
; APPLICANT: Paris, Mary
; APPLICANT: Hubert, Rene S.
; APPLICANT: Morrison, Karen Jane Meyrick
; APPLICANT: Jakobovits, Aya
; TITLE OF INVENTION: Nucleic Acid and Corresponding Protein
; TITLE OF INVENTION: Entitled 161P2F10B Useful in Treatment and Detection of
; TITLE OF INVENTION: Cancer

```

```
; FILE REFERENCE: 51158-20062.00
; CURRENT APPLICATION NUMBER: US/10/005,480A
; CURRENT FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 765
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 751
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-005-480A-751

Query Match      100.0%; Score 4804; DB 14; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKQNTLKKYKIACIVLLALLVMSLGLGLGRKLEKQSGCRKCFD 60
Db 1 MESTLTATEQPVKQNTLKKYKIACIVLLALLVMSLGLGLGRKLEKQSGCRKCFD 60
QY 61 ASFRGLENCRCVACKDRGDCWDFEDTCVSTRIMWKNKFRGCTREASLCSDDCL 120
Db 61 ASFRGLENCRCVACKDRGDCWDFEDTCVSTRIMWKNKFRGCTREASLCSDDCL 120
QY 121 QKDCADYKSVCOGETSWLENCDDTAQSCQPEGFDLPVILFSDMGFRAEYLTYWDTL 180
Db 121 QKDCADYKSVCOGETSWLENCDDTAQSCQPEGFDLPVILFSDMGFRAEYLTYWDTL 180
QY 181 MENINKLTCGHSKYWEAMYPKTPTFNHYTIVTGLYPESHGIIIDNNMYDVLNKNFSL 240
Db 181 MENINKLTCGHSKYWEAMYPKTPTFNHYTIVTGLYPESHGIIIDNNMYDVLNKNFSL 240
QY 241 SKEONNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVPEERIS 300
Db 241 SKEONNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVPEERIS 300
QY 301 TLLKWLDPKAEPRFYTMYPEEDPSGSHAGGPVSARVICALQVVDHAFGLMEGLKQRN 360
Db 301 TLLKWLDPKAEPRFYTMYPEEDPSGSHAGGPVSARVICALQVVDHAFGLMEGLKQRN 360
QY 361 LHCNVNIIILLADHGMQDQYCNKMEYMTDYPFRINFFYMEGAPRIRAHNI PHDFFS 420
Db 361 LHCNVNIIILLADHGMQDQYCNKMEYMTDYPFRINFFYMEGAPRIRAHNI PHDFFS 420
QY 421 EEIVRLNSCRKPDQHFKPYLTPDLKRLHYAKNVIDKVHLFVDCQWLAVRSKNTNCGG 480
Db 421 EEIVRLNSCRKPDQHFKPYLTPDLKRLHYAKNVIDKVHLFVDCQWLAVRSKNTNCGG 480
QY 481 GNEGYNNEFRSMAIIFLAHGPSFKEKTEVEPPENIEVYNLMCDLLRIQAPANNTHGS 540
Db 481 GNEGYNNEFRSMAIIFLAHGPSFKEKTEVEPPENIEVYNLMCDLLRIQAPANNTHGS 540
QY 541 HLLKVPYEPESHABEYSKFSVCGFANPLPTESLDCFCPLQNSQLEQVNMNLNLTQEEI 600
Db 541 HLLKVPYEPESHABEYSKFSVCGFANPLPTESLDCFCPLQNSQLEQVNMNLNLTQEEI 600
QY 601 TATVKVNLPGRPVLOKQNVHCLLYHREYVSGFGKAMRPMWSSYTVPLGDSPLPT 660
Db 601 TATVKVNLPGRPVLOKQNVHCLLYHREYVSGFGKAMRPMWSSYTVPLGDSPLPT 660
QY 661 VPCDLRADVRPSESQKCSFYADKNITHGFLYPPASNRTSDSQYDALITSNLVPMYEE 720
Db 661 VPCDLRADVRPSESQKCSFYADKNITHGFLYPPASNRTSDSQYDALITSNLVPMYEE 720
QY 721 FRKWDYFHSVLLIKHATERGVNVWSGPIFDYNDGHFDAPDEITKHLANTDVP 780
Db 721 FRKWDYFHSVLLIKHATERGVNVWSGPIFDYNDGHFDAPDEITKHLANTDVP 780
QY 781 FVLTSCNKSHTPENCGLDVLPTIIPHRPTNVESCPEGKEALWVERFTHARVR 840
Db 781 FVLTSCNKSHTPENCGLDVLPTIIPHRPTNVESCPEGKEALWVERFTHARVR 840
QY 841 DVELLTGLDFYQDKVPVSEILQLKTYLPTFETI 875
Db 841 DVELLTGLDFYQDKVPVSEILQLKTYLPTFETI 875

RESULT 7
US-10-291-241-3
; Sequence 3, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Paris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison
; APPLICANT: Pia M. Challita-Eid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 51158-20062.20
; CURRENT APPLICATION NUMBER: US/10/291,241
; CURRENT FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-3

Query Match      100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKQNTLKKYKIACIVLLALLVMSLGLGLGRKLEKQSGCRKCFD 60
Db 1 MESTLTATEQPVKQNTLKKYKIACIVLLALLVMSLGLGLGRKLEKQSGCRKCFD 60
QY 61 ASFRGLENCRCVACKDRGDCWDFEDTCVSTRIMWKNKFRGCTREASLCSDDCL 120
Db 61 ASFRGLENCRCVACKDRGDCWDFEDTCVSTRIMWKNKFRGCTREASLCSDDCL 120
QY 121 QKDCADYKSVCOGETSWLENCDDTAQSCQPEGFDLPVILFSDMGFRAEYLTYWDTL 180
Db 121 QKDCADYKSVCOGETSWLENCDDTAQSCQPEGFDLPVILFSDMGFRAEYLTYWDTL 180
QY 181 MENINKLTCGHSKYWEAMYPKTPTFNHYTIVTGLYPESHGIIIDNNMYDVLNKNFSL 240
Db 181 MENINKLTCGHSKYWEAMYPKTPTFNHYTIVTGLYPESHGIIIDNNMYDVLNKNFSL 240
QY 241 SKEONNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVPEERIS 300
Db 241 SKEONNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVPEERIS 300
QY 301 TLLKWLDPKAEPRFYTMYPEEDPSGSHAGGPVSARVICALQVVDHAFGLMEGLKQRN 360
Db 301 TLLKWLDPKAEPRFYTMYPEEDPSGSHAGGPVSARVICALQVVDHAFGLMEGLKQRN 360
QY 361 LHCNVNIIILLADHGMQDQYCNKMEYMTDYPFRINFFYMEGAPRIRAHNI PHDFFS 420
Db 361 LHCNVNIIILLADHGMQDQYCNKMEYMTDYPFRINFFYMEGAPRIRAHNI PHDFFS 420
QY 421 EEIVRLNSCRKPDQHFKPYLTPDLKRLHYAKNVIDKVHLFVDCQWLAVRSKNTNCGG 480
Db 421 EEIVRLNSCRKPDQHFKPYLTPDLKRLHYAKNVIDKVHLFVDCQWLAVRSKNTNCGG 480
```

QY 481 GNHGYNNEFRSMEAI FLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPANNNGTHGSLN 540
DB 481 GNHGYNNEFRSMEAI FLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPANNNGTHGSLN 540
QY 541 HLLKVPFYEFSHAEVSKFVCGFANPLPTESDCFCPLHONSTQLEQVNMNLTQEEI 600
DB 541 HLLKVPFYEFSHAEVSKFVCGFANPLPTESDCFCPLHONSTQLEQVNMNLTQEEI 600
QY 601 TATVKVNLPGRRVRLQKNDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDTSPLPPT 660
DB 601 TATVKVNLPGRRVRLQKNDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDTSPLPPT 660
QY 661 VPCLRADVRVPSESOKCSFYLDKXNI THGFLYPPASNTSDSYDALITSNLVPYEE 720
DB 661 VPCLRADVRVPSESOKCSFYLDKXNI THGFLYPPASNTSDSYDALITSNLVPYEE 720
QY 721 FRKWDYFHSVLLI KHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPPIPTHY 780
DB 721 FRKWDYFHSVLLI KHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPPIPTHY 780
QY 781 FVLTSCNKSHTPENCPCGWLVDLPFI IHRPTNVESCEGKPEALWVEERTAHIAVR 840
DB 781 FVLTSCNKSHTPENCPCGWLVDLPFI IHRPTNVESCEGKPEALWVEERTAHIAVR 840
QY 841 DVELLTGLDFYQDKVQVSEILQLKTYLPTFETI 875
DB 841 DVELLTGLDFYQDKVQVSEILQLKTYLPTFETI 875

RESULT 8

US-10-291-241-11
; Sequence 11, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Faris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison
; APPLICANT: Pia M. Challita-Eid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; FILE REFERENCE: 51158-20062.20
; CURRENT APPLICATION NUMBER: US/10/291,241
; PRIOR FILING DATE: 2003-03-16
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-11

Query Match 100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MESTLTATEQPVKNTLKKYKACIVLLALVIMSLGLGLGRLEKQSGCRKCFD 60
DB 1 MESTLTATEQPVKNTLKKYKACIVLLALVIMSLGLGLGRLEKQSGCRKCFD 60
QY 61 ASFRGLENCRCVACKRGDCWDFEDTCVSTRIMWKNKFRCGTRELASLCSGSDCL 120

DB 61 ASFRGLENCRCVACKRGDCWDFEDTCVSTRIMWKNKFRCGTRELASLCSGSDCL 120
QY 121 OKKDCADYKVCOCGETSWLEBNCDTAQOOCPEGFDLPPVILFSDMGFRAEYLYTWDTL 180
DB 121 OKKDCADYKVCOCGETSWLEBNCDTAQOOCPEGFDLPPVILFSDMGFRAEYLYTWDTL 180
QY 181 MPNINKLTCGIGHSKYWRAMYPTKTFPNHYITVGLYPESHGIIIDNNMYDVNLNKNFSL 240
DB 181 MPNINKLTCGIGHSKYWRAMYPTKTFPNHYITVGLYPESHGIIIDNNMYDVNLNKNFSL 240
QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINSGFPSIYMPYNGSVPFEEIS 300
DB 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINSGFPSIYMPYNGSVPFEEIS 300
QY 301 TLLKWLDPKAEPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360
DB 301 TLLKWLDPKAEPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360
QY 361 LHNCVNIILLADHGMDOOTYCNKMEYMTDYPRINFYMYEGPAPRIAHNI PHDFFSFS 420
DB 361 LHNCVNIILLADHGMDOOTYCNKMEYMTDYPRINFYMYEGPAPRIAHNI PHDFFSFS 420
QY 421 EEIVRNLSCKRPDQHFPRYLTPDLPKELHYAKNVRIDKVLHFDVQDQWLAVRSKNTNCG 480
DB 421 EEIVRNLSCKRPDQHFPRYLTPDLPKELHYAKNVRIDKVLHFDVQDQWLAVRSKNTNCG 480
QY 481 GNHGYNNEFRSMEAI FLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPANNNGTHGSLN 540
DB 481 GNHGYNNEFRSMEAI FLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQAPANNNGTHGSLN 540
QY 541 HLLKVPFYEFSHAEVSKFVCGFANPLPTESDCFCPLHONSTQLEQVNMNLTQEEI 600
DB 541 HLLKVPFYEFSHAEVSKFVCGFANPLPTESDCFCPLHONSTQLEQVNMNLTQEEI 600
QY 601 TATVKVNLPGRRVRLQKNDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDTSPLPPT 660
DB 601 TATVKVNLPGRRVRLQKNDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDTSPLPPT 660
QY 661 VPCLRADVRVPSESOKCSFYLDKXNI THGFLYPPASNTSDSYDALITSNLVPYEE 720
DB 661 VPCLRADVRVPSESOKCSFYLDKXNI THGFLYPPASNTSDSYDALITSNLVPYEE 720
QY 721 FRKWDYFHSVLLI KHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPPIPTHY 780
DB 721 FRKWDYFHSVLLI KHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPPIPTHY 780
QY 781 FVLTSCNKSHTPENCPCGWLVDLPFI IHRPTNVESCEGKPEALWVEERTAHIAVR 840
DB 781 FVLTSCNKSHTPENCPCGWLVDLPFI IHRPTNVESCEGKPEALWVEERTAHIAVR 840
QY 841 DVELLTGLDFYQDKVQVSEILQLKTYLPTFETI 875
DB 841 DVELLTGLDFYQDKVQVSEILQLKTYLPTFETI 875

RESULT 9

US-10-291-241-16
; Sequence 16, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Faris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison
; APPLICANT: Pia M. Challita-Eid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; FILE REFERENCE: 51158-20062.20

```

; CURRENT APPLICATION NUMBER: US/10/291,241
; CURRENT FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-16

Query Match      100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIVLLALVIMSLGLGLGRLEKQSGCRKCCFD 60
Db 1 MESTLTATEQPVKNTLKKYKIACIVLLALVIMSLGLGLGRLEKQSGCRKCCFD 60
QY 61 ASFRGLENCRCVACKDRCDCWDPEDTCTVSTRIMWNCNFKRCGETRLEASLCSDDCL 120
Db 61 ASFRGLENCRCVACKDRCDCWDPEDTCTVSTRIMWNCNFKRCGETRLEASLCSDDCL 120
QY 121 QKCCADYKSCVCGQTSWLENCDDTAQOQSCPEGDFLPVILFSDGFRABLYLTWDTL 180
Db 121 QKCCADYKSCVCGQTSWLENCDDTAQOQSCPEGDFLPVILFSDGFRABLYLTWDTL 180
QY 181 MNINKLTCGTHSKYMRAMYPKTTPNHYITVGLYPESHGIIDNNYDVNLNKNFSL 240
Db 181 MNINKLTCGTHSKYMRAMYPKTTPNHYITVGLYPESHGIIDNNYDVNLNKNFSL 240
QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSPFSIYMPYNGSVPEERIS 300
Db 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSPFSIYMPYNGSVPEERIS 300
QY 301 TLLKWLDPKAEPRFYTMFEEDPSSGHAGGVPVSARVICALQVVDHAFGLMEGLKORN 360
Db 301 TLLKWLDPKAEPRFYTMFEEDPSSGHAGGVPVSARVICALQVVDHAFGLMEGLKORN 360
QY 361 LHCNVNIIILLADHGMQTYCNKMEYMTDYFPRINFYMYEGPAPRIAHNI PHDFFSFS 420
Db 361 LHCNVNIIILLADHGMQTYCNKMEYMTDYFPRINFYMYEGPAPRIAHNI PHDFFSFS 420
QY 781 FVVLTSCKNSHTPENCPCGMLDVLPIIHRPTNVESCEPKGEALWVERFTAHIAVR 840
Db 781 FVVLTSCKNSHTPENCPCGMLDVLPIIHRPTNVESCEPKGEALWVERFTAHIAVR 840

; CURRENT APPLICATION NUMBER: US/10/291,241
; CURRENT FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-16

Query Match      100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIVLLALVIMSLGLGLGRLEKQSGCRKCCFD 60
Db 1 MESTLTATEQPVKNTLKKYKIACIVLLALVIMSLGLGLGRLEKQSGCRKCCFD 60
QY 61 ASFRGLENCRCVACKDRCDCWDPEDTCTVSTRIMWNCNFKRCGETRLEASLCSDDCL 120
Db 61 ASFRGLENCRCVACKDRCDCWDPEDTCTVSTRIMWNCNFKRCGETRLEASLCSDDCL 120
QY 121 QKCCADYKSCVCGQTSWLENCDDTAQOQSCPEGDFLPVILFSDGFRABLYLTWDTL 180
Db 121 QKCCADYKSCVCGQTSWLENCDDTAQOQSCPEGDFLPVILFSDGFRABLYLTWDTL 180
QY 181 MNINKLTCGTHSKYMRAMYPKTTPNHYITVGLYPESHGIIDNNYDVNLNKNFSL 240
Db 181 MNINKLTCGTHSKYMRAMYPKTTPNHYITVGLYPESHGIIDNNYDVNLNKNFSL 240
QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSPFSIYMPYNGSVPEERIS 300
Db 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSPFSIYMPYNGSVPEERIS 300
QY 301 TLLKWLDPKAEPRFYTMFEEDPSSGHAGGVPVSARVICALQVVDHAFGLMEGLKORN 360
Db 301 TLLKWLDPKAEPRFYTMFEEDPSSGHAGGVPVSARVICALQVVDHAFGLMEGLKORN 360
QY 361 LHCNVNIIILLADHGMQTYCNKMEYMTDYFPRINFYMYEGPAPRIAHNI PHDFFSFS 420
Db 361 LHCNVNIIILLADHGMQTYCNKMEYMTDYFPRINFYMYEGPAPRIAHNI PHDFFSFS 420
QY 421 EEIVRLSCRKPDQHPKPYLTDPDLKRLHYAKNVRIDKVHLFVDQOQWLAVRSKNTNCG 480
Db 421 EEIVRLSCRKPDQHPKPYLTDPDLKRLHYAKNVRIDKVHLFVDQOQWLAVRSKNTNCG 480
QY 481 GNGHYNNERSMEALFLAHGSPFKEKTEVEPPENIEVNLMDLLRIQAPNNGTHGSLN 540
Db 481 GNGHYNNERSMEALFLAHGSPFKEKTEVEPPENIEVNLMDLLRIQAPNNGTHGSLN 540
QY 541 HLLKVPPEYSHABEYKSFVCGFANPLPTESLDCFCPLHNSLTQLEQVNMNLTOEEI 600
Db 541 HLLKVPPEYSHABEYKSFVCGFANPLPTESLDCFCPLHNSLTQLEQVNMNLTOEEI 600
QY 601 TATVKVNLPGRRPRVLQXNDHCLLYHREYVSFGKAMPWSSYTVPLGDTSLPPT 660
Db 601 TATVKVNLPGRRPRVLQXNDHCLLYHREYVSFGKAMPWSSYTVPLGDTSLPPT 660
QY 661 VPDCLRADVPPSESOKCSFYLDKNI THGFLYPPASNETSDSQYDALITSNLVPMYEE 720
Db 661 VPDCLRADVPPSESOKCSFYLDKNI THGFLYPPASNETSDSQYDALITSNLVPMYEE 720
QY 721 FRKMWDYFHSVLLIKHATERGVNVSGPIFDYNYDGHFDAPDEITKHLANTDVPITPHY 780
Db 721 FRKMWDYFHSVLLIKHATERGVNVSGPIFDYNYDGHFDAPDEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNSHTPENCPCGMLDVLPIIHRPTNVESCEPKGEALWVERFTAHIAVR 840
Db 781 FVVLTSCKNSHTPENCPCGMLDVLPIIHRPTNVESCEPKGEALWVERFTAHIAVR 840
```

QY 421 EEI VRNLS CRKPDQHFHFKPYLTPDL PKELH YAKNVRIDKVHL FVDQQLAVRSKNTNCGG 480
DB 421 EEI VRNLS CRKPDQHFHFKPYLTPDL PKELH YAKNVRIDKVHL FVDQQLAVRSKNTNCGG 480
QY 481 GNEGYNNEFRSMEAI FLAHGSPSKEKTEVEPFENIEVYNLMCDLIRIQAPANNTHGSLN 540
DB 481 GNEGYNNEFRSMEAI FLAHGSPSKEKTEVEPFENIEVYNLMCDLIRIQAPANNTHGSLN 540
QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESIDCFPHLQNSTOLEQVNMNLNLTQEEI 600
DB 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESIDCFPHLQNSTOLEQVNMNLNLTQEEI 600
QY 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRMPMSSYTVPOLGDTSPLPPT 660
DB 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRMPMSSYTVPOLGDTSPLPPT 660
QY 661 VPCLRADVRVPSESKFSYLADKNITHGFLYPPASNRTSDSDYDALITSNLVPMYEE 720
DB 661 VPCLRADVRVPSESKFSYLADKNITHGFLYPPASNRTSDSDYDALITSNLVPMYEE 720
QY 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPITPHY 780
DB 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNKSHTPENCPCGWLVDLPIIHPRTNVSCEGKPEALWVEERTAHIAVR 840
DB 781 FVVLTSCKNKSHTPENCPCGWLVDLPIIHPRTNVSCEGKPEALWVEERTAHIAVR 840
QY 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFTETI 875
DB 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFTETI 875

RESULT 11

US-10-291-241-22
; Sequence 22, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Faris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison
; APPLICANT: Pia M. Challita-Bid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; FILE REFERENCE: 51158-20062.20
; CURRENT APPLICATION NUMBER: US/10/291,241
; PRIOR FILING DATE: 2003-03-18
; PRIOR FILING DATE: 2001-11-07
; PRIOR FILING DATE: 2001-11-07
; PRIOR FILING DATE: 2002-01-31
; PRIOR FILING DATE: 2002-01-31
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-22

Query Match 100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MESTLTLATEQPVKNTLKKYKACIVLALLVIMSLGLGLKLEKQSGCRKCFD 60

DB 1 MESTLTLATEQPVKNTLKKYKACIVLALLVIMSLGLGLKLEKQSGCRKCFD 60
QY 61 ASFRGLENCRCVACKRGDCNDPFCVETRIWMCNKFRCGETRLASLCSGSDCL 120
DB 61 ASFRGLENCRCVACKRGDCNDPFCVETRIWMCNKFRCGETRLASLCSGSDCL 120
QY 121 QKDCADYKSCVCGEISWLEENCDTAAQSCPCGFDLPVILFSDMGFAEVLTYTWDTL 180
DB 121 QKDCADYKSCVCGEISWLEENCDTAAQSCPCGFDLPVILFSDMGFAEVLTYTWDTL 180
QY 181 MPNINKLTCGISHKYNRAMPYTKTFPNHYTIVTGLYPESHGIIIDNNYDVNLNKNFSL 240
DB 181 MPNINKLTCGISHKYNRAMPYTKTFPNHYTIVTGLYPESHGIIIDNNYDVNLNKNFSL 240
QY 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPFSIYMPYNGSVPFEEIS 300
DB 241 SKEQNPAAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPFSIYMPYNGSVPFEEIS 300
QY 301 TLLKWLDPKAEPRFRFTMYFEEPDSSGHAGGPVSARVICALQVVDHAFGLMEGLKQRN 360
DB 301 TLLKWLDPKAEPRFRFTMYFEEPDSSGHAGGPVSARVICALQVVDHAFGLMEGLKQRN 360
QY 361 LHNCVNIILLADHGMDQTYCNKMEYMTDYPFRINFFYMYEGPAPRIRAHNIPHDFFSFS 420
DB 361 LHNCVNIILLADHGMDQTYCNKMEYMTDYPFRINFFYMYEGPAPRIRAHNIPHDFFSFS 420
QY 421 EEI VRNLS CRKPDQHFHFKPYLTPDL PKELH YAKNVRIDKVHL FVDQQLAVRSKNTNCGG 480
DB 421 EEI VRNLS CRKPDQHFHFKPYLTPDL PKELH YAKNVRIDKVHL FVDQQLAVRSKNTNCGG 480
QY 481 GNEGYNNEFRSMEAI FLAHGSPSKEKTEVEPFENIEVYNLMCDLIRIQAPANNTHGSLN 540
DB 481 GNEGYNNEFRSMEAI FLAHGSPSKEKTEVEPFENIEVYNLMCDLIRIQAPANNTHGSLN 540
QY 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESIDCFPHLQNSTOLEQVNMNLNLTQEEI 600
DB 541 HLLKVPFYPESHAEVSKFSVCGFANPLPTESIDCFPHLQNSTOLEQVNMNLNLTQEEI 600
QY 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRMPMSSYTVPOLGDTSPLPPT 660
DB 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRMPMSSYTVPOLGDTSPLPPT 660
QY 661 VPCLRADVRVPSESKFSYLADKNITHGFLYPPASNRTSDSDYDALITSNLVPMYEE 720
DB 661 VPCLRADVRVPSESKFSYLADKNITHGFLYPPASNRTSDSDYDALITSNLVPMYEE 720
QY 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPITPHY 780
DB 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNKSHTPENCPCGWLVDLPIIHPRTNVSCEGKPEALWVEERTAHIAVR 840
DB 781 FVVLTSCKNKSHTPENCPCGWLVDLPIIHPRTNVSCEGKPEALWVEERTAHIAVR 840
QY 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFTETI 875
DB 841 DVELLTGLDFYQDKVQPVSEILQLKTYLPTFTETI 875

RESULT 12

US-10-291-241-81
; Sequence 81, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Faris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison

APPLICANT: Pia M. Challita-Bid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 51158-20062.20
; CURRENT APPLICATION NUMBER: US 10/291,241
; PRIOR FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 81
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-81

Query Match 100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGURKLEKQSGCRKCFD 60
Db 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGURKLEKQSGCRKCFD 60
QY 61 ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWNCNFKRCGETRLEASCSDCL 120
Db 61 ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWNCNFKRCGETRLEASCSDCL 120
QY 121 QKDDCCADYKSVCOGETSWLEENCNTAQOQCPGFDLPVILFMSDGFRAEYLYTWDTL 180
Db 121 QKDDCCADYKSVCOGETSWLEENCNTAQOQCPGFDLPVILFMSDGFRAEYLYTWDTL 180
QY 181 MPNINKLTCGIIHSHKYNRMWPKTTPNHYITVGLYPESHGIIIDNNYDVLNKNFSL 240
Db 181 MPNINKLTCGIIHSHKYNRMWPKTTPNHYITVGLYPESHGIIIDNNYDVLNKNFSL 240
QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVVPEERIS 300
Db 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVVPEERIS 300
QY 301 TLLKWLDPKAEPRFYTWYFEBPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360
Db 301 TLLKWLDPKAEPRFYTWYFEBPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360
QY 361 LHCNVIIILLADRGMDQTYCNKVEYMTDYPFRINFFYMEGAPRAIRAHNIHPDPSFNS 420
Db 361 LHCNVIIILLADRGMDQTYCNKVEYMTDYPFRINFFYMEGAPRAIRAHNIHPDPSFNS 420
QY 421 EEIVRNLSCKRPQHPKPYLTDPDKRLHYAKNVRIDKVLHFDVQOQWLAVRSKSNTCGG 480
Db 421 EEIVRNLSCKRPQHPKPYLTDPDKRLHYAKNVRIDKVLHFDVQOQWLAVRSKSNTCGG 480
QY 481 GNGYNNPFRSMEAIFLAHGSPFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNGYNNPFRSMEAIFLAHGSPFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
QY 541 HLLKVPYFESHAEVSKFSCGFANPLPTESLDCFCPLHONSTOLEQVNMNLNTOEBI 600
Db 541 HLLKVPYFESHAEVSKFSCGFANPLPTESLDCFCPLHONSTOLEQVNMNLNTOEBI 600
QY 601 TATVKVNLPGFRVRLQKVDHCLLYHREYVSGFGKAMRPMWSSYTVPOLGDTSLPPT 660
Db 601 TATVKVNLPGFRVRLQKVDHCLLYHREYVSGFGKAMRPMWSSYTVPOLGDTSLPPT 660
QY 661 VPDCLRADVRVPSESOKCSFYLDKNI THGFLYPPASNETSDQYDALITSLNLPWYEE 720
Db 661 VPDCLRADVRVPSESOKCSFYLDKNI THGFLYPPASNETSDQYDALITSLNLPWYEE 720

QY 721 FRKWDYFHSVLLIKKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITPHY 780
Db 721 FRKWDYFHSVLLIKKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITPHY 780
QY 781 FVVLTSCKNKSHTPENCPCGMDLVLPFIIPHRPTNVSCPCGKPEALWVERFTAHARVR 840
Db 781 FVVLTSCKNKSHTPENCPCGMDLVLPFIIPHRPTNVSCPCGKPEALWVERFTAHARVR 840
QY 841 DVELLTGLDFYQDKVQPVSEILOLKYLTPTFETTI 875
Db 841 DVELLTGLDFYQDKVQPVSEILOLKYLTPTFETTI 875

RESULT 13
US-10-291-241-94
; Sequence 94, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Paris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison
; APPLICANT: Pia M. Challita-Bid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; TITLE OF INVENTION: CANCER
; FILE REFERENCE: 51158-20062.20
; CURRENT APPLICATION NUMBER: US/10/291,241
; PRIOR FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-94

Query Match 100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGURKLEKQSGCRKCFD 60
Db 1 MESTLTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLGURKLEKQSGCRKCFD 60
QY 61 ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWNCNFKRCGETRLEASCSDCL 120
Db 61 ASFRGLENCRCVACKDRGCCWDFEDTCVESTRIWNCNFKRCGETRLEASCSDCL 120
QY 121 QKDDCCADYKSVCOGETSWLEENCNTAQOQCPGFDLPVILFMSDGFRAEYLYTWDTL 180
Db 121 QKDDCCADYKSVCOGETSWLEENCNTAQOQCPGFDLPVILFMSDGFRAEYLYTWDTL 180
QY 181 MPNINKLTCGIIHSHKYNRMWPKTTPNHYITVGLYPESHGIIIDNNYDVLNKNFSL 240
Db 181 MPNINKLTCGIIHSHKYNRMWPKTTPNHYITVGLYPESHGIIIDNNYDVLNKNFSL 240
QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVVPEERIS 300
Db 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSPSIYMPYNGSVVPEERIS 300
QY 301 TLLKWLDPKAEPRFYTWYFEBPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360
Db 301 TLLKWLDPKAEPRFYTWYFEBPDSSGHAGGPVSARVIKALQVVDHAFGLMEGLKQRN 360

Db 301 TLLKWLDPKAEPRFYMTYFEBPSSGHAGGVPVSAVRIKALQVVDHAFGLMEGLKQRN 360
QY 361 LHNCVNIILLADHGMDOQYCNKMEYMTDYPRINFYMEGPAIPRAHNI PHDFFSFS 420
Db 361 LHNCVNIILLADHGMDOQYCNKMEYMTDYPRINFYMEGPAIPRAHNI PHDFFSFS 420
QY 421 EEIVRNLSCKRPQDHFKEPYLTPDLKRLHYAKNVRIDKVLHFDVQOQWLAVRSKSNNTCCG 480
Db 421 EEIVRNLSCKRPQDHFKEPYLTPDLKRLHYAKNVRIDKVLHFDVQOQWLAVRSKSNNTCCG 480
QY 481 GNHGYNNEFRSMEAI FLAHGFSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNHGYNNEFRSMEAI FLAHGFSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
QY 541 HLLKVPFYEPSHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVNMNLNQEEI 600
Db 541 HLLKVPFYEPSHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVNMNLNQEEI 600
QY 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDGTSLPPT 660
Db 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDGTSLPPT 660
QY 661 VPDCLRADVRVPSESKFSYLADKNI THGFLYPPASNRSDSQYDALITSNLVPMBE 720
Db 661 VPDCLRADVRVPSESKFSYLADKNI THGFLYPPASNRSDSQYDALITSNLVPMBE 720
QY 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
Db 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
QY 781 FVLTSCNKSHTPENCPCGWLVDLPII PHRPNVESCEGKPEALWVERFTAIAVR 840
Db 781 FVLTSCNKSHTPENCPCGWLVDLPII PHRPNVESCEGKPEALWVERFTAIAVR 840
QY 841 DVELLTGLDFYQKQVQVSEILQKYLPTFETI 875
Db 841 DVELLTGLDFYQKQVQVSEILQKYLPTFETI 875

RESULT 14

US-10-291-241-95
; Sequence 95, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano
; APPLICANT: Mary Faris
; APPLICANT: Rene S. Hubert
; APPLICANT: Wangmao Ge
; APPLICANT: Karen Jane Meyrick Morrison
; APPLICANT: Robert Kendall Morrison
; APPLICANT: Pia M. Challita-Eid
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
; TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
; FILE OF INVENTION: CANCER
; FILE REFERENCE: 51158-20062.20
; CURRENT APPLICATION NUMBER: US/10/291,241
; CURRENT FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: US 10/005,480
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 10/062,109
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 875
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-291-241-95

Query Match 100.0%; Score 4804; DB 15; Length 875;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESTLTTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLRLEKQGSCKKCFD 60
Db 1 MESTLTTATEQPVKNTLKKYKIACIVLLALLVIMSLGLGLRLEKQGSCKKCFD 60
QY 61 ASFRGLENCRCVACKRGDCWDFEDTCVESTIWMCNKFRGETBLEASCSDDCL 120
Db 61 ASFRGLENCRCVACKRGDCWDFEDTCVESTIWMCNKFRGETBLEASCSDDCL 120
QY 121 QKQCCADYKVCQGETSWLENCDDTAQOQCPGFDLPVILFSDMGFRAEVLTYWDTL 180
Db 121 QKQCCADYKVCQGETSWLENCDDTAQOQCPGFDLPVILFSDMGFRAEVLTYWDTL 180
QY 181 MPNINKLTCGIHSHKYNRMYPTKTFPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240
Db 181 MPNINKLTCGIHSHKYNRMYPTKTFPNHYTIVTGLYPESHGIIIDNNMYDVNLNKNFSL 240
QY 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSFPSIYMPYNGSVFFPERIS 300
Db 241 SKEQNNPAWHGQPMWLTAMYQGLKAATYFWPGEVAINGSFPSIYMPYNGSVFFPERIS 300
QY 301 TLLKWLDPKAEPRFYMTYFEBPSSGHAGGVPVSAVRIKALQVVDHAFGLMEGLKQRN 360
Db 301 TLLKWLDPKAEPRFYMTYFEBPSSGHAGGVPVSAVRIKALQVVDHAFGLMEGLKQRN 360
QY 361 LHNCVNIILLADHGMDOQYCNKMEYMTDYPRINFYMEGPAIPRAHNI PHDFFSFS 420
Db 361 LHNCVNIILLADHGMDOQYCNKMEYMTDYPRINFYMEGPAIPRAHNI PHDFFSFS 420
QY 421 EEIVRNLSCKRPQDHFKEPYLTPDLKRLHYAKNVRIDKVLHFDVQOQWLAVRSKSNNTCCG 480
Db 421 EEIVRNLSCKRPQDHFKEPYLTPDLKRLHYAKNVRIDKVLHFDVQOQWLAVRSKSNNTCCG 480
QY 481 GNHGYNNEFRSMEAI FLAHGFSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
Db 481 GNHGYNNEFRSMEAI FLAHGFSFKEKTEVEPPENIEVYNLMCDLLRIQAPNNGTHGSLN 540
QY 541 HLLKVPFYEPSHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVNMNLNQEEI 600
Db 541 HLLKVPFYEPSHAEVSKFSVCGFANPLPTESLDCFCPLHNSQLEQVNMNLNQEEI 600
QY 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDGTSLPPT 660
Db 601 TATVKVNLPRGRPRVLQKNVDHCLLYHREYVSGFGKAMRPMWSSYTVPLQDGTSLPPT 660
QY 661 VPDCLRADVRVPSESKFSYLADKNI THGFLYPPASNRSDSQYDALITSNLVPMBE 720
Db 661 VPDCLRADVRVPSESKFSYLADKNI THGFLYPPASNRSDSQYDALITSNLVPMBE 720
QY 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
Db 721 FRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHDADPEITKHLANTDVPITPHY 780
QY 781 FVLTSCNKSHTPENCPCGWLVDLPII PHRPNVESCEGKPEALWVERFTAIAVR 840
Db 781 FVLTSCNKSHTPENCPCGWLVDLPII PHRPNVESCEGKPEALWVERFTAIAVR 840
QY 841 DVELLTGLDFYQKQVQVSEILQKYLPTFETI 875
Db 841 DVELLTGLDFYQKQVQVSEILQKYLPTFETI 875

RESULT 15

US-10-291-241-96
; Sequence 96, Application US/10291241
; Publication No. US20030206905A1
; GENERAL INFORMATION:
; APPLICANT: Agensys, Inc.
; APPLICANT: Aya Jakobovits
; APPLICANT: Arthur B. Raitano

APPLICANT: Mary Paris
APPLICANT: Rene S. Hubert
APPLICANT: Wangmao Ge
APPLICANT: Karen Jane Meyrick Morrison
APPLICANT: Robert Kendall Morrison
APPLICANT: Pia M. Challita-Eid
TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN
TITLE OF INVENTION: ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF
TITLE OF INVENTION: CANCER
FILE REFERENCE: 51158-20062.20
CURRENT APPLICATION NUMBER: US/10/291,241
CURRENT FILING DATE: 2003-03-18
PRIOR APPLICATION NUMBER: US 10/005,480
PRIOR FILING DATE: 2001-11-07
PRIOR APPLICATION NUMBER: US 10/062,109
PRIOR FILING DATE: 2002-01-31
PRIOR APPLICATION NUMBER: US 60/282,739
PRIOR FILING DATE: 2001-04-10
NUMBER OF SEQ ID NOS: 103
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 96
LENGTH: 875
TYPE: PRT
ORGANISM: Homo Sapiens
US-10-291-241-96

Query Match 100.0%; Score 4804; DB 15; Length 875;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 875; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESTLTATQPVKXNTLKXKACIVLLALLVMSLGLGLGRKLEKQSGCRKCPD 60
Db 1 MESTLTATQPVKXNTLKXKACIVLLALLVMSLGLGLGRKLEKQSGCRKCPD 60

Qy 61 ASFRGLENCRCVACKRGDCDCCDFEDTCVETRIWNCFRGCTREASLSCSDCL 120
Db 61 ASFRGLENCRCVACKRGDCDCCDFEDTCVETRIWNCFRGCTREASLSCSDCL 120

Qy 121 QKDCADYKSVCGGETSWLEENCDDTAQSQCPGFDLPVILFSDGFRABEYLYTDTL 180
Db 121 QKDCADYKSVCGGETSWLEENCDDTAQSQCPGFDLPVILFSDGFRABEYLYTDTL 180

Qy 181 MPNTNKLKTCGIHSHKYNRMVPTTFFPHYITVGLPESHGIIIDNNYDVLNKNPFLS 240
Db 181 MPNTNKLKTCGIHSHKYNRMVPTTFFPHYITVGLPESHGIIIDNNYDVLNKNPFLS 240

Qy 241 SKEQNPAAWHGQPMWLTAMTQGLKAATYFWPGSEVAINGSPPSIYMPYNGSVPFERIS 300
Db 241 SKEQNPAAWHGQPMWLTAMTQGLKAATYFWPGSEVAINGSPPSIYMPYNGSVPFERIS 300

Qy 301 TLLKWLDPKAEPRFRFTYMEEPDSSGHAGGPVSARVICALQVVDHAFGLMEGLKORN 360
Db 301 TLLKWLDPKAEPRFRFTYMEEPDSSGHAGGPVSARVICALQVVDHAFGLMEGLKORN 360

Qy 361 LHCNVIILLADHGMDQTCNKMETWTDYFRINFFYMGPAIRIAHNIPIHDFFSFNS 420
Db 361 LHCNVIILLADHGMDQTCNKMETWTDYFRINFFYMGPAIRIAHNIPIHDFFSFNS 420

Qy 421 EEIVANLSCKRPDQHFKPYLTPDLPRHLHYAKNRIDKVLHFDVQQMLAVRSKNTNCGG 480
Db 421 EEIVANLSCKRPDQHFKPYLTPDLPRHLHYAKNRIDKVLHFDVQQMLAVRSKNTNCGG 480

Qy 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQPAFNNGTGSLN 540
Db 481 GNHGYNNEFRSMEALFLAHGSPFKEKTEVEPFENIEVYNLMCDLLRIQPAFNNGTGSLN 540

Qy 541 HLLKVPFYPGSHAEVSKFSVCGFANPLPTESLDCFCFHLQNSTQLEQVQMLNLTQEEI 600
Db 541 HLLKVPFYPGSHAEVSKFSVCGFANPLPTESLDCFCFHLQNSTQLEQVQMLNLTQEEI 600

Qy 601 TATVKVNIIPGEPRLVQKVDHCLLYHREYVSGFKAMEMWSSYTVPOLGDTSPLPPT 660
Db 601 TATVKVNIIPGEPRLVQKVDHCLLYHREYVSGFKAMEMWSSYTVPOLGDTSPLPPT 660

Qy 661 VPDCLRADRVPPPSQKCSFYLDKNITHGFLYPPASNRRTSDSQYDALITSNLPVMEY 720
Db 661 VPDCLRADRVPPPSQKCSFYLDKNITHGFLYPPASNRRTSDSQYDALITSNLPVMEY 720

Qy 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITY 780
Db 721 FRKWDYFHSVLLIKHATERNGVNVSGPIFDYNDGHFDAPDEITKHLANTDVPITY 780

Qy 781 FVVLTSCKNKSHTPENCPCGMLDVLFPFIIPHRPTNVSCPEGKPEALWVEERFTHIARVR 840
Db 781 FVVLTSCKNKSHTPENCPCGMLDVLFPFIIPHRPTNVSCPEGKPEALWVEERFTHIARVR 840

Qy 841 DVELLTGLDFYQDKVQPVSEILQKTYLPTETTTI 875
Db 841 DVELLTGLDFYQDKVQPVSEILQKTYLPTETTTI 875

Search completed: July 6, 2004, 13:26:07
Job time : 59 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 6, 2004, 13:11:52 ; Search time 26 Seconds
(without alignments)
3237.215 Million cell updates/sec

Title: US-10-005-480A-743
Perfect score: 4804
Sequence: 1 MESTLTATEQPVKKNTLKK.....QPVSILQKLYLPFTETI 875

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR 78:*

1: Pir1.*

2: Pir2.*

3: Pir3.*

4: Pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|--------|-------------|--------|----------|-----------------------------------|
| 1 | 3972 | 82.7 | 875 | 1 A57080 | cell surface antigen RB13-6 - rat |
| 2 | 2498.5 | 52.0 | 925 | 1 A39216 | nucleotide diphosph |
| 3 | 2411.5 | 50.2 | 905 | 1 A37410 | nucleotide diphosph |
| 4 | 2043.5 | 42.5 | 885 | 1 A55433 | nucleotide diphosph |
| 5 | 2040.5 | 42.5 | 915 | 1 A55144 | autotaxin precursor |
| 6 | 743.5 | 15.5 | 496 | 2 T09931 | probable phosphodi |
| 7 | 737.5 | 15.4 | 479 | 2 T03293 | probable phosphodi |
| 8 | 712.5 | 14.8 | 457 | 2 T09932 | probable phosphodi |
| 9 | 680.5 | 14.2 | 461 | 2 T09933 | probable phosphodi |
| 10 | 644 | 13.4 | 477 | 1 A59390 | probable phosphodi |
| 11 | 637 | 13.3 | 485 | 2 T40657 | probable phosphodi |
| 12 | 632.5 | 13.2 | 477 | 1 A59391 | probable phosphodi |
| 13 | 632 | 13.2 | 300 | 2 A41179 | protein kinase PC- |
| 14 | 630.5 | 13.1 | 429 | 2 T33724 | probable phosphodi |
| 15 | 629.5 | 13.1 | 453 | 1 A59389 | probable phosphodi |
| 16 | 623 | 13.0 | 829 | 2 T19494 | hypothetical prote |
| 17 | 553 | 11.5 | 451 | 2 T97407 | hypothetical prote |
| 18 | 508 | 10.6 | 674 | 2 T19495 | hypothetical prote |
| 19 | 499.5 | 10.4 | 433 | 2 B82537 | probable phosphodi |
| 20 | 434 | 9.0 | 743 | 2 S19437 | hypothetical prote |
| 21 | 412.5 | 8.6 | 493 | 2 S50443 | probable phosphodi |
| 22 | 374 | 7.8 | 614 | 2 T30973 | hypothetical prote |
| 23 | 301 | 6.3 | 96 | 2 A25274 | phosphodiesterase |
| 24 | 222.5 | 4.6 | 434 | 2 F96958 | ap superfamily (im |
| 25 | 222.5 | 4.6 | 453 | 2 T16795 | hypothetical prote |
| 26 | 212 | 4.4 | 133 | 2 T09934 | hypothetical prote |
| 27 | 209 | 4.4 | 422 | 2 A51232 | pyrophosphatase ho |
| 28 | 195.5 | 4.1 | 422 | 2 A51614 | weakly pyrophospha |
| 29 | 150 | 3.1 | 360 | 2 T20867 | hypothetical prote |

30 146.5 3.0 370 2 C71052
31 138.5 2.9 369 2 A75091
32 135 2.8 476 2 JC7189
33 132 2.7 474 2 A57480
34 129 2.7 369 2 A34614
35 126 2.6 2004 2 AC0314
36 121 2.5 4543 1 A53102
37 120.5 2.5 479 2 C75099
38 118 2.5 781 2 S43534
39 117 2.4 696 2 T27402
40 116.5 2.4 758 2 S62432
41 116 2.4 704 2 A34287
42 116 2.4 2150 2 T32497
43 115.5 2.4 454 2 A46498
44 115 2.4 397 2 T35880
45 114.5 2.4 1327 2 T14594

ALIGNMENTS

RESULT 1

A57080
cell surface antigen RB13-6 - rat
N/Contains: phosphodiesterase I (EC 3.1.4.1)
C/Species: Rattus norvegicus (Norway rat)
C/Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 10-Sep-1999
C/Accession: A57080
R/Deissler, H.; Lottspeich, F.; Rajewsky, M.F.
J. Biol. Chem. 270, 9849-9855, 1995
A/Title: Affinity purification and cDNA cloning of rat neural differentiation and tumor
A/Reference number: A57080; MUID:9524775; PMID:7730366
A/Accession: A57080
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-875 <DB1>
A/Cross-references: DB:247987; NID:G806378; PIDN:CAA88029.1; PID:G806379
C/Superfamily: nucleotide pyrophosphatase; somatomedin B homology
C/Keywords: exonuclease; glycoprotein; phosphoprotein; phosphoric diester hydrolase; su:
F/1-22/Domain: cytosolic #status predicted <CYT>
F/23-45/Domain: transmembrane #status predicted <TM>
F/46-875/Domain: extracellular #status predicted <EXT>
F/51-94/Domain: somatomedin B homology <SBH>
F/95-138/Domain: somatomedin B homology <SBH2>
F/206/Binding site: AMP (Thr) (covalent) #status predicted
F/237,280,289,533,574,594,702,789/Binding site: carbohydrate (Asn) (covalent) #status p

Query Match 82.7%; Score 3972; DB 1; Length 875;
Best Local Similarity 81.2%; Pred. No. 7.2e-272;
Matches 711; Conservative 77; Mismatches 86; Indels 2; Gaps 2;

QY 1 MESTLTATEQPVKKNTLKKYKIACIVLLALLVMSIGLGLGLRLKLRKQ-GSCRRKCF 59

DB 1 MDSRLALATEEPIKKSLSIKYKILCAVLLALLVLSLGLGLRLKPEEHIGSCRRKCF 60

QY 60 DASFRGLENCDCVACDGRGCCWDPEDTCESTRIMWKNKFCGSTRLEASLCSDDC 119

DB 61 DSHRGLEGRCDSDGCTDRGDCWDPEDTCESTRIMWKNKFCGSTRLEASLCSDDC 120

QY 120 LQKDCADYKSCVQGETSMLENCDDTAQSCQCEGFDLPVILFSDGQFRAEYLYTWD 179

DB 121 LQKDCADYKSCVQGETSMLENCDDTAQSCQCEGFDLPVILFSDGQFRAEYLYTWD 180

QY 180 LMPINKLKTGHIHUKYWRAMYPTKTPPNHYTIVTGLYPESHGIIIDNNYVDMNKNFSL 239

DB 181 LMPINKLKTGHIHUKYWRAMYPTKTPPNHYTIVTGLYPESHGIIIDNNYVDMNKNFSL 240

QY 240 SSKSQNNPAMWHGQPMWLTAQYQGLKAATYFWPGSEVAINGSPFSPYMPYNGSVPPERI 299

DB 241 SSVKSNPAMWNGSQPIWLTAQYQGLKAATYFWPGSEVAINGSPFSPYMPYNGSVPPERI 300

QY 300 STLLKWLIDLPAERPRYTYMYFEPDSSGHAGQPVSAARVIALQVVDHAFGLMEGLKOR 359

Db 301 ATLLQWLDPKAERPSFYTIYVEBPDGAGHKSQVSAVIAKALQVLVDADFGMLMEGLKQR 360
Qy 360 NLHNCVNIILLADHGMQDTYCNKMEYMTDPEPRINFYMYEGAPRIAHNIHDPFSFN 419
Db 361 NLHNCVNIILLADHGMQDTYCNKMEYMTDPEPRINFYMYEGAPRIAHNIHDPFSFN 419
Qy 420 SEIIVRNLSCKRQDQHFYLPDLPKRLHYAKNVRIDKVLHFDQOVLAVRSKNTNG 479
Db 420 SEIIVRNLSCKRQDQHFYLPDLPKRLHYAKNVRIDKVLHFDQOVLAVRSKNTNG 479
Qy 480 GQNHCVNNEFSMEALFLAHGSPKTEVEPPENIEVNLMDLLRIQAPNNGTHGSL 539
Db 480 GQNHCVNNEFSMEALFLAHGSPKTEVEPPENIEVNLMDLLRIQAPNNGTHGSL 539
Qy 540 NLLKVPFYPESHABEVSKFVCGFANPLPTESLDCCPHLONSTQLEQVQMLNLTQEE 599
Db 540 NLLKVPFYPESHABEVSKFVCGFANPLPTESLDCCPHLONSTQLEQVQMLNLTQEE 599
Qy 600 ITATVKNLPCRPRVLQNDVHCLLYHREYVSGFGKAMPMWSSYVPLQDTSPLPP 659
Db 600 ITATVKNLPCRPRVLQNDVHCLLYHREYVSGFGKAMPMWSSYVPLQDTSPLPP 659
Qy 660 TVPDCRADVRPSPESQKSFYLDKNITHGFLYPPASNRTSDSQDALITSNLVPMYK 719
Db 660 TVPDCRADVRPSPESQKSFYLDKNITHGFLYPPASNRTSDSQDALITSNLVPMYK 719
Qy 720 EFRKMDYFHSVLLIKHATERGVNVVSGPIFDYNDGHFADAEITKHLANTDVPPTH 779
Db 720 EFRKMDYFHSVLLIKHATERGVNVVSGPIFDYNDGHFADAEITKHLANTDVPPTH 779
Qy 780 YFVLTSCNKSHTPENCGLDVLPTIIPHRPTNVSCPEGKPEALWVEERFTHIARV 839
Db 780 YFVLTSCNKSHTPENCGLDVLPTIIPHRPTNVSCPEGKPEALWVEERFTHIARV 839
Qy 840 RDVELLTGLDYPQKQVPSVILQKYLPTFTTII 875
Db 840 RDVELLTGLDYPQKQVPSVILQKYLPTFTTII 875

RESULT 2
A39216
Nucleotide diphosphatase (EC 3.6.1.9) - human
C:Species: Homo sapiens (man)
C:Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 03-Jun-2002
C:Accession: A39216; S21706; S23587; S51030
R:Buckley, M.F.; Lovelland, K.A.; McKinstry, W.J.; Garson, O.M.; Goding, J.W.
J. Biol. Chem. 265, 17506-17511, 1990
A:Title: Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, and
A:Reference number: A39216; MUID:91009202; PMID:2211644
A:Accession: A39216
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-925 <BUC>
A:CROSS-references: GB:J05654
R:Funakoshi, I.; Kato, H.; Horie, K.; Yano, T.; Hori, Y.; Kobayashi, H.; Inoue, T.; Suzuki, Arch. Biochem. Biophys. 295, 180-187, 1992
A:Title: Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase.
A:Reference number: S21706; MUID:92246539; PMID:1315502
A:Accession: S21706
A>Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-925 <FUN1>
A:Accession: S23587
A:Molecule type: protein
A:Residues: 116-121;247-271, 'X', 273-275;279-280, 'X', 282-283;303-316;362-364;449-465;482-483

A>Note: it is uncertain whether Met-1 or Met-53 is the initiator
R:Belli, S.I.; Goding, J.W.
Eur. J. Biochem. 226, 433-443, 1994
A:Title: Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphatase activity.
A:Reference number: S51030; MUID:95094801; PMID:8001561
A:Accession: S51030

A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-80 <BEL>
C:Genetics:
A:Gene: GDB:PDNPI; M651; NPDS
A:CROSS-references: GDB:132615; OMIM:173335
A:Map position: 6q22-6q23
C:Superfamily: nucleotide pyrophosphatase; somatomedin B homology
C:Keywords: coenzyme A; glycoprotein; phosphoprotein; phosphoric diester hydrolase; transmembrane protein; transmembrane #status predicted <TM>
F:104-144/Domain: somatomedin B homology <SBH1>
F:145-188/Domain: somatomedin B homology <SBH2>
F:179,285,341,477,578,585,643,700,731,748/Binding site: carbohydrate (Asn) (covalent) #s F1256/Binding site: AMP (Thr) (covalent) #status predicted

Query Match 52.0%; Score 2498.5; DB 1; Length 925;
Best Local Similarity 53.1%; Pred. No. 6e-168;
Matches 465; Conservative 137; Mismatches 250; Indels 23; Gaps 11;

Qy 10 BQVKK-----NTLK---KYKACIVLLALLVIMSLGLGLGLGLKLEKOGSKRCKCFDAS 62
Db 57 EEPLKAAARTAKDPNTYKVLVSLVSVCLVLTILGCIFFGLPKPSCAKEVSKCKGCFERT 116
Qy 63 FRGLENCRCVACKRGDCWDPEDTCVZSTRIMWCMKFCGCTRIEASLCSDDCLOK 122
Db 117 F---GNCRCDAACVELGNCCLDQETCIEPIHWTCNKFCGCKLRSCLACSDCKDK 173
Qy 123 KCCADYKVCQGETSWLEENCDTAQSQCPGDFLPPVILFSMDGFRAYLYTDTLMP 182
Db 174 GDCINTSYSCQGEKSWEEPCEINEPQCAGFETPTLLFSLDGFRAEYLTHTWGGLP 233
Qy 183 NINKLTKCGHSKMYAMPTKTFPNHYITVGLYPESHGIDNNMYDVNLKNFSLSK 242
Db 234 VISKLKCGTYTKNMPVPTKTFPNHYSIVTCLYPESHGIDNNMYDPNNAFLASK 293
Qy 243 EONNPAMWQPMWLTAMTQGLKAATYFPGSEVAINGSPSIYMPYNGSVPFEBRISTL 302
Db 294 EKFNPEWYKGEPTWYAKYGLKSGTFPFGSDVEINGFPDIYKMYNGSVPEERILAV 353
Qy 303 LKWLDPKAERPRFYTWYPEEPPDSGHAGGVSARVIAKALQVVDVHAFGLMEGLKORNH 362
Db 354 LQWLDPKAERPRFYTWYPEEPPDSGHAGGVSARVIAKALQVVDVHAFGLMEGLKORNH 362
Qy 363 NCVNIILLADHGMQDTYCNKMEYMTDPEPRINFYMYEGAPRIAHNIHDPFSFNSEE 422
Db 414 RCLNLIISDHGMEQSKKTYLNKYLGDVKNIKYVIGPAARLSPSDVPDKYYSFNTEG 473
Qy 423 IVNLSCKRQDQHFYLPDLPKRLHYAKNVRIDKVLHFDQOVLAVRSKNTNGCGG 481
Db 474 IARNLSCEPNOHFYLPDLPKRLHYAKNVRIDKVLHFDQOVLAVRSKNTNGCGG 533
Qy 482 NHGYNNEFSMEALFLAHGSPKTEVEPPENIEVNLMDLLRIQAPNNGTHGSLNH 541
Db 534 FHGSDNVFSNQALFVYGPGFKHGEADTFENIEVNLMDLLRIQAPNNGTHGSLNH 593
Qy 542 LLKVPFYPESHABEVSKFVCGFANPLPTESLDCCPHLONSTQLEQVQMLNLTQEE 600
Db 594 LLKVPFYPESHABEVSKFVCGFANPLPTESLDCCPHLONSTQLEQVQMLNLTQEE 649
Qy 601 TATVKNLPCRPRVLQNDVHCLLYHREYVSGFGKAMPMWSSYVPLQDTSPLPP 660
Db 650 KIIKHETLPYGRPRVLQKENTICLLSQHQFMGYSQDILMPLWTSYTVDR--NDSFSTED 707
Qy 661 VPDCLRADVRPSPESQKSFYLDKNITHGFLYPPASNRTSDSQDALITSNLVPMYK 719
Db 708 VPDCLRADVRPSPESQKSFYLDKNITHGFLYPPASNRTSDSQDALITSNLVPMYK 767
Qy 720 EFRKMDYFHSVLLIKHATERGVNVVSGPIFDYNDGHFADAEITKHLANTDVPPTH 776
Db 768 SFQVIRYFHTDLRLRYAERGVNVVSGPIFDYNDGHFADAEITKHLANTDVPPTH 827
Qy 777 PTHYFVLTSCNKSHTPENCGLDVLPTIIPHRPTNVSCPEGKPEALWVEERFTHI 836

Db 828 PTHFFIVLTGKDTSTQTLHCEN-LDTLAFILPHRTDENSECVHKGHDSWVEBLLMLHR 886

QY 837 ARVRDVELLTGLDFYQDKVQVSEIQLKLTPLTF 871

Db 887 ARITDVEHITGLSFYQQRKEPVSDILKTLPLTF 921

RESULT 3

A27410

Nucleotide diphosphatase (EC 3.6.1.9) - mouse

Nucleotide names: nucleotide pyrophosphatase (EC 3.6.1.9); phosphodiesterase I (EC 3.1.1.1)

C:Species: Mus musculus (house mouse)

C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 03-Jun-2002

C:Accession: A27410; EMBL:159055; S38354

R:van Driel, I.R.; Goding, J.W.

J. Biol. Chem. 262, 4882-4887, 1987

A:Title: Plasma cell membrane glycoprotein PC-1. Primary structure deduced from cDNA cloc

A:Reference number: A27410; MUID:87165906; PMID:3104326

A:Accession: A27410

A:Molecule type: mRNA

A:Residues: 1-905 <VAR>

A:Cross-references: GB:J02700; NID:G200236; PIDN:AAA39893.1; PID:G200237

A:Note: The authors translated the codon CAG for residue 24 as Glu

R:van Driel, I.R.; Wilks, A.F.; Pieterse, G.A.; Goding, J.W.

Proc. Natl. Acad. Sci. U.S.A. 82, 8619-8623, 1985

A:Title: Murine plasma cell membrane antigen PC-1: Molecular cloning of cDNA and analysis

A:Reference number: I59055; MUID:86094275; PMID:3001713

A:Accession: I59055

A>Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 203-219 <RES>

A:Cross-references: GB:M12552; NID:G200234; PIDN:AAA39892.1; PID:G200235

R:Beili, S.I.; van Driel, I.R.; Goding, J.W.

Eur. J. Biochem. 217, 421-428, 1993

A:Title: Identification and characterization of a soluble form of the plasma cell membra

A:Reference number: S38354; MUID:94039066; PMID:8223581

A:Accession: S38354

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 35-219 <BEL>

A:Cross-references: EMBL:104516

C:Genetics:

A:Introns: 62/3; 87/1; 126/1; 168/1; 188/2

C:Superfamily: nucleotide pyrophosphatase; somatomedin B homology

C:Keywords: coenzyme A; Glycoprotein; phosphoprotein; phosphoric diester hydrolase; tran

F:86-126/Domain: somatomedin B homology <SBH1>

F:127-170/Domain: somatomedin B homology <SBH2>

F:161,267,323,453,567,624/Binding site: carboxydrate (Asn) (covalent) #status predicted

F:238/Binding site: AMP (Thr) (covalent) #status predicted

Query Match 50.2%; Score 2411.5; DB 1; Length 905;

Best Local Similarity 50.7%; Pred. No. 7.9e-162;

Matches 445; Conservative 152; Mismatches 251; Indels 29; Gaps 10;

QY 10 EOPVKK-----NTKKYKXIAIVLLALVIMSLGLGLGLRLKLEKQSGCRKKCF 59

Db 39 EEPLEKADGARPAKDNT---YKVLISLVSVCLTILGICIFGLKPSCAKEVKSGKGRCF 95

QY 60 DASFRLENCRCVACKDCCWDDEDICVETSTRIMCNKRCGTRLEASLCSGSDC 119

Db 96 ERTF---SNCRDAACVSLGNCCLDFQETCVETHTLWTCNFKRCGERLRSFVCSADC 152

QY 120 LQKDCADYKVCQGETSLMEENCDAQOSQCEGFDPPLPVILFMDGFRAYLYTWDT 179

Db 153 KTHNDCCINYSVCQDKSKSVECTCSIDTPECPAFESPPTLLFSLDGFRAEYLHTWG 212

QY 180 LMPNINKLTCGTHSKYMRAMYPTKTPPNHYITVTLGLYPESHGIIINNYDVNLKNFSL 239

Db 213 LLPVSKLNCGTGTYTKMRPMYPTKTPPNHYISVITGLYPESHGIIIDNKMYDPKMNASFSL 272

QY 240 SSKEQNPANWGHQPMWLTAVYGLKAATYFPGSEVANGSPSPYMPYNGSVPPPEERI 299

Db 273 KSKEFNPLWKQPIWTAHNEVKSGTYFNWGSDEIDGILPDIYKYNGSVPPPEERI 332

QY 300 STILLKWLDFKABRPFRFYTWYFEEPDSSGHAGGPGVSGARVVKALQVVDHAFGLMEGLKOR 359

Db 333 LAVLEMLQLPSHERPHFYTLYLEEPDSSGHGFSSEVIKALQKQVDRIVGLMLMDGLKOL 392

QY 360 NLHNCVNIILLADHGMDOQYCNKMEYMTDYFPRINFFYMYVEGAPRIRAHNIPHDFFSFN 419

Db 393 GLDKCLNLLISDHGMEQSCKYVYLNKYLGDVNNKVYVYGAARLPTDVPETYYSFN 452

QY 420 SEBIVNLSCRKPDQHFHFKPYLTPDLKRLHYAKNVRIDKVLHLEVDQOM-LAVRSKNTNC 478

Db 453 YEALAKNLSCREBNQHFRPYLKFPLKRLHFAKSDRIEPLTFYLDLPQWQLALNPSERKYC 512

QY 479 GCGNHGVNNEFRSNEALFLAHGSPKTEKTEVEFENIEVYNLMCDLLRLQCPAPNNGTHGS 538

Db 513 GSGFHGSDNLSNNQALFICYGAFKHGAEDVSFENIEVYNLMCDLLGLLIPAPNNGSHGS 572

QY 539 LNHLLKVPFPEPSHABEVSFSCVGFANPLPTEBSLDCFCFHLQNSQLQLEOVNOMLNTQE 598

Db 573 LNHLLKKPIYNPSHPKEEGLSQC---PIKSTNDLGCCTCDPWIVPIKDFEQLNLTE 628

QY 599 EITATVKVNLPPGPRVRLQKNVDHCLLYHREYVSGKAMRMPMWSYITVPQLGDTSPLP 658

Db 629 D-DDIVHNTVPYGGPRILLKQHEVCLLQQOQFLTGYSLDLLMPLWASYTF--LRNQOFSR 685

QY 659 PTVDPCLARADVPPBSQSCSFVLADKNITHGFLYPPASNRITSDSOY-DALITSLNIVPM 717

Db 686 DDFSNCMYQDLRPLSPVHKCSYKSKLSYGFLTPPRLNRYSNHITSEALLTSNIVPM 745

QY 718 YEEFRKMDYFHSVLLIKHATERNGVNVSIGPIFDYNDYGHFADPDEITHK---LANTDV 774

Db 746 YQSPQVIMHYLHDTLLQRYAHERNGINVSGPVEDFDYDGRYDSLEILKONSVIRSQEI 805

QY 775 PIPHYFVLTSCNKKSHTEPCGMDVLFPILPHRPTNVESCEGKPEALWVEERFTA 834

Db 806 LIPHFVITVTSKQLSETPLECSA-LESSAYILPHRPDNIESCTHGKRESSWVEELLTL 864

QY 835 HIARVRDVELLTGLDFYQDKVQVSEIQLKLTPLTF 871

Db 865 HRAVRTDVELITGLSFYQDRQESVSELLRLKTLPLF 901

RESULT 4

A55453

Nucleotide diphosphatase (EC 3.6.1.9) - rat

N:Contains: nucleotide pyrophosphatase (EC 3.6.1.9); phosphodiesterase I (EC 3.1.4.1)

C:Species: Rattus norvegicus (Norway rat)

C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 03-Jun-2002

C:Accession: A55453; J00187

R:Narita, M.; Goji, J.; Nakamura, H.; Sano, K.

J. Biol. Chem. 269, 28235-28242, 1994

A:Title: Molecular cloning, expression, and localization of a brain-specific phosphodie

A:Reference number: A55453; MUID:95050605; PMID:7961762

A:Accession: A55453

A:Molecule type: mRNA

A:Residues: 1-885 <NAR>

A:Cross-references: GB:D28560; NID:G464196; PIDN:BAA05910.1; PID:G464197

R:Narita, M.; Goji, J.; Sano, K.; Nakamura, H.

submitted to JIPID, February 1994

A:Description: Cloning and expression of brain-specific nucleotide diphosphohydrolase.

A:Reference number: J00187

A:Accession: J00187

A:Molecule type: mRNA

A:Residues: 1-66,'Q',68-81,'T',83-94,'C',96,'A',98-195,'A',197-514,'E',516-621,'E',623-6

A:Experimental source: strain Sprague-Dawley

C:Superfamily: nucleotide pyrophosphatase; somatomedin B homology

C:Keywords: coenzyme A; exonuclease; glycoprotein; phosphoprotein; phosphoric diester hy

F:54-97/Domain: somatomedin B homology <SBH1>

F:98-141/Domain: somatomedin B homology <SBH2>

F:53,150,396,408,522,608,829/Binding site: carboxydrate (Asn) (covalent) #status predict

F:207/Binding site: AMP (Thr) (covalent) #status predicted

Query Match 42.5%; Score 2043.5; DB 1; Length 885;

| | | |
|-----|---|-----|
| 482 | NHGYNNEFRSMEALFLAHGSPFKFKTEVEPFENIEVNLWCDLLRTOQAPNNGTIGSLNH | 541 |
| QY | | |
| 526 | DHGPDKNVNSMOTVFGYGTFFKYTKTPPFENIELYNWCDLLGKLPAPNNGTIGSLNH | 585 |
| DBb | | |
| 542 | LLKVPFPEPSHAERVSFKESVCGANPLPTESLQFCF-PHLQNSTQLEQVOMNLNTQEEI | 600 |
| QY | | |
| 596 | LLRNTFRPTPEERTNPYNGINLOSDFLGTCTODDKVEPKKULDEINKGLHTK---- | 641 |
| DBb | | |
| 601 | TATVKVNLPGFRPVLQKNVDHCLLYHREYVSFGKAMRMPMWSVTVFQLGDTSLPPT | 660 |
| QY | | |
| 642 | GSTERHLLYGRPAVLVR-TRYDILYHTDESGYSBIFLMLWTSYTVSKQAEVSSVPDH | 700 |
| DBb | | |
| 661 | VPCDLRADVRVPPSESKOKSFYLADKNMTHGFLYPPASNETSOSVDALITSNLVPMYSE | 720 |
| QY | | |
| 701 | LTSCVRPDRVSPFSFQNLAYKNDKQKSGFLPPPVLSSSPKAYDAFLVTNMWPMYFA | 760 |
| DBb | | |
| 721 | FRKMDWPHSVLLIKHATERGNVNVSGPFDYNDGHFDAPDIBTKHLANTDVPITPHY | 780 |
| QY | | |
| 761 | FRVWNYEQRVLVVKYASERNVNIISGPFIDYDGLHTEDEKIKQYVEGSSIPVPHY | 820 |
| DBb | | |
| 781 | FVLTITSCNKSHTPENCFGLWDVLFPITPHRPTNVSECPGKPEALWVEERFTHAIVAR | 840 |
| QY | | |
| 821 | YSIITSLCDFQPADKCDGPLSVSSFILPHRPDNECSNGSESKWVEELMKMHTARVR | 880 |
| DBb | | |
| 841 | DVELLTGDLDFQDKVQVPSBILQJLKTULPFTETI | 875 |
| QY | | |
| 881 | DIEHTLSLDFFRKTSRSYFELTKTULHTYSEI | 915 |
| DBb | | |

RESULT 6
T09931
probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) T161L4.
C-Species: Arabidopsis thaliana (mouse-ear cress)
C-Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 16-Aug-2002
C-Accession: T09931
R:RBevan, M.; Rose, M.; Hempel, S.; Entian, K.D.; Bancroft, I.; Mewes, H.W.; Mayer, K.F.X.
submitted to the Protein Sequence Database, June 1999
A:Reference number: Z16897

| | | | | |
|---------------------------|--------|--------------------|------------|-------------|
| Query Match | 15.5% | Score 743.5; | DB 2; | Length 496; |
| Best Local Similarity | 41.0%; | Pred. No. 1.4e-44; | | |
| Matches 159: Conservative | 71; | Mismatches 141; | Indels 17; | Gaps 9; |

| | | | | |
|----|--|-----|---|-----|
| QY | | 157 | D L P P V I L S M G C F R A E Y I Y T W D T L M P N I N K L U C T G H S K Y - M E A M Y P T K T F P N H X I T V T G | 216 |
| Db | | 105 | K X P V L L I S S D G F - F G Y Q F K T L P S I H R L I A N G T A E T G L I P V P T F T F P N H X I T V T G | 162 |
| QY | | 216 | L Y P E S H G I D N M Y D V N L M K N F S L S S K E Q N N P A M W H Q P M W L T A M Y Q G L K A A T Y M P G S E | 275 |
| Db | | 163 | L Y P A Y H G I I N N H F V D P E T C N V F T W A S H E - - - P E W L G E P L W E T V V N Q G L K A A T Y M P G S E | 219 |
| QY | | 276 | V A I N G S F - - - P S I Y M P Y N G S V P F P E E R I S T L K W L D L P K A E R P P Y T M Y F E E P D S S H A G G | 332 |
| Db | | 220 | V H - K G S W N C P Q G L C N Y A N G S V F D R V D T I L S Y F D L P S N E I P S F M T L Y F E D P D H Q H Q V G | 278 |
| QY | | 333 | P Y S A R V I K A L O V V D H A F G M L M E G L K O R N L H C N V I I L L A D H G M D Q T Y C N K M E Y M T D Y P P R | 392 |
| Db | | 279 | P D D Q T E A V N I D R L I G R L I D G L E K R G I F E D V T M I W G D H G M V C D K L V L D D L A P W | 338 |
| QY | | 393 | I N F - - - F Y M Y E G P A P R I A H N I P H D F S F N S E E I V R N L S C R K P D - - O H F K P Y I T P D L P K R | 447 |
| Db | | 339 | I K T P S S W O Y Y T P L L A I O P P S - G H D A A I V A - K I N E G L S S K Y E N G K Y L V K I L K E D L P G R | 396 |

| | | | |
|----|-----|---|-----|
| Qy | 448 | LYHAKNVEIDKVLHFDVQQLAVRSKNTNCGGNGHYNNNEPRSEMAIPLAHGPPFKBKKT | 500 |
| Db | 397 | LYHVDSDRIPIIGLVDEGFKVQKSKAKCEGGAHGYDNAPFSMTETIIGHGWPFSKGR | 456 |
| Qy | 508 | EVEPEPNEIYVNLMDLLRLTQAPNNGT | 535 |
| Db | 457 | KYPSENVQIYNVTSIIHGKAAPNNGS | 484 |

RESULT 7
T02203

nucleotide diphosphatase (EC 3.6.1.9) - rice
 nucleoside phosphodiesterase I (EC 3.1.4.1) /
 C:Species: Oryza sativa (rice)
 C:Date: 24-Mar-1999 #sequence_revision 24-Mar-1999 #text_change 16-Aug-2002
 C:Accession: T01293
 R:Hsieg, V. C.; Tsao, C. V.; Chow, T.; Hsieh, J.; Chen, Z.
 submitted to the EMBL Data Library, April 1995
 A:Description: Rice early embryogenesis gene.
 A:Reference number: Z14889

| | | | | |
|-----------------------|--------------|--------------------|-----------------|-------------|
| Query Match | 15.4%; | Score 737.5; | DB 2; | Length 479; |
| Best Local Similarity | 42.0%; | Pred. No. 3.4e-44; | | |
| Matches 163; | Conservative | 64; | Mismatches 140; | Indels 21; |
| | | | | Gaps 10; |

| | | | |
|-----|----|--|-----|
| 159 | QY | PPVILFMSDGRABEYLYTWTLPNINKLTCQHSKY--MRAMYPKTFEPNHYITVITGLY | 211 |
| 90 | Db | PVWILISDSDGRFCYQKAAAT--PHIHLIGNGHSAAATGLVPITPTTLPFNHYSIATGLY | 147 |
| 218 | QY | PESHGIIIDNNMYDNLNKNFSLSSKEQNNPAWHGQPMWLTAMYQGJKAATYFPGSEVA | 277 |
| 148 | Db | PSSHGIIINNVPDPDISGDTFMSHSE--PKWMLGEPLWYTAADQGIQAATYFPGSEVK | 204 |
| 278 | QY | INGSF--PSIY-MPYNGSVFPEERISTILKWLDLPKAEPRFYTWYFEEDPOSSGHAGPVP | 334 |
| 205 | Db | --KGSWDPCDKRYHNGSVFPEERVDAILGYFDLPSEMPQFLTLYFEDPDHQHGQVCPD | 263 |
| 335 | QY | SARVIKALQVVDHAFGMLEGLKORNLHNCVNIILLADHGNDQYCNKMEYNTDYFRIN | 394 |
| 264 | Db | DPATEAVVRIDEMIGRLIAGLEERGVPEDNVILVGDHGMVGWCDKKLVLDELAPWIK | 323 |
| 395 | QY | P---FYMWEGPAPIRAHNIHPDFFSNS--EEIVRNLSCKRPD--QHFKPLYLTPDLPKR | 447 |
| 324 | Db | LEEDWILSMTELLAIR-----PPDMSLIPDVVAKNNEGKSGKVENGEVLRMYLKEDLPSP | 379 |
| 448 | QY | LHYAKNVRIDKPHLVFDQOQWLAVRSKNTNCGGNHGYNNFRSMEAIFLAGHSFSKEXT | 507 |
| 380 | Db | LHYADSYRIPILGLPEBGYKVKMRSDKNECGGAHYGDYNAFFSMRTIFIAHGFRFEGR | 439 |
| 508 | QY | EVEPEENTIEVYMLCDLLRIQAPANNGT | 535 |
| 440 | Db | VYPSFENVEIYNIASILNLEPANNGS | 467 |

RESULT 8
FC9932

T09933 Probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) T1616
 CSpecies: Mus musculus mus musculus / Mus musculus thalliana (mouse-ear cress)
 CAccession: T09932 #sequence_revision 16-Jul-1999 #text_change 16-Aug-2002
 RRevised: T09932
 RReviewed: Rose, M.; Hempel, S.; Enliant, K.D.; Bancroft, I.; Mewes, H.W.; Mayer, K.F.P.
 Submitted to the Protein Sequence Database, June 1999
 AReference number: Z16897
 AAccession: T09932

Db 58 PVVLMISCDFRGYQFKTDT--PNIDLLISGTEAKHGLIPVFPPTWTFPNHYSIATGLY 115

QY 218 PESHGIIIDNMVDVNLKAFSLSSKEQNPPAWHGGQPMWLTAMYQGLKAATYFWPGSEVA 277

Db 116 PAYHGIIIMKFTDPVTGVEFNKGLQ---PKWMLGELWVTAVNQLKAVTYFWPGSEVL 171

QY 278 ING-SFSPSIYMP-YNGSVFPEERISTLLKWLDPKAEPRFVTMYFEEDSSGHAGPVS 335

Db 172 KSSWTCPEGYCHFNLSVPLEERVDSVLSHFDEDEVDDLMLFDEPQSHNYGPD 231

QY 336 ARVICALQVUDHAFGLMELGLKORNHNVCNIIILADHGM-DQTYCN-RMEYMTDYFPR 393

Db 232 PRVTTAVSDVKVIGSVIKGLKQREIFDEHVHILLGDHGMVNTCNEKAIYIDDLADI 291

QY 394 NFFMYEGAPRIRAHNIPHDFFSFNSE-----EIVNLSR-----KPDQ 434

Db 292 KI-----PAAMIQAYS---PVLAINPQWKDVENQSEKNAEVVAKMEALSLSGKVKG 342

QY 435 HPKPIYLPDLPKRLHYAKNVRIDKVLH FVDQQLAVRSKSNNTCCGGNHGYNNEFRSMEA 494

Db 343 FLKVYLKELPERLHFSYSRIPPIIGIVGELGVMVRQNRNAQVCYGDHGYDNELFSKRT 402

QY 495 IFLAGPSPFKETVEPPENIEVNLMDLLRIQAPNNGT 535

Db 403 IFVGHGSFRSKKVPSENVQIVNVVAELGLRPAPNGS 443

RESULT 10

A59390

probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) 5 - mo

N:Alternate names: ecdonucleotide pyrophosphatase/phosphodiesterase 5; NPP5

C:Species: Mus musculus (house mouse)

C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 16-Aug-2002

C:Accession: A59390

R:Gijbbers, R.; Ceulemans, H.; Stalmans, W.; Bollen, M.

J. Biol. Chem. 276, 1361-1368, 2001

A:Title: Structural and catalytic similarities between nucleotide pyrophosphatases/phosph

A:Reference number: A59390; MUID:21125673; PMID:11027689

A:Accession: A59390

A:Molecule type: DNA

A:Residues: 1-477 <GUI>

A:Cross-references: GB:AF233377; NID:GI2231525; PIDN:AAG49143.1

A:Experimental source: strain C57BL/6J

C:Superfamily: human phosphodiesterase I / nucleotide pyrophosphatase 4

C:Keywords: coenzyme A; metalloprotein; phosphoric diester hydrolase

F:72/Active site: Thr #status predicted

Query Match 13.4%; Score 644; DB 1; Length 477;

Best Local Similarity 32.8%; Pred. No. 1.3e-37;

Matches 146; Conservative 89; Mismatches 154; Indels 46; Gaps 11;

QY 144 CDTAQSQCEGFDLPVILLFPMGDFRAEYLYTWDTLMPNINKLTCGIHSKYNRMVPT 203

Db 16 CHSAFSLQEE---QKVLVSPGDFNDLYKYPT--PHFHYMKNGVHVQVNTVFI 70

QY 204 KTFPNHNTIVTGLYPESHGIDNNMYDNLNKNPFLSKSE-QNNPAWHGGQPMWLTAMYQ 262

Db 71 KTFPNHYTLVTGLFAENHGVANDMDFPIKLSFSLHMDIYDSKFWEETAPIWITNQA 130

QY 263 GLKAATYFWPGSEVAINGSPFSIYMPYNGSVPPFEERISTLLKWLDPKAEPR-RFYTMVF 321

Db 131 GHASGAAMFGADVKIHDSPFTYLPVNESVSFEDRAKIEWF---TAKDPINLGLFLY 187

QY 322 EEPDSSGHAGPVSARVICALQVUDHAFGLMELGLKORNHNVCNIIILADHGMDOQTYCN 361

Db 188 EEPDQDGHVGPDSPLMGSVISDVDDKLGVLIIKMLKRAKLNNVNLIVTSDHGMTCQSK 247

QY 382 KMERYMTDYFPRINFFMYEGAPRIRAHNIPHDFFSFNSEEIVNLSRCPDQHFPEYLT 441

Db 248 RVIELORYLDEHYTLIDHSFVAI-----LPKE---GKFEVYDALAGHP--NLTVYKK 298

QY 442 PDLKRLHYAKNVRIDKVLH FVDQQLAVRSKSNNTCCGGNHGYNNEFRSMEAIFLAHP 501

Db 299 EIPERWHYKNDRVQIVAVADEGWYILQNKSD-DFLGNHGYDNALAEHPIFLAHGP 357
QY 502 SPKEKEVEPFENIEVYINLMCDLLRIQAPNNGTHGSLNHLKLVFPFEPFSAEVSKEFSV 561
Db 358 AFKNFTKEAMSTDLISLCHLLNLALTALPHNGSFNNVQDLL----- 399
QY 562 CGFANPLPTESDCFCFHLQNSTOL 586
Db 400 -SSATPKP-----IPYQTSTLL 416

RESULT 11

T40657
probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) SPBC72
C:Species: Schizosaccharomyces pombe
C>Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 16-Aug-2002
C:Accession: T40657
R:Lyne, M.; Rajandream, M.A.; Barrell, B.G.; Rieger, M.
submitted to the EMBL Data Library, November 1998
A:Reference number: Z21889
A:Accession: T40657
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Cross-references: EMBL:AL034352; PIDN:CAA22177.1; GSPDB:GN00067; SPDB:SPBC725.05c
A:Experimental source: strain 972h-; cosmid c725
C:Genetics:
A:Gene: SPDB:SPBC725.05c
A:Map position: 2
C:Superfamily: human phosphodiesterase I / nucleotide pyrophosphatase 4
C:Keywords: coenzyme A; metalloprotein; phosphoric diester hydrolase

Query Match 13.3%; Score 637; DB 2; Length 485;

Best Local Similarity 37.5%; Pred. No. 4.2e-37; Matches 146; Conservative 64; Mismatches 165; Indels 14; Gaps 8;

QY 161 VILFSDMGFAEYLYTWTDLMPNINKLTCGHSKYRMYPTKTPPNHYTIVTGLYPS 220
Db 76 VIVISLDGFEADLYRGFT--PNLLSLAENVHVPELIPSPFSLTFPPNHYTIVTGLYPS 133

QY 221 HGIIDNNMVDVNLKNSLSKQCN-NPAW-HGQPMWLTAMYQGLKAATYWPQSEVAL 278

Db 134 HGVSNFFDPVTGQFVNSMPCNKDPTWMDXGEPIWNAERNVRSVHVMPGNEVEN 193

QY 279 NGSPFSIYMPYNGSVPFEEIRISLLKWLDPKAEPRFVTWYFEEPDSSCHAGGPVSARV 338

Db 194 HGRPTYSDGFNFTILREXKORILEWLDLPKDRFQLLAVAPHVDMVGHAFGDPSPFL 253

QY 339 IKALQVVDHAFGLMEGLKQKRNHNCVNIILLADHGMDQTYCNKMEYMTDYPFRINFFYM 398

Db 254 NIILQEVDIIVIGELIEGLKRNKDKHNIIFLSDHGWAPTSNRLIWLDMNENLSAVHR 313

QY 399 YEGPAPRIRAHNIPHPDFFSNSEIYVNLSCRKPD-QHKPYLTPDLPKRLHYAKNVRID 457

Db 314 DAMPLQGFROGESDLDDEYIY--BSLVNYSRSSLPSEAENMNVSFKDIPSRWHYSNNRRIA 371

QY 458 KVHLFVDDQWLAV----RSKSNNTCCGGNHGYNNEFRSMEAIFLAHGPSFK--EKTEVEEP 511

Db 372 PVAMIPDVGSLVSMLDHSPLEVEPLGVHGYDNLSPVVRALFIAGSSFFKNPKGKKLAP 431

QY 512 FENIEVNLCDLLRIQAPNNGTH-GSL 539

Db 432 FONTEIYGILSHLDLPAPQPNNGTYEGAL 460

RESULT 12

A59391
probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) 5 - hu
N:Alternate names: ectonucleotide pyrophosphatase/phosphodiesterase 5; NPP5
C:Species: Homo sapiens (man)
C>Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 16-Aug-2002
C:Accession: A59391
R:Smalley, C.

submitted to the EMBL Data Library, September 1999
A:Description: Contains actin, gamma pseudogene 9, a gene similar to PLASMA-CELL MEMBRAN
A:Reference number: A59391
A:Accession: A59391
A:Molecule type: DNA
A:Residues: 1-477 <SMA>
A:Cross-references: GB:AL035701; MID:G5924007; PIDN:CAE56566.1
R:Gijbbers, R.; Ceulemans, H.; Stalmans, W.; Bollen, M.
J. Biol. Chem. 276, 1361-1368, 2001
A:Title: Structural and catalytic similarities between nucleotide pyrophosphatases/phosph
A:Reference number: A59390; MUID:21125673; PMID:11027689
A:Contents: annotation
C:Genetics:
A:Gene: ENPP5
A:Map position: 6p11.2-6p21.1
C:Superfamily: human phosphodiesterase I / nucleotide pyrophosphatase 4
C:Keywords: coenzyme A; metalloprotein; phosphoric diester hydrolase
F:72/Active site: Thr #status predicted

Query Match 13.2%; Score 632.5; DB 1; Length 477;

Best Local Similarity 34.4%; Pred. No. 8.6e-37; Matches 140; Conservative 80; Mismatches 134; Indels 33; Gaps 10;

QY 156 FDLPP----VILFSDMGFAEYLYTWTDLMPNINKLTCGHSKYRMYPTKTPPNHYT 211

Db 21 FSLQPDQKQVLLVSDFGFRWDLYKVPT--PAPHYIMKYGVHVQVTVNVPITKTPPNHYT 78

QY 212 IVTGLYPESHGIIIDNNMVDVNLKNSLSKKE-QNNFAWVHGQPMWLTAMYQGLKAATYF 270

Db 79 LVTGLFAENHGVIVANDMPDIRNKSFLSDHNMVIVDSKFWEBAEPIWITNQSAGTSGAAM 138

QY 271 WPGSEVAINGSPSIYMPYNGSVPFEEIRISLLKWLDPKAEPRFVTWYFEEPDSSGHA 330

Db 139 WPGTDVILKHFPHYMPYNSVSFEDRVAKIEM--FTSKEPINLGLLYWEDPDDMGHH 196

QY 331 GGPVSARVIALQVVDHAFGLMEGLKQKRNHNCVNIILLADHGMDQTYCNKMEYMTDYP 390

Db 197 LGPDSPLMGPIVSDIDKGLYLIQMLKAKLWNLNLIITSDHGMTQCSERLIELDQYL 256

QY 391 PRINFFVMEGPAPRIRAHNIPHPDFFSNSEIYVNLSCRKPDQHKPYLT---PDLPK 446

Db 257 DRDHYTLIDQSPVAI-----LPKE---GKFDEVYEALT-----HAPNLTIVYKKEVDPE 303

QY 447 RLHYAKNVRIDKVLHFDVQDWLAVRSKSNNTCCGGNHGYNNEFRSMEAIFLAHGPSFKK 506

Db 304 RWHYKNSRIQPIITAVADEGWHILQNKSD-DFLGNHGYDNALADHPIFLAHGPAFRKN 362

QY 507 TEVEPFENIEVNLCDLLRIQAPNNGTHGSLNHLK-----VFP 547

Db 363 FSKAMNSTDLYPLCHLLNITAMPHNGSFNNVQDLLNSAMPVVPY 409

RESULT 13

A41179
protein kinase PC-1 (EC 2.7.1.1) - bovine (fragments)
N:Alternate names: MAPK; major acidic fibroblast growth factor-stimulated phosphoprotein;
C:Species: Bos primigenius taurus (cattle)
C>Date: 28-May-1992 #sequence_revision 22-Apr-1995 #text_change 30-Apr-1999
C:Accession: A41179; A49308
R:Oda, Y.; Kuo, M.D.; Huang, S.S.; Huang, J.S.
J. Biol. Chem. 266, 16791-16795, 1991
A:Title: The plasma cell membrane glycoprotein, PC-1, is a threonine-specific protein k
A:Reference number: A41179; MUID:91358477; PMID:1715869
A:Accession: A41179
A:Molecule type: protein
A:Residues: 1-26;36-56;59-67;68-133;134-144;145-267;268-300 <ODA>
A:Experimental source: liver
R:Oda, Y.; Kuo, M.D.; Huang, S.S.; Huang, J.S.
J. Biol. Chem. 268, 27318-27326, 1993
A:Title: The major acidic fibroblast growth factor (aFGF)-stimulated phosphoprotein fro
A:Reference number: A49308; MUID:94086550; PMID:7505270
A:Accession: A49308

RESULT 12

A59391
probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) 5 - hu
N:Alternate names: ectonucleotide pyrophosphatase/phosphodiesterase 5; NPP5
C:Species: Homo sapiens (man)
C>Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 16-Aug-2002
C:Accession: A59391
R:Smalley, C.

A:Molecule type: protein
A:Residues: 27-35, 'X', 37-58 <OD2>
A:Experimental source: liver

C:Note: sequence extracted from NCBI backbone (NCBI:141583)
C:Species: nucleotide pyrophosphatase; somatomedin B homology
C:Superfamily: glycoprotein; phosphoprotein; phosphotransferase
C:Keywords: somatomedin B homology (fragment) <SBH>
F:1-25/Domain: somatomedin B homology (fragment) <SBH>
F:36/Binding site: AMP (Thr) (covalent) (status predicted)

Query Match 13.2%; Score 632; DB 2; Length 300;
Best Local Similarity 21.8%; Pred. No. 4.9e-37;
Matches 174; Conservative 51; Mismatches 71; Indels 504; Gaps 13;
13;

Qy 57 KCFDAAGRLGNCRCVACHKDRGDCWDDEDTCTVETRIWCMKFCGTRLEASLCSGS 116

Db 2 KCFERTF---GNCRCDAACVCLGNCCLD----- 26

Qy 117 DDCLQKKDCCADYKSCQGETSLEENCDAQOSQCEGFDLPPVILFMSDFRAEYLVT 176

Db 27 ----- 26

Qy 177 WDTLMPNINKLTCGHSKYMRYMTKTPFNHYITVTGLYPESHGIIIDNNYDNLNKN 236

Db 27 -----NMREYVPTKTPFNHYSITVTGLYPESHGIIIDNK----- 58

Qy 237 FSLSSKEQNNPAMWHGQPMWLTAMYQGLKAATYFPGSEVAINGSPSPSYMPYNGSVRPE 296

Db 59 -----GEPIWLTA-----KSGIFFWPGSDVKINGFPDIYXV---SVFPE 95

Qy 297 ERITLLKMLDLPKAEPRFYMTYFEPDSSGHAGGVSARVAKLVVDFHAGMLMEGL 356

Db 96 ERITAILKWLQLP----- 108

Qy 357 KQNLHNCVNIILLADHGMDQTYCNKMYMTDYFFRINFYMEGPAPIRAHNIPHDF 416

Db 109 KEUNLHRCNLILISDHGMEQSGK-----YY 135

Qy 417 SFNSEIIVRNLSCKRPDQHFKPYLTDPKPLHLYAKQVRIDKVLFDQW-LAVRSKN 475

Db 136 SPDYEGI-----AKSDRIERLTFLYDLPQWLALNPSER 168

Qy 476 TNCGGHGVNNEFRSMEALFLAHGSPFKEKTEVFPFENIEVYNLMDLLRIQAPNNGT 535

Db 169 KYCGGFGHSDNLFNLQALFXXXXXXHXSTEVDSFENIEVYNLMDLLNLTAPNNGT 228

Qy 536 HGSNLHLKVPFYPERSHAEVSKFSCVGFANPLPTESLDCFCPLQNSQLQEVNQMLN 595

Db 229 H----- 229

Qy 596 TOEBITATKVNLPFGPRVLQKNVDHCLLYHREYVSGFKAMRPMWSSYTPQLGDT 655

Db 230 ----- 229

Qy 656 PUPPTVPDCLRADRVPPSSQKSFYLADKNITHGFLYPPASNTSDSQY-DALITSNL 714

Db 230 -----LSYGFLSPOLHKGSGQVSEALTTNI 257

Qy 715 VPMYEEFRKWDYFHSVLLIKHATERNGVNVVSGPIFDYNDGHFADPEITKHLANTDV 774

Db 258 VPMYQSQFQ----- 265

Qy 775 PIPTHFVVLTSCKNKSHTPENCQWLDVLPFIIPHRPTNVESCEPKPEALWVEERTA 834

Db 266 -----VTH-----ESLWVEELKL 279

Qy 835 HIARVDVELLGLDPYQDK 854

Db 280 HTARITDVHITGLSFYQQR 299

RESULT 14
T33724

probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) - Zym

C:Species: Zymomonas mobilis

C:Date: 29-Oct-1999 #sequence_revision 29-Oct-1999 #text_change 16-Aug-2002

C:Accession: T33724

R:Lee, J.S.; Jin, S.J.; Kang, H.L.; Kang, H.S.

submitted to the EMBL Data Library, August 1998

A:Description: Sequence analysis of 67E10 cosmid clone of Zymomonas mobilis 2M4.

A:Reference number: Z21392

A:Accession: T33724

A:Status: translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-429 <LEE>

A:Cross-references: EMBL:AF086791; NID:G3820581; PID:G3089614; PIDN:AAC70363.1

C:Superfamily: human phosphodiesterase I / nucleotide pyrophosphatase 4

C:Keywords: coenzyme A; metalloprotein; phosphoric diester hydrolase

Query Match 13.1%; Score 630.5; DB 2; Length 429;

Best Local Similarity 35.4%; Pred. No. 1e-36;

Matches 135; Conservative 76; Mismatches 143; Indels 27; Gaps 10;

Qy 160 PVILFSDGFRAEVLYTWTLMFNINKLTCGHSKYMRYMTKTPFNHYITVTGLYPE 219

Db 49 PLILISIDGFRADYIKR--GLTFLNLSLAENGSAKYAKMHPSPFSITFPNHYITVTGLYPD 106

Qy 220 SHGIIDNNYDNL--NKNFSLSSKE--QNNPAMW-HGQPMWLTAMYQGLKAATYFPGSE 275

Db 107 HGVGNMDDAHTTPDSHFMSDQAATDRWNWDEGEPLVTAEGQVVSATMFWPGSE 166

Qy 276 VAINGSPSYMPYNGSVPPFEEISTLLKWLDPKAEPRFYMTYFEPDSSGHAGGVS 335

Db 167 ADIEGVPEPMWRFDSHVPFSEVQVFSWLAYPEKKRPQFILTYPENVDHAGLYGPD 226

Qy 336 ARVICALQVVDHAFGLMEGLKORNLHNCVNIILLADHGMDQTYCNKMYMTDYPPRINF 395

Db 227 QEVNDNLVKIDQITQGVQGLKQKGIK--ANLVISDHGMAATSDRVALNKILDPDLY 284

Qy 396 FYM----YEGPAPIRAHNIPHDFFSNSEIIVRNLSCKRPDQHFKPYLTDPKPLHYA 451

Db 285 HVTGGAYAGIEPS--SGHSLKDLPLFASHD-----HMQWPKQIQIPARFHYG 331

Qy 452 KVRIDKVLHFLVQDQWLAVRSKS--NTNCGGNGHYNNFESMEALFLAHGSPFKEKTEVE 510

Db 332 QNRPVPAVCAAEVGVSGIMGDDSNAAHATKGNHGYNDQTEMGALFIANGPAQKHVIE 391

Qy 511 PFENIEVYNLMDLLRIQAP 531

Db 392 SMDNIDVQLVAQVQLK-AP 411

RESULT 15

A59389

probable phosphodiesterase I (EC 3.1.4.1) / nucleotide diphosphatase (EC 3.6.1.9) 4 - hu
N:Alternate names: ectonucleotide pyrophosphatase/phosphodiesterase 4; KIAA0879 protein;
C:Species: Homo sapiens (man)

C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 16-Aug-2002

C:Accession: A59389; B59391

R:Nagase, T.; Ishikawa, K.; Suyama, M.; Kikuno, R.; Hirose, M.; Miyajima, N.; Tanaka, J. Biol. Chem. 276, 1361-1368, 2001

A:Title: Prediction of the coding sequences of unidentified human genes. XII. The complete

A:Reference number: A59389; MUID:99156230; PMID:10048485

A:Molecule type: mRNA

A:Residues: 1-453 <NAG>

A:Cross-references: GB:AB020686; NID:G4240247; PIDN:BAA74902.1

A:Experimental source: adult brain

R:Gijssels, R.; Ceulemans, H.; Stalmans, W.; Bollen, M.

J. Biol. Chem. 276, 1361-1368, 2001

A:Title: Structural and catalytic similarities between nucleotide pyrophosphatases/phosph

A:Reference number: A59390; MUID:21125673; PMID:11027689

A:Contents: annotation

R:Smalley, C.

submitted to the EMBL Data Library, September 1999

A:Description: Contains actin, gamma pseudogene 9, a gene similar to PLASMA-CELL MEMBRAN

A:Reference number: A59391

Search completed: July 6, 2004, 13:20:28
Job time : 29 secs

This Page Blank (uspto)